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ABSTRACT 
Elizabeth Tacket Rogawski: Are our favorite drugs killing the wrong bugs? The impact of 
antibiotic treatment on diarrhea and growth in early childhood 
(Under the direction of Daniel J. Westreich) 
 
Diarrhea is a recurring illness in childhood that is associated with malnutrition, stunted 
growth, and cognitive impairment. Children with diarrhea and other common childhood illnesses 
are frequently treated with antibiotics, often against recommendations. Antibiotic exposures 
early in life may increase susceptibility to infections and affect child growth through 
modifications of the gastrointestinal microbiota. We assessed the impact of antibiotic treatment 
on diarrheal risk and growth in a birth cohort from 2009 to 2013 of 497 children from semi-
urban slums of Vellore, India.  
 We estimated the effect of antibiotic treatment for diarrhea on the timing of a subsequent 
episode using inverse probability of exposure-weighted Kaplan-Meier curves. We also estimated 
the effect of any early life antibiotic exposure on rates of diarrhea using negative binomial 
regression. Based on these results, we used the parametric g-formula to model the impact of 
hypothetical interventions to prevent unnecessary antibiotic exposures. To assess the impact on 
growth, we estimated the effects of antibiotic exposures in the first 6 months on height and 
weight z-scores using longitudinal general linear regression. 
More than half of children were given at least one course of antibiotics in the first 6 
months and more than half of these exposures were likely unnecessary. Antibiotic treatment of 
diarrhea was associated with reduced time to a subsequent episode, especially among younger 
iv 
 
infants. In addition, the adjusted relative incidence rate of diarrhea from 6 months to 3 years of 
age was higher among children who received any antibiotics before 6 months compared to those 
who did not, especially among children who were no longer exclusively breastfed by 6 months. 
We estimated that preventing unnecessary antibiotic exposures before 6 months could 
substantially reduce the incidence of diarrhea in early childhood. There were no associations 
between early antibiotic use and growth in the first 6 months and from 6 months to 3 years. 
Early life antibiotic exposure was associated with increased diarrheal risk, but had no 
association with growth. While antibiotics must be used for treatment when necessary, the 
potential for increased susceptibility to diarrhea should be considered when making treatment 
decisions. 
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CHAPTER I: SPECIFIC AIMS 
 
Diarrhea is a universal and recurring disease during childhood with the highest burden in 
low and middle-income countries (LMICs). India has the most childhood deaths due to diarrhea 
compared to all other countries, with an estimated 200,000 deaths in 2010. These deaths 
accounted for 13% of all deaths in Indian children under 5 years of age [1]. The overall incidence 
of diarrhea in India is also high: 2.5 episodes per child year in the first 6 months of life and more 
than 3 episodes per child-year among ages 6-23 months [2]. Early childhood diarrhea is a risk 
factor for malnutrition, stunted growth, and cognitive impairment, and contributes to a cycle 
between malnutrition and increased susceptibility to infections [3–6].  
Children with diarrhea in India are often treated with antibiotics despite the fact that 
diarrhea is almost always due to infections that do not respond to antibiotics. The World Health 
Organization correspondingly does not recommend routine use of antibiotics to treat diarrhea [7–
10]. However, antibiotics have quickly become a common exposure early in life given their use 
for the treatment of diarrhea and other childhood illnesses like upper respiratory infections and 
otitis media. In the United States (US) and United Kingdom (UK), for example, approximately 
one third of children received antibiotics before 6 months of age [11,12]. 
 Antibiotics affect the gastrointestinal microbiota, which is the complex population of 
microorganisms in the human gastrointestinal tract. Animal and small scale human studies 
suggest that antibiotics decrease the diversity of the microbiota, can cause long-term changes in 
microbiota composition, and result in increased susceptibility to the emergence of pathogens 
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[13–19]. Microbiota development is critical during infancy and early childhood, when diversity 
of organisms at this time is important for normal intestinal and enteric immune system 
development [20,21]. Further, the microbiota plays an important role in supporting nutrient 
absorption and other metabolic functions associated with growth [22,23]. Antibiotic exposures 
early in life, and especially during infancy, may cause the largest and most long-lasting 
perturbations to the microbiota, resulting in the greatest impact on related health outcomes 
during this period [24]. While longitudinal patterns of diarrhea through childhood have been 
well-characterized [25–27], the effects of antibiotic treatment on diarrheal risk and development 
among children in LMICs have not been studied. 
 We assessed the impact of antibiotic treatment among young children on diarrheal 
risk (Aim 1) and growth outcomes (Aim 2). We completed a secondary analysis of existing 
data collected in a cohort study of 497 children in semi-urban slums of Vellore, Tamil Nadu, 
India from 2009 to 2013 [28]. Field workers visited the homes of enrolled children twice-weekly 
from birth to 3 years of age and captured diarrhea incidence data based on a 3-day recall period. 
Height and weight were measured monthly. Children in the cohort had a high incidence of 
diarrhea (half had 4 or more episodes in the first 3 years of life), and a quarter of episodes were 
treated with antibiotics. This study provided highly detailed existing data on antibiotic exposures, 
diarrhea incidence and severity, and growth trajectories.  
 
Specific Aim 1: Estimate the effect of antibiotic treatment on future diarrheal risk among 
children in the first 3 years of life. 
 
3 
 
Aim 1A: Estimate the effect of antibiotic treatment for diarrhea on the incidence of a 
subsequent diarrhea episode. 
Hypothesis 1: Antibiotic treatment for diarrhea reduced the time to subsequent diarrhea. 
 
Aim 1B: Estimate the effect of any early life antibiotic exposure on rates of diarrhea 
from 6 months to 3 years of age. 
Hypothesis 2: Children exposed to antibiotics early in life had increased rates of diarrhea 
from 6 months to 3 years of age compared to children who are not exposed to antibiotics 
before 6 months of age. 
 
Aim 1C: Evaluate the impact of realistic interventions which prevent unnecessary 
antibiotic exposures early in life on rates of diarrhea from 6 months to 3 years of age. 
Hypothesis 3: Interventions that remove unnecessary antibiotic exposures would have a 
substantial impact on reducing diarrhea incidence and would make an important contribution 
to public health. 
 
Specific Aim 2: Estimate the effect of early life antibiotic exposures on short-term (0-6 
months) and long-term growth (6 months to 3 years).  
Hypothesis 3: Children exposed to antibiotics early in life had different growth rates compared to 
children not exposed to antibiotics, both in the short and long-term.  
  
Understanding the impact of widespread antibiotic treatment among children is important 
for making treatment decisions and may support efforts to encourage rational antibiotic use. This 
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study also contributes epidemiologic evidence to the rapidly accumulating laboratory data which 
suggest that antibiotic-mediated changes to the microbiota may affect susceptibility to disease.  
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CHAPTER II: BACKGROUND AND SIGNIFICANCE 
 
Burden and epidemiology of early childhood diarrhea 
Burden 
A large proportion of global child morbidity and mortality from infectious diseases is due 
to acute diarrheal diseases. Based on inconsistent data quality and quantity from around the 
world [29], estimates of child mortality due to diarrhea in the first 5 years of life from 2010 
range from 6.8 to 14.3 million. The majority of these deaths are due to infectious causes, with 
diarrhea causing 600,000 to 1.4 million of those deaths [1,30–34]. In 2013, an estimated 6.3 
million children died in their first 5 years, with diarrhea causing 578,000 of those deaths [35]. 
The burden of mortality is highest in Africa and Asia, and India has had the most childhood 
deaths due to diarrhea compared to all other countries. Diarrhea caused an estimated 334,000 
deaths in Indian children in 2005, corresponding to 1 in 82 Indian children dying from diarrhea 
in the first 5 years of life [36,37], and more than 200,000 deaths in 2010 [1]. These deaths 
comprised 13-14% of all deaths in Indian children under 5 years of age, approximately 10% of 
deaths in infants (0-11 months) and 24% of deaths in children 1-4 years of age [1,36,38]. Other 
researchers have estimated that up to one third of Indian childhood deaths are due to diarrhea 
based on data from 2008 [39]. Because more than 70% of deaths from diarrhea occur in the first 
2 years of life, interventions targeted in early childhood may have the largest impact on mortality 
[30]. 
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As oral rehydration therapy for diarrhea has become more widespread, deaths due to 
diarrhea have declined dramatically over the last 20 years. The absolute number has declined by 
more than half from 1990 to 2010 despite increases in population size [31,40]. In the first decade 
of the 21st century, deaths due to diarrhea dropped by almost 400,000 [1]. However, while gains 
have been made in mortality, the incidence of acute diarrheal illnesses and associated morbidity 
remains high. Less than 2% of diarrhea episodes progress to severe disease, and the case fatality 
rate for severe diarrhea is only approximately 2% [30,41]. Given the substantial number of 
deaths due to diarrhea, the denominator of these proportions, corresponding to the total number 
of diarrhea episodes, is very large. 
 The global incidence of diarrhea in the first 5 years of life in 2010 was estimated to be 
2.7 episodes per child-year, which corresponds to 1.7 billion episodes in 2010 [30]. Incidence is 
highest at age 6-11 months (4.5 episodes per child-year) and then decreases and levels off after 
two years of age (2.3 episodes per child-year) [2,40]. In India, diarrhea incidence in 2010 was 
estimated to be 2.50 episodes per child year in the first 6 months of life, and 3.82, 3.09, and 1.98 
episodes per child year in ages 6-11 months, 12-23 months, and 24-59 months respectively [2]. 
The third National Family Health Survey (NFHS-3), a nationally representative household 
survey of over 100,000 households completed in 2005-2006 sponsored by the Ministry of Health 
and Family Welfare, Government of India, found that 9.0% of children under the age of 5 and 
18.1% of children 6-11 months reported diarrhea in the 2 weeks prior to survey [7,8]. The 
coverage evaluation [42] and 10-district [43] surveys by the United Nations International 
Children's Emergency Fund (UNICEF) conducted in India in 2009 similarly estimated that 
14.3% of Indian children aged 0-23 months and 19.8% of Indian children aged 2-59 months from 
the 10 districts had diarrhea in the 2 weeks prior to the two surveys respectively. The estimate 
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was 15.3% for the state of Tamil Nadu in the coverage evaluation survey [42] and 28.4% for the 
sampled Krishnagiri district of Tamil Nadu in the 10-district survey [43]. 
The mean duration of diarrhea episodes assessed in the community in LMICs has been 
estimated to be 4.3 days. In India, median duration was estimated to be 3 days in the UNICEF 
10-district survey [43]. The majority of diarrhea cases (65%) are mild, with only 5% becoming 
persistent (lasting 14 days or more). Severe cases have longer duration (8.4 days) and high 
prevalence of dehydration [41]. Estimates of the proportion of diarrhea episodes with blood in 
the stool range from 1 to 12% [7,8,43].  
The estimated cost to households per diarrhea episode was estimated to be US$ 6.47 in 
India, the majority of which covered direct medical costs. Given the high incidence rates of 
diarrhea, these costs aggregate to billions of dollars globally [44]. 
 
Etiology 
 A wide range of microbes cause childhood diarrhea, including bacteria, parasites, and 
viruses. The relative frequencies of pathogens associated with diarrhea vary by geography, 
season, child’s age, breastfeeding practices, hygiene practices, immunocompetence, and secular 
time trends. The methods for pathogen testing, for example by culture or polymerase chain 
reaction (PCR), and the number of pathogens tested for in each study also influence prevalence 
estimates. Determination of etiology is complicated by co-infections, carriage of multiple 
potential pathogens, and the inability to identify pathogens in a third of cases [34,45]. Rotavirus, 
Cryptosporidium, Shigella, and enterotoxigenic Escherichia coli (ETEC) are most responsible 
for diarrheal diseases globally, and specifically for moderate-to-severe diarrhea in children 
[31,46]. Other E. coli virotypes, including enteroaggregative (EAEC), enteropathogenic (EPEC), 
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enteroinvasive (EIEC), and enterohaemorrhagic E. coli (EHEC), as well as Campylobacter 
jejuni, Vibrio cholera O1 and O139, and Salmonella are also regularly identified as bacterial 
causes of diarrhea in different regions of the world. Giardia duodenalis, Entamoeba histolytica, 
and Cryptosporidium are the common protozoal causes [10].   
The Global Enteric Multicenter Study (GEMS) in 2007-2011 identified that 
approximately one quarter of moderate-to-severe diarrhea episodes in the first two years of life 
were attributable to rotavirus in Kolkata, India. Cryptosporidium was attributed with 7-12% of 
episodes. In older children aged 24-59 months, moderate-to-severe diarrhea was more often 
attributed to Shigella and rotavirus [46]. A multicentric hospital-based study in 1991 detected 
Shigella in 20% of acute diarrheal cases among children aged 0-35 months in Vellore, India, 
rotavirus in 18%, enterotoxigenic E. coli in 14%, and Campylobacter jejuni in 15%. However, 
these organisms were also isolated in relatively high frequencies from control children without 
diarrhea [47]. A more recent study in Kolkata isolated rotavirus (48%), E. coli (19%—including 
enteroaggregative E. coli in 12%), Vibrio (19%—including V. cholera O1 in 16.4%), Giardia 
(14%), adenovirus (12%), and Cryptosporidium (11%) from hospitalized children with diarrhea 
under 5 years of age [48]. Overall among hospitalized cases of gastroenteritis in India, rotavirus 
has been identified as the cause of 6-45% (median approximately 20%) of episodes, with other 
viruses such as caliciviruses (includes norovirus and sapovirus), adenovirus, and astrovirus 
contributing to a lesser extent [34,49–52]. The proportion of symptomatic cases attributable to 
rotavirus in the community is lower, approximately 15% (range 4-30%) [50]. 
Enteric pathogens most responsible for diarrhea mortality are rotavirus, Vibrio cholerae, 
Shigella, Salmonella, and E. coli [45]. A recent review of global diarrhea mortality completed by 
the Child Health Epidemiology Reference Group (CHERG) estimated that 55% of diarrhea 
9 
 
deaths were due to either rotavirus, EPEC, caliciviruses, or ETEC based on etiologies of 
hospitalized cases [34]. Bacterial and parasitic causes of diarrhea confer higher risk of diarrhea 
persistence and mortality when compared to viral infections [53–55]. However, given the high 
prevalence of rotavirus-associated diarrhea, estimates from 2008 suggest that 37% of diarrhea 
deaths in children were due to rotavirus [56]. The Million Death Study estimated 113,000 deaths 
in Indian children under the age of 5 were due to rotavirus in 2005, 4.14 deaths per 1000 live 
births. The rotavirus mortality rate estimated for Tamil Nadu was lower, 2.1 deaths per 1000 live 
births, with an estimated 2,400 deaths in 2005 [37]. Several diarrheal diseases, such as cholera, 
shigellosis, and typhoid, are also of special importance given they have been closely associated 
with extreme poverty due to their association with contaminated water and lack of sanitation and 
hygiene among the poorest populations [45].  
 
Risk factors 
Transmission of pathogens associated with acute diarrhea is seasonal, with peak 
incidence of most diarrheas in the wet season [26,57,58]. Heavy rainfall events in Ecuador have 
been linked to increases in diarrhea incidence following dry periods and decreases in diarrhea 
following wet periods, suggesting climate vulnerability may be common in areas with 
insufficient water treatment infrastructure [59]. Increases in ambient temperature are also 
associated with increases in diarrhea [58,60]. Conversely, rotavirus diarrhea, which is not 
associated with transmission through water, often peaks in the cold, dry season [61,62].  
Diarrhea incidence rates also vary with age through the first 5 years of life. Children 
under 6 months of age are partially protected by breastfeeding through nutrients and maternal 
antibodies in breast milk. Peak incidence of diarrhea is seen in the months following weaning, 
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during the remainder of the first and the second year of life. Risk of persistent diarrhea is also 
highest at this young age [63]. Diarrhea incidence then decreases and stabilizes in the next 3 
years of age [2,25,27,57]. Diarrheal risk is also dependent on previous episodes, such that risk is 
highest among children with recent, prolonged (duration 7-13 days), or persistent (duration ≥ 14 
days) diarrhea [53,54,64–69]. Risk decreases as time elapses since the last diarrhea episode [25–
27]. A longitudinal study of persistent diarrhea in a birth cohort from Brazil described increased 
burdens of acute diarrhea 3 months before and 18 months after episodes of persistent diarrhea 
[27]. Concurrent or recent non-diarrheal illnesses, such as pneumonia, intestinal parasitic 
infection, and positive blood culture, increase risk of death among children with diarrhea 
[25,55,65,70].  
Malnourishment, as assessed by anthropomorphic measurements, is a risk factor for 
diarrhea incidence as well as poor outcomes such as persistence and death [53,55,65,70–73]. 
Micronutrient deficiencies, especially for zinc and vitamin A, increase risk of diarrhea and 
persistence of episodes [63,74,75]. Vitamin A deficiency compared to other nutritional 
deficiencies is most consistently associated with increased frequency, severity, and/or fatality of 
almost all infectious diseases. Most other vitamin deficiencies are also synergistic with infectious 
disease under some conditions, especially among malnourished individuals [74].  
Breastfeeding, and specifically exclusive breastfeeding, is a well-known protective 
practice against diarrhea. Breast milk is a hygienic and rich source of nutrition and includes 
immune system components such as antibodies, lymphocytes, macrophages, lysozymes, and 
lactoferrin, which protect infants from gastrointestinal infections [76]. Children who are not 
exclusively breastfed or are weaned early have a one to two-fold increase in risk of acute 
diarrhea, persistent diarrhea, and diarrhea-associated death [54,57,70,72,73,77–83]. 
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Male children in India have shown slightly higher prevalences of diarrhea than female 
children in national surveys [8,42,43]. Other host genetic factors also contribute to susceptibility 
to infection. Certain alleles of the genes encoding the histo-blood group antigens, which function 
as receptors for norovirus infection, have been found to prevent infection in some individuals 
[84]. Similarly, variants of the histo-blood group antigens, Lewis genes, and secretor genes 
mediate susceptibility to rotavirus infection [85,86]. Genes associated with the immune response, 
such as polymorphisms at the human leukocyte antigen (HLA) locus may modify an individual’s 
ability to present and recognize microbial antigen. Variations in inflammatory response and 
presence of host receptors for pathogens may also affect the outcome of pathogen exposure [45]. 
For example, anergy and delayed hypersensitivity responses to standard skin-test antigens have 
been shown to increase diarrheal risk and duration in several studies [87]. Finally, an allele of the 
ApoE cholesterol transport protein has been shown to reduce the impact of diarrhea and 
malnutrition on cognitive impairment [45].  
Factors associated with fecal-oral transmission of disease, such as hygiene practices and 
water quality, have been repeatedly associated with diarrheal risk. Hygiene practices around 
defecation, such as lack of latrine or toilet usage, improper disposal of feces, and lack of hand 
washing after defecation, have been associated with diarrhea incidence and duration in children 
in studies from Africa, South America, South Asia, and Southeast Asia [25,57,72,75,77,88–93]. 
Inconsistent maintenance of latrines and lack of education about their proper use may contribute 
to diarrheal risk even when improved sanitation facilities are present [94]. Unsafe or inadequate 
water sources also increase risk for diarrhea, specifically open storage of water, use of open 
water compared to pipe borne water, and consumption of water without boiling 
[72,73,77,88,91,95–99]. Similarly, behaviors related to food preparation and disposal, including 
12 
 
irregular food preparation, lack of hand washing before preparation, open storage of food, 
consumption of raw food, use of dirty milk bottles without cleaning with soap and hot water, and 
improper garbage disposal, have been associated with diarrhea in children [77,82,89–
91,100,101]. Higher levels of contact with others who could transmit pathogens through day care 
attendance, crowding in the home, and exposure to domestic animals has also been associated 
with increased diarrheal risk [69,71,72,82,89,90,101,102]. Finally, recent or concurrent diarrhea 
episodes in other members of the household predict diarrheal illness in children [89,103]. 
While diarrhea affects all classes in society, highest morbidity and mortality occurs 
among the poor, and social factors have a large impact on diarrhea burden. Low socio-economic 
status and level of education of mothers is associated with diarrhea incidence, severity, and 
mortality [25,54,73,80,88,90,91,98,101,104]. Conversely, mothers’ knowledge about the 
infectious spread of diarrhea and preventive measures are protective [88,91].  
Longitudinal studies of childhood diarrhea have incorporated hierarchical and random 
effects modeling techniques to simultaneously assess proximal and distal causes of diarrhea 
incidence and duration. A study among children aged 0-36 months in northeastern Brazil was 
analyzed using an effect decomposition strategy to explain hierarchical relationships among risk 
factors for diarrhea, including socioeconomic status, sanitary and living conditions, child and 
care related-data, hygiene behavior, intestinal parasitic infections, and disease history indicators. 
The authors report direct effects of poor sanitation conditions and child and care-related 
variables such as prenatal examination during antenatal care visits, height-for-age z-score, and 
intestinal parasitic infections on increased risk for diarrhea. The observed effect of low 
socioeconomic status on diarrhea incidence was mainly mediated by lack of sanitation, 
inadequate neighborhood infrastructure, and poor housing conditions. Poor sanitation conditions 
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had the largest effect among children aged 13-36 months [25]. Socioeconomic status was also 
highly associated with duration of diarrhea, an effect also likely mediated by environmental 
conditions and hygiene behaviors [75]. 
Interventions to improve water, sanitation, and hygiene have demonstrated improvements 
in both diarrheal rates and longer-term morbidity, including growth and cognitive development 
[105]. For example, a meta-analysis of hand washing interventions found an overall 32% 
reduction in diarrhea burden associated with the interventions in LMICs [106]. Similarly, a study 
of the effect of a city-wide sanitation program on diarrhea prevalence found that improved 
connection to a sewerage system reduced diarrhea prevalence among children under 3 years of 
age in Brazil [107]. Improved sanitation reduced the association between poverty and diarrhea in 
this area, further supporting the evidence that diarrhea is associated with low socioeconomic 
status through poor sanitation and environmental conditions among the poor [108]. However, 
interventions to improve water, sanitation, and hygiene must be appropriately implemented to 
meet local needs. Latrine promotion and construction alone, for example, without education and 
consistent use may not be effective, as was the case in a rural sanitation program in Odisha, India 
[94]. Overall, these studies suggest age, nutritional status, and recent diarrhea burden are 
important host risk factors for diarrhea, while sanitation and hygiene have the largest impact on 
diarrheal risk among the environmental factors. 
 
Diarrhea and growth 
 Malnutrition is both a risk factor and outcome of diarrhea, resulting in a bi-directional 
relationship between increased susceptibility to infection and poor growth outcomes. This often 
termed, “vicious cycle,” was first characterized in the 1960s and was heavily studied in the 
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1970s and 1980s [109,110]. Studies of the cyclical association between diarrhea and growth have 
been discussed in great detail and are complicated by issues of temporality, confounding by host 
and environmental factors, and modification of effects by age, growth parameter analyzed, and 
duration of follow-up [3,5,109,111–113]. The cycle between enteric infection and malnutrition in 
children is associated with intestinal damage, malabsorption, and impaired immune response. 
Outcomes of the cycle include growth failure and decreased fitness and cognitive function. 
Several opportunities for intervention to interrupt components this cycle are available, including 
drugs and vaccines against enteric pathogens, nutrient supplementation, modification of the 
microbiota, and interventions towards clean water and sanitation [114]. 
 Undernourishment, as measured by height and weight measurements below the 
international growth reference standards, has been associated with an increase in diarrhea 
incidence and duration in the two months to one year following anthropomorphic measurement. 
Multiple studies have demonstrated an increase in duration of diarrheal disease in 
undernourished children [6,54,68,111,115–118]. For example, weight-for-age z-scores below -3 
were associated with an approximate doubling of average duration of diarrhea in the following 
two months among children under 5 years of age in Brazil [115]. Effects of malnutrition on 
diarrhea incidence are less pronounced, with effect sizes (e.g. risk ratios) for the association 
between undernourishment and diarrhea incidence between 1 and 2 [68,115,119–122]. Several 
studies have reported no association between weight and/or height and diarrhea incidence, often 
when controlling for confounding by socio-economic status indicators [116,117,119]. For 
example, an intervention that gave a daily lipid-based nutrient supplement to Haitian infants aged 
6–11 months in an urban slum did not reduce diarrhea prevalence despite improvements in linear 
growth [123]. As etiologic information on diarrhea episodes has become more common, studies 
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have explored the effect of malnutrition on etiology-specific diarrhea episodes, and results 
remain mixed. Weight and height-for-age z-scores were not associated with Giardia infection in 
the first 3 years of life in Peru [124]. In Bangladesh, weight-for-age z-scores below -2 were 
associated with incidence of diarrhea due to  ETEC, Cryptosporidium sp., and Entamoeba 
histolytica, but not other bacterial or viral diarrheas in children 2-5 years of age [125]. 
Growth failure as an outcome of diarrhea has been thoroughly characterized in the last 5 
decades. Early documentation of growth charts showed that while children in LMICs may follow 
average growth trajectories in the first 6 months of life while breastfeeding, growth stalls and 
children fall below the average growth curve as repeated episodes of diarrhea and other 
infections accumulate [109,111,112,126,127]. Subsequent studies have corroborated the 
evidence towards an effect of diarrhea on malnutrition in South America, South Asia, and Africa 
[27,54,57,117,128–150]. The associations are nuanced by definition of exposure (prevalence 
versus incidence of diarrhea) and duration of effects (long versus short term). Measures of 
longitudinal prevalence (proportion of time spent with diarrhea) have demonstrated the largest 
effects on growth parameters and are often used as the most relevant predictors of growth 
outcomes [144]. Evidence that prolonged and persistent episodes of diarrhea have larger impacts 
on weight and height compared to acute episodes (<7 days) support the conclusion that total time 
with diarrhea is an important predictor of growth [54]. 
Many early studies focused on the short-term impact of diarrhea on growth, such as 
effects on anthropomorphic measurements 1 to 3 months following diarrhea ascertainment. 
Short-term effects of diarrhea on weight 
[27,54,57,117,128,130,131,133,134,136,139,142,144,148,150,151], and to a lesser extent on 
height shortfalls [27,54,57,128–130,133–135,139,142,148,150], have been consistently 
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demonstrated. These results have been challenged by the hypothesis of “catch-up growth,” such 
that rebounds in growth during and after convalescence negate a majority of the short-term 
effects of diarrhea. Several studies confirm that effects on growth may be transient [124,133–
135,137,144,145,152], while others have found that effects sustain for up to several years 
[117,128,137,138,140,143,147,149]. Opportunity for catch-up growth is modified by age, 
nutritional status, the pathogen causing diarrhea, and burden of recurrent diarrhea and other 
common illnesses [113,153,154]. Younger children often face the most serious growth shortfalls, 
and malnourished children of low socioeconomic status (who face higher burden of illness 
overall) may be less able to recover from growth deficits [3,118,134,135].  
A recent meta-analysis of 7 cohort studies in Peru, Brazil, Guinea-Bissau, and 
Bangladesh demonstrated short-term (1 month) associations of diarrhea prevalence with weight 
at all ages under 24 months. While weight shortfalls were transient, effects on height were more 
apparent in the long-term, as children with average or greater diarrhea burdens were 0.38 cm 
shorter than children without diarrhea at 24 months of age [4]. Similarly, a multi-country 
analysis identified linear associations between both cumulative diarrheal incidence and 
longitudinal diarrhea prevalence with the log odds of stunting (height-for-age z-score ≤ -2) at 24 
months of age. Specifically, the pooled odds of stunting increased by 16% (95% confidence 
interval (CI): 7, 25) for every 5% increase in longitudinal diarrhea prevalence [155].  
 Biological mechanisms for the effect of diarrhea on growth involve reductions in nutrient 
availability due to direct loss and intestinal malabsorption, increased metabolic needs, tissue 
degradation, and decreased nutrient intake due to disease-induced anorexia or withholding of 
food [111,156–159]. Healthy absorptive function of the intestinal tract is most important in the 
first few years of life when nutrients are needed for normal growth and development of the brain 
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[45]. Sustained exposure to pathogens can cause environmental enteropathy (or 
tropical/environmental enteric dysfunction), a frequently subclinical condition termed the 
“impoverished gut,” which is associated with living in poor unhygienic environments and results 
in impaired function and structure of the small intestine. The intestinal villi of people with 
environmental enteropathy have reduced surface area such that they are decreased in height or 
even flat, resembling a flatter leaf-like structure rather than the normal fingerlike structure. These 
changes reduce the ability to absorb nutrients, such as sugars, nitrogen, fats, and micronutrients 
[3,111,113,160–164]. Studies of infants in tropical countries have shown that these changes in 
villus architecture occur during the first few months of life, which suggests malabsorption and 
associated growth failure among children in these areas begins at an early age [163]. In a study 
of largely malnourished Indian children with chronic diarrhea, almost three-quarters showed 
abnormal histology of the jejunum and approximately two-thirds showed atrophy of villi [165]. 
In addition, chronic intestinal inflammation associated with environmental enteropathy 
leads to elevated immune response and increased permeability of the intestinal tract, which 
allows pathogens to more easily cross the intestinal barrier [3,111,113,160–163]. Continuously 
high levels of cytokines and increased blood leptin concentrations may also contribute to the 
suppression of appetite associated with disease [113]. Indicators of intestinal permeability, such 
as the lactulose:mannitol urinary excretion ratio, and indicators of chronic immunostimulation, 
such as fecal lactoferrin, have been associated with growth faltering in animal models and human 
studies [3,45,111,113,163,166–168]. For example, the highest values of an enteric enteropathy 
score, based on fecal levels of alpha-1-antitrypsin, neopterin, and myeloperoxidase, were 
associated with linear growth deficits of about 1 cm over 6 months in the first year of life among 
children across several LMIC sites [169]. Nutrition interventions aimed at strengthening the 
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immune system, improving mucosal barrier function, and compensating for malabsorption have 
been able to offset the negative effects of diarrhea on growth, indicating the importance of 
gastrointestinal health in mediating the relationship between diarrhea and malnutrition 
[3,5,111,113,170]. 
  The effects of diarrhea on growth have been extended to effects on cognitive function, 
school performance, fitness, and chronic disease later in life. Longitudinal diarrhea prevalence 
has been negatively associated with cognitive outcomes such as intelligence quotient (IQ), age at 
starting school, appropriateness of age for the current school grade, and other cognitive tests 
[140,171–175]. The association between diarrhea and cognitive function is likely not a direct 
effect, but mediated by poor growth outcomes associated with diarrhea [172]. Diarrhea in the 
first two years of life has also been correlated with reduced fitness at 6–9 years of age as 
assessed by the Harvard Step Test [175]. In the last few years, links have also been made 
between early childhood diarrhea and metabolic syndrome later in life. Increased diarrhea 
burdens and associated growth faltering are followed by an increase in risk factors for 
cardiovascular disease, such as dyslipidemia, hypertension, and glucose intolerance, several 
decades later [3,176,177]. 
 The sum of evidence points towards substantial long-term effects of childhood diarrhea 
on gastrointestinal function, malnutrition, growth, cognition, and risk for chronic disease. These 
findings have prompted several researchers to recommend updating the calculations for diarrhea 
disability adjusted life years (DALYs) to include long-term morbidity associated with diarrhea 
[178,179]. Interventions that improve nutrition and reduce diarrheal disease burden may impact 
multiple elements of the complex relationships among these outcomes.  
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Available and recommended treatments 
 Improved treatment of acute diarrhea in children with oral rehydration therapy has been 
largely responsible for the drops in diarrhea-related mortality in children under 5 in the last few 
decades [45]. The World Health Organization (WHO) recommends that treatment of diarrhea 
involve three main tenants: fluid replacement to prevent or treat dehydration, zinc 
supplementation to reduce severity and duration of the episode, and continued feeding to prevent 
malnutrition [10]. Caregivers should give more fluids than usual, ideally appropriate homemade 
fluids containing salt (referred to as recommended home fluids), to children with diarrhea but 
without signs of dehydration  [10,180]. Oral rehydration therapy with oral rehydration salts 
(ORS) solution given orally and intravenously is preferred for addressing moderate and severe 
dehydration respectively. The currently recommended ORS solution is a low osmolarity mixture 
of glucose and several salts dissolved in water [10]. ORS alone can effectively treat 90% of 
diarrheas with some dehydration. ORS containing cooked rice powder instead of glucose may 
provide additional benefit by reducing the rate of stool output [181]. Children should be fed a 
normal diet appropriate for their age throughout the episode, including breastfeeding for young 
children [10]. 
Zinc supplementation (10-20 mg/day) for 10 to 14 days is recommended for all children 
with diarrhea. Supplementation replaces zinc lost during diarrhea and reduces risk of a 
subsequent diarrhea episode in the following 2 to 3 months [10,182]. A Cochrane review of trials 
for zinc supplementation during diarrhea concluded that zinc reduces duration of acute and 
persistent diarrhea among children greater than 6 months of age, especially among children with 
signs of moderate malnutrition. However, this effect may be reversed among young infants 
[183]. Zinc also reduces the proportion of children with diarrhea persisting more than 3 and 7 
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days, and may have a protective effect against hospitalizations and death [183–185]. 
Unfortunately, the uptake of this recommendation has been suboptimal in many settings. 
Antidiarrheal drugs, such as adsorbents, antimotility drugs, and bismuth subsalicylate, 
have no practical benefit and can be dangerous in children. Therefore, they should never be 
given for treatment of acute diarrhea. Anti-protozoal drugs are also rarely indicated [10]. 
Recently, the antisecretory drugs racecadotril and diosmectite have showed some evidence of 
reducing stool output and duration, though contradictory results have also been reported and 
these drugs are not recommended in India [186–188]. 
A large variety of probiotic formulations are available as supplemental treatment for 
diarrhea. However, a minority of strains have been found to conclusively provide benefit, 
specifically Lactobacillus rhamnosus GG and Saccharomyces boulardii, which both reduce 
duration of diarrhea. Optimal timing and dosing of probiotic treatment is unknown. In addition, 
randomized control trials of probiotics have almost all been completed in populations from high-
income countries, and effectiveness in LMICs has not been demonstrated [186,187]. Treatment 
guidelines in India do not recommend probiotics given the lack of evidence in Indian populations 
[188].  
 
Antibiotics 
Antibiotics are not recommended for routine treatment of acute or persistent diarrhea, 
except for acute bloody diarrhea (dysentery) and suspected cholera with severe dehydration. 
Because acute bloody diarrhea is likely to be caused by Shigella, children should receive 
ciprofloxacin for 3 days or another antibiotic effective against local Shigella such as ceftriaxone 
or pivmecillinam for 5 days. Many common antibiotics are ineffective for treatment of 
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shigellosis and should not be considered, including metronidazole, streptomycin, amoxicillin, 
tetracyclines, chloramphenicol, sulfonamides, hydroxyquinolines, nitrofurans (nitrofurantoin, 
furazolidone), aminoglycosides (neomycin, gentamicin, kanamycin), and first and second 
generation cephalosporins (cephalexin, cefamandole) [10,189–191].  
Suspected cholera should be treated with doxycycline, tetracycline, or erythromycin [10]. 
Appropriate antibiotic treatment of cholera reduces stool output and duration of diarrhea, which 
reduces fluid loss, necessity of hospitalization, and shedding of V. cholera in stool [181]. 
Diagnosed, laboratory-confirmed infections should be treated following standard guidelines, but 
antibiotics should not be used for presumptive treatment. For example, only laboratory-proven, 
symptomatic infection with Giardia duodenalis, Entamoeba histolytica, and amoebiasis should 
be treated with metronidazole [10,181]. Some have recommended that severe or prolonged 
diarrhea cases with potential for complications such as sepsis or intravascular coagulation should 
be treated with antibiotics [191]. In special populations, such as severely malnourished children 
and children with signs of septic shock, broad spectrum antimicrobials, such as gentamicin and 
ampicillin, can be given when admitted to a hospital [10].  
Antibiotics are contraindicated for the majority of acute diarrhea because: 1) most cases 
are self-limiting regardless of etiology; 2) antibiotics are not effective against most pathogens 
associated with diarrhea; 3) antibiotics may have adverse reactions and make the illness worse in 
the long-term; 4) antibiotics needlessly increase cost of treatment; and 5) indiscriminate use may 
increase resistance of disease-causing organisms to antibiotics [189,191,192]. Clinically, it is not 
possible to distinguish diarrhea episodes that might be effectively treated with antibiotics, such 
as those caused by ETEC, from those that do not respond to antibiotics, such as those caused by 
rotavirus and Cryptosporidium [10]. Even if pathogens are isolated in the stool, they may not be 
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the causative agent of diarrhea given the substantial asymptomatic prevalence of enteric 
pathogens in stools of children in LMICs. Antibiotics that are given inappropriately increase the 
risks for persistent diarrhea and other adverse outcomes, including hemolytic uremic syndrome 
in EHEC infections and prolonged carriage and shedding of Salmonella [53,78,193]. In addition, 
treatment with antibiotics may reduce focus on, delay, or even replace recommended treatment 
with ORS, zinc, and continued feeding [189,194]. 
Treatment with antibiotics is complicated by high prevalence of pathogens resistant to 
many common antibiotics. Local information on antibiotic sensitivity profiles of the causative 
microbe is needed to choose the appropriate antibiotic for treatment, but is generally not 
available [10]. Outbreaks of Shigella resistant to more than three antibiotics have been reported 
in India. Specifically Shigella isolates from 2001-2005 in the Indian Subcontinent (India and 
Bangladesh) were found to be resistant to cotrimoxazole (sulfamethoxazole/trimethoprim; 99% 
isolates resistant), nalidixic acid (97% isolates resistant), and ciprofloxacin and/or norfloxacin 
(38.5% isolates resistant). Almost all isolates, however, remained sensitive to 
cefixime/ceftriaxone. Median percentage of Shigella isolates resistant to more than three 
antimicrobials (multidrug resistant) was 97% across study sites [187]. Similarly, Vibrio cholera 
has been reported to be resistant to cotrimoxazole, ampicillin and furazolidone, though almost all 
isolates from a clinic in Uttar Pradesh, India in 2006 were sensitive to the recommended 
treatment with doxycycline [187]. 
 
Antibiotic prescribing patterns 
 International organizations as well as Indian national organizations, including the WHO, 
UNICEF, the Indian Academy of Paediatrics, and the Ministry of Health, Government of India, 
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recommend against the routine treatment of diarrhea with antibiotics [10,188,195]. However, 
antibiotic treatment of diarrhea is widespread in India, mirroring high levels of inappropriate 
antibiotic use around the world. Multiple surveys of prescribing practices for diarrhea have been 
undertaken in India to gauge the level of inappropriate use and identify potential strategies for 
improving rational treatment rates. 
The majority of studies have been completed in the hospital setting and report antibiotic 
prescription rates for acute childhood diarrhea ranging from 0% to 90% [196–203]. For example, 
among children aged 6 months to 5 years with acute diarrhea (without dysentery, severe 
malnutrition, or any systemic illness) at an outpatient department of a medical college in West 
Bengal in 2009-2010, 88.7% and 74.7% were prescribed an antibiotic by a general practitioner 
and pediatrician respectively—82.5% overall [203]. At a New Delhi medical college in 2005, 
53% of outpatient prescriptions by pediatric residents for acute watery diarrhea included 
antibiotics [199]. Antibiotic prescription rates were similarly high among primary and secondary 
health care facilities. Among rural and urban government (public) and private facilities at four 
sites including Vellore, India in 2008, 71% of patients of all ages received an antimicrobial 
prescription for diarrhea, and 78% of patients with fever and diarrhea were prescribed 
antimicrobials [204]. Presence of fever was associated with antibiotic prescriptions in several 
studies; 100% of children aged 1-12 years presenting with fever and diarrhea at a private primary 
healthcare facility in Chennai in 2005 were prescribed antibiotics [7,198,202,204,205]. 
Fluoroquinolones were the most commonly reported drugs prescribed for diarrhea across 
several studies, specifically norfloxacin, ciprofloxacin, and ofloxacin in combination with the 
antiparasitic, ornidazole [9,201,202,206,207]. Norfloxacin was also commonly combined with 
metronidazole in a study from Darjeeling, West Bengal [208]. Private providers tend to prescribe 
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antibiotics more frequently than public providers, and higher medical education is associated 
with lower antibiotic prescription rates [9,205,207]. In addition, patients of higher 
socioeconomic status and with more educated mothers are more likely to receive antibiotic 
prescriptions compared to patients of less-educated and lower socioeconomic status families 
[7,204,207]. 
Studies of antibiotic usage in the community are less common than studies of antibiotic 
prescription rates. NFHS-3 recorded antibiotic usage and reported that among children under 5 
who had diarrhea in the two weeks preceding survey, 16% reported treatment with antibiotics 
and another 30% were treated with unknown drugs [8]. The proportion reporting antibiotic use 
nationwide had declined from 32% in the first NFHS survey (NFHS-1) [7]. However, use 
practices varied by state, and the proportion treated with antibiotics in the state of Tamil Nadu 
(8.5%) during NFHS-3 was half that of the national average [8]. The UNICEF 10-district survey 
in 2009 estimated that only 5.6% of most recent diarrhea episodes in the 10 surveyed districts 
(3.8% in Krishnagiri district, Tamil Nadu) had been treated with antibiotics. Service providers 
reported they gave antibiotics to children if there was blood in the stools, the child was vomiting, 
or the child showed signs of severe dehydration [43].  
Access to antibiotics in India is controlled by the Central Drugs Standard Control 
Organization. In the Drugs and Cosmetics Act 1940 and Rules 1945 (updated in 2005), 
antibiotics are classified as “Schedule H” drugs, which cannot be purchased over the counter 
without the prescription of a registered medical practitioner [209]. However, these regulations 
are not well-enforced and antibiotics are widely available in pharmacies without a prescription 
[210]. In the 2011 National Policy for Containment of Antibiotic Resistance, the Government of 
India acknowledged misuse of antimicrobials. The document includes strategies to establish a 
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monitoring system and to better enforce current regulations, including a separate schedule, H1, 
which would have unique provisions applied exclusively to the sale of antibiotics [211]. Despite 
the ongoing effort to regulate antibiotic use, the drugs are still commonly available in local 
pharmacies and can be purchased by caregivers without consulting a qualified doctor.  
Mothers and other caregivers find antidiarrheal drugs acceptable and desirable since they 
perceive that treatment with these drugs is effective in stopping diarrhea quickly [210]. Because 
treatment with ORS solution does not reduce stool volume or duration of diarrhea, caregivers 
may question its efficacy and turn to other drugs [181]. Physicians often cite parental pressure as 
a reason for prescribing antibiotics and antibiotic prescription rates are associated with 
physicians’ perceptions of patients’ expectations [210,212,213]. Several strategies for reducing 
inappropriate antibiotic use that address these tendencies have been proposed. A randomized 
effectiveness trial of zinc supplementation in acute diarrhea determined that antibiotic use was 
approximately half as prevalent in the group receiving zinc compared to the control group [214]. 
Zinc decreases the duration of diarrhea and may reduce the incentive for caregivers to give 
antibiotics when diarrhea persists. In addition, the simple receipt of zinc tablets to treat the 
diarrhea may satisfy mothers who associate pills with better treatment. A doctor working in a 
community health clinic in Vellore, India noticed his trend; once doctors at the clinic began 
giving zinc tablets for diarrhea treatment, the demand for antibiotics decreased [215]. Others 
have suggested that rapid diagnosis of rotavirus may also reduce inappropriate antibiotic 
prescribing for diarrhea by providing direct evidence that antibiotics would not be effective for 
that specific episode [216]. 
A recent study of the quality of healthcare for childhood diarrhea in rural Bihar, India 
found a large gap between provider knowledge and practice with respect to antibiotic prescribing 
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for diarrhea [217]. In structured interviews, the majority of providers (72%) said they would 
prescribe ORS for uncomplicated diarrhea, and about a quarter (27%) said they would prescribe 
antibiotics in addition to ORS. Another 21% said they would prescribe antibiotics or other 
medicines without ORS. In interactions with standardized patients, however, almost all providers 
(89%) prescribed antibiotics or other harmful drugs, and only 17% of these prescriptions were 
given in combination with ORS. The large difference between knowledge of appropriate diarrhea 
treatment (as demonstrated through interviews) and practice (as demonstrated through 
interactions with standardized patients) suggests other incentives drive antibiotic prescribing 
practices beyond provider knowledge. 
Antibiotic treatment of other childhood illnesses is similarly common around the world, 
especially for uncomplicated cases of acute gastroenteritis (AGE), upper respiratory infections 
(URI), and acute otitis media (AOM) [218–220]. Antibiotic treatment is also often unnecessary 
for these illnesses since most cases are self-limiting regardless of etiology [221,222]. Again, 
antibiotics are not effective against viral pathogens often responsible for these illnesses 
[218,223,224], and antibiotics may have adverse reactions or make the illness worse [191,218]. 
Correspondingly, international organizations, including the World Health Organization, 
recommend against routine use of antibiotics to treat URI [10,188,218]. Treatment of AOM with 
antibiotics is more controversial and is recommended for the youngest children. However, 
deferred antibiotic treatment is often preferred in uncomplicated cases [221,222,225–227]. In the 
northeastern US, one third of mothers reported that their child received antibiotics before 6 
months of age [12]. This prevalence was nearly equivalent to that (32%) reported in a 
longitudinal birth cohort in the UK [11], though a separate study in Pennsylvania reported only 
14% were exposed in early infancy [228]. Given greater access to antibiotics without 
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prescriptions in low and middle income countries, we would expect similar or higher antibiotic 
usage rates in India. 
Since their discovery in the mid-20th century, antibiotics have quickly become a common 
exposure among children around the world, even among young infants below 6 months of age. 
While antibiotic prescription and usage rates vary across patient settings and geographic areas, 
misuse of antibiotics has been documented across India. Major concerns often focus on the 
development of pathogen resistance to antibiotics, but direct harm to patients due to 
inappropriate antibiotic use is also possible and often overlooked [15]. An improved 
understanding of the effects of this common exposure on short and long-term health is needed. 
  
Effect of antibiotics on diarrhea 
Antibiotic-associated diarrhea 
 Discussions of the impact of antibiotics on diarrheal risk most often focus on short-term 
effects of antibiotic treatment and the incidence of antibiotic-associated diarrhea (AAD). AAD is 
a broadly defined disease that is characterized by any diarrhea that cannot be explained by 
another cause occurring within 8 weeks of exposure to antibiotics [229,230]. Severity of AAD 
ranges from uncomplicated diarrhea to bloody diarrhea and pseudomembranous colitis [229]. 
Early onset of diarrhea within 2 to 7 days of antibiotic treatment is common and onset is 
generally earlier in children than adults. However, delayed onset 2 to 8 weeks after completing 
antibiotic treatment has also been reported [231].  
 The prevalence of AAD among patients treated with antibiotics is estimated to range 
from 5 to 25% depending on the type of antibiotic received, host factors, and hospitalization 
status. Inpatients generally have higher rates of AAD than outpatients [13,229,230]. Other host 
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factors that increase risk for AAD are young (<6 years) and old (>65 years) age, underlying 
disease or comorbid illness, immunosuppression, and history of AAD [13,230,232,233]. 
Pediatric prevalence of AAD is not well known, and no studies have been completed in India. 
Estimates from around the world have been 6.2% (Thailand), 11% (US), 16% (Finland), and 
17% (Poland) of children who received antibiotics developed AAD. A Cochrane review of trials 
of probiotics among children 0 to 18 years for pediatric AAD prevention found prevalences of 
AAD in control groups ranging from 11% to 22% [234]. A study from the United States found 
highest incidence among kids aged 2 months to 2 years [235]. 
 All antibiotics may potentially be implicated as the cause of AAD, though antibiotics 
with broad-spectrum activity are most often responsible, especially those targeted against 
enterobacteria and anaerobic bacteria. Antibiotics with high intraluminal concentration in the 
intestinal tract, which means that they are poorly absorbed in the upper intestine and reach the 
colon in high concentrations or are secreted in the intestine through bile ducts, result in the 
highest risk for AAD [230,236]. Longer duration of antibiotic therapy, including prolonged or 
repeated therapy, and combination therapies also increase risk for AAD [13,236,237]. Second 
and third generation cephalosporins, ampicillin, amoxicillin, amoxicillin-clavulanate, 
clindamycin, and broad-spectrum penicillins have the largest effects on risk of AAD 
[13,236,238,239]. Fluoroquinolones, tetracyclines, and macrolides have also been implicated in 
patients with AAD in multiple studies [236,240]. Estimates of AAD prevalences for specific 
antibiotics include approximately 5-10% of patients treated with ampicillin, 10-25% treated with 
amoxicillin-clavulanate, 15-20% treated with cefixime, and 2-5% treated with other 
cephalosporins, fluoroquinolones, clarithromycin, azithromycin, erythromycin and tetracycline 
[230,239].  
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 The microbes responsible for AAD include Clostridium difficile, Klebsiella oxytoca, 
Clostridium perfringens type A, Candida albicans and other Candida sp., Salmonella, and 
Staphylococcus aureus [13,238,239]. However, no etiologic agent can be identified in 
approximately 60% of AAD cases, and their etiologies are unknown [229]. Colloquially, C. 
difficile is most often associated with AAD, but the prevalence of C. difficile toxin in stool 
samples from patients with AAD is generally only 10-20% among hospitalized patients [230]. 
Other researchers estimate that up to one-third of AAD cases are attributable to C. difficile [229]. 
In children, this proportion is estimated to be lower, between 2.5 and 18% [235,241]. In the 
Indian pediatric population, 3.6% of AAD was associated with C. difficile in 1994, and a chart 
review from an Indian tertiary care hospital in 2008 reported that 6.3% of 60 pediatric AAD 
cases were associated with C. difficile. Studies from Brazil, Europe, and the United States 
suggest the incidence of C. difficile-associated diarrhea acquired in the community may be 
increasing in children [235,241]. 
C. difficile-associated diarrhea (CDAD) is generally characterized by more severe 
diarrhea and is responsible for almost all cases of pseudomembranous colitis [229]. Similar 
antibiotics have been implicated in CDAD as in non-C. difficile associated diarrhea, especially 
clindamycin, cephalosporins, and penicillins, which are broad spectrum but have little activity 
against C. difficile [230,238,239,242]. Conversely, metronidazole has been associated with 
decreased risk of CDAD [237]. Initially, fluoroquinolones such as ciprofloxacin were not 
thought to be a major cause of CDAD given they do not have a large effect on anaerobes in the 
gastrointestinal tract [230,240]. Newer fluoroquinolones, however, such as moxifloxacin, 
levofloxacin, and gatifloxacin, have greater activity against anaerobic microorganisms in vitro 
[242]. Correspondingly, more recent reviews, while still showing mixed results, suggest that the 
30 
 
overall evidence demonstrates fluoroquinolones play a role in CDAD, even if not necessarily 
greater than other broad spectrum antibiotics [242,243].  
Longer-term effects of AAD and CDAD have been documented in the recurrence of 
symptoms [229,235]. Approximately 15-60% of patients with CDAD will experience recurrent 
disease, which increases length of hospitalization, risk of medical complications, usage of 
antibiotics, and associated costs. Patients with recurrent CDAD also present with more severe 
disease [229]. Overall, information on AAD from LMICs is rare, and studies within Indian 
pediatric populations are needed to understand burden, risk factors, and potential opportunities 
for prevention [235]. 
 
Other effects 
Studies of the effects of antibiotics on diarrheal risk outside of AAD and CDAD are rare. 
However, inappropriate treatment with antibiotics was a risk factor for diarrhea becoming 
persistent among children below 5 years of age in Pakistan in 1993-1994 [244]. Studies from 
Bangladesh and India also found that prior antibiotic treatment was associated with persistent 
diarrhea [245]. In addition, prior antibiotic treatment has been associated with increased 
susceptibility to E. coli, Salmonella, Shigella and Campylobacter infections and with longer 
duration of infection compared to patients who did not receive antibiotics [246–248]. Antibiotic 
treatment also reduces the inoculum required to cause infection with Salmonella [248]. 
Supplementation with beneficial bacteria, Lactobacilli species, and the yeast, Saccharomyces 
boulardii, have shown the opposite effect of antibiotics by reducing viral shedding and the 
duration of rotavirus-associated diarrhea [249].   
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Long-term effects of antibiotics on chronic disease have also been documented, 
especially for asthma and other allergic diseases. These effects are hypothesized to be due to 
reduced exposure to microbes, failed development of regulatory immune responses, and 
promotion of the T-helper type-2 (TH2) immune response [250,251]. Other immune-mediated 
pathologies, especially autoimmune disorders, have also been attributed to lack of exposure to 
microorganisms early in life [251]. Because it could take months or longer for the body to return 
to a pre-antibiotic exposed state, long-term increased risk for infections after antibiotic treatment 
is biologically plausible [231]. However, the effects of antibiotics on long-term diarrheal risk are 
unknown, especially among populations with high incidence of diarrhea such as children in 
resource-poor settings. 
 
Maternal antibiotic use 
Other potential exposures to antibiotics beyond direct administration involve exposure in 
utero and ingestion through breast milk among infants whose mothers are treated with 
antibiotics. Women who give birth by Cesarean section are commonly given prophylactic 
antibiotics prior to surgical incision [252]. Women who test positive for Group B Streptococcus 
are also given antibiotics at the beginning of labor to prevent early-onset group B strep disease in 
their infants [24]. These treatments may expose infants to antibiotic effects before and during 
delivery. After delivery, antibiotic treatment of mothers may affect their children through breast 
milk. Recommendations for drug use among women while breastfeeding are based on limited 
data, but lactating mothers are commonly advised to discontinue breastfeeding while taking 
antibiotics due to concerns about increased risk of diarrhea in the infant [253–257]. Some 
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antibiotics are considered to be consistent with breastfeeding, while others are contraindicated 
among lactating women due to reasons unrelated to diarrhea and are not discussed here.  
Almost all (90-99%) breastfeeding women receive medicines within the first week post-
delivery [254]. A study of women delivering at the Christian Medical College (CMC) in Vellore, 
India estimated 37.8% of postpartum mothers were prescribed antibiotics for up to 6 weeks after 
delivery in 1989. Almost all women having a Cesarean section received antibiotics (96.0%) 
compared to 35.7% and 20.8% of women receiving antibiotics among instrumental and normal 
deliveries respectively. Most women received the drugs prophylactically (73.5%), while the 
remainder of prescriptions were therapeutic. However, 37% of women receiving prophylactic 
treatment had their prescription extended due to infection or other complication. Cephaloridine 
was the most common drug prescribed, followed by penicillin/gentamicin combination. These 
drugs were commonly combined with metronidazole [258]. Similarly, in Chandigarh in 1990, 
90% of women who delivered in a tertiary care hospital (45% Cesarean sections) were prescribed 
antibiotics. However, this proportion was much lower (13%) among women delivering in a 
community hospital or at home. In this setting, ampicillin was most widely prescribed [259]. 
Non-compliance among mothers is common given concerns about transferring the antibiotics to 
infants through breast milk [254]. 
Estimation of infant exposure to antibiotics through breast milk is difficult to determine 
given the myriad factors that affect transfer of drugs into breast milk and subsequent absorption 
in the infant, such as gestational age, time since delivery, maternal factors, inherent 
characteristics of the drug and drug bioavailability, maternal dosage history, amount of breast 
milk consumed, and time of antibiotic ingestion relative to infant feeding [254,256,260]. Because 
most antibiotics are excreted in breast milk, breastfed infants will likely be exposed, but to a dose 
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much lower than that received by the mother (<1-10%) [254,260]. The clinical relevance of this 
exposure is not well described, but likely minimal [254]. In addition, because antibiotics are 
usually prescribed for short periods of time, the infant’s exposure is likely to be transient 
[255,258]. However, newborn infants and infants born prematurely or with comorbidities are at 
higher risk of adverse events [255].  
β-lactam antibiotics (penicillins, ampicillin, amoxicillin), aminoglycosides, tetracyclines, 
cephalosporins, vancomycin, and nitrofurantoin are found in low concentrations in breast milk, 
and low drug bioavailability suggests low risk for their use in breastfeeding mothers 
[254,255,261]. However, the possibility of diarrhea in the breastfeeding infant due to penicillin 
or cephalosporin exposure has been suggested, though there is no large scale evidence of this 
phenomenon. Fluoroquinolones, macrolides, sulfonamides, clindamycin, and azithromycin are 
found in higher concentrations in breast milk, but negligible concentrations are observed in the 
breastfed infant suggesting the exposure to these antibiotics through breast milk is not clinically 
relevant. Data on exposure to metronidazole and chloramphenicol is limited and long-term 
effects on infant health are unknown [254,261], though no adverse effects of metronidazole 
exposure through breast milk have been reported [257]. 
One case report described a 2-month-old infant with perforated pseudomembranous 
colitis after exposure to ciprofloxacin through breast milk, though evidence of causation is weak 
[254]. Another case report documents bloody diarrhea associated with exposure to gentamicin 
and clindamycin through breast milk [256]. In the study of prescribing practices in Vellore, one 
out of 539 infants developed diarrhea while the mother was taking ampicillin [258]. 
Development of pseudomembranous colitis due to C. difficile after exposure to clindamycin 
through breast milk is a concern, but is expected to be rare. Evidence of diarrhea and rash among 
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breastfeeding infants associated with penicillins and sulfonamides have also been documented as 
rare adverse events [255]. While macrolides and, to a small extent, azithromycin can cause 
diarrhea due to affinity for the motilin receptor, these drug effects have not been consistently 
documented among breastfed infants [254].  
Because a majority of breastfeeding women receive medicines after delivery, better data 
on infant exposure to drugs through breast milk and resulting health effects are needed. 
Unnecessary interruption of breastfeeding withholds the many benefits of breastfeeding for the 
infant and should be advised carefully [254]. 
 
Mechanism through the microbiota 
 The hypothesized mechanism for the effect of antibiotics on diarrhea involves 
modification of the gastrointestinal (GI) microbiota. The GI microbiota refers to the complex 
community of microorganisms, including bacteria, archaea, and fungi, inhabiting the human 
gastrointestinal tract. Approximately 1014 microbes live in the GI tract, outnumbering the host’s 
human cells by an order of magnitude and composing up to 60% of fecal matter [20,262]. The 
total number of genes across the collective species of the microbiota, termed the microbiome, is 
2-4 million, which is 100-150 times greater than the number of human genes [18,22,263]. The 
microbiota has evolved through millennia of host-microorganism interactions resulting in a 
commensal and symbiotic relationship [21]. The microbiota can be considered a functional organ 
that plays indispensable roles in the homeostasis of human hosts [22,263,264]. Members of the 
microbiota are mutualists in that they serve functions for the host and also benefit from the 
nutrient-rich environment in the host [14,265]. Because the majority of bacteria in the 
gastrointestinal microbiota cannot be cultured, early studies of the microbiota that relied on 
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bacterial culture likely provide a skewed representation of microbiota composition. Newer 
molecular techniques, which most commonly amplify and characterize nucleic acids from the 
16S rRNA conserved gene through terminal-restriction fragment length polymorphism, 
denaturing/temperature gradient gel electrophoresis, and high-throughput sequencing 
technologies, have allowed much higher resolution in the analyses and closer examination of the 
complex and diverse communities of the microbiota [266]. 
 
Microbiota development  
 The microbiota develops early in infancy. Exposure to microorganisms as a developing 
fetus is limited, though the intestinal tract of the fetus during pregnancy is not sterile as 
previously assumed [21,22,267,268]. Childbirth provides the first major opportunity for 
microorganisms to colonize the gastrointestinal tract, and mode of delivery has a large effect on 
the types of organisms that are first introduced to the neonate [269]. For example, infants who 
are delivered vaginally acquire microorganisms from the mother’s vaginal and gastrointestinal 
flora, especially Lactobacillus, Prevotella, and Bifidobacterium. Conversely, babies delivered by 
Cesarean section are colonized by organisms common to the skin and non-maternally derived 
environmental bacteria, such as Staphylococcus [21,268,270]. The microbiota of Cesarean 
section infants is initially less diverse, and intestinal colonization by Lactobacillus, 
Bifidobacterium, and Bacteroides is delayed [20,21,271].  
Hygiene practices during delivery also affect the establishment of the microbiota. 
Relatively clean deliveries in high-income countries reduce exposure to bacteria and may delay 
establishment of the microbiota. Infants delivered in LMICs are exposed to a higher bacterial 
load and have a more diverse microbiota early in life [271–274]. Cesarean section babies from 
36 
 
LMICs acquire bacteria common to the intestine in addition to skin and other environmental 
bacteria, suggesting fecal contamination of the hospital environment in these settings [274]. 
Vaginally born and Cesarean section born infants in Pune, India were found to be colonized in 
high levels by Acinetobacter spp. and C. difficile respectively [275], suggesting high exposure to 
potential pathogens in this setting. 
Individuals vary greatly in terms of microbial composition, and in contrast to the adult 
microbiota, the microbiota of infants is unstable and dynamic [23,262,264]. Infants residing in 
the same geographic area had microbiotas with wide variation in composition over the first year 
of life. However, the similarities between microbiotas of twins suggest common genetics and/or 
environmental exposures contribute to the distinctive characteristics of microbiotas across infants 
[276]. The greatest changes in composition of the microbiota occurs during a process of bacterial 
succession throughout infancy, in which diversity increases with time [267,277]. Initially, the 
gastrointestinal environment in the infant is aerobic and encourages colonization of aerobes and 
facultative anaerobes, including enterobacteria and Firmicutes, specifically Enterococcus, 
Streptococcus, Staphylococcus, and Lactobacillus [20,271,278,279]. However, early colonizers 
reduce oxygen levels, which results in the growth of obligate anaerobes, such as 
Bifidobacterium, Clostridium, and Bacteroides [262,268,271,278,280]. The weaning process, 
with the introduction of solid foods, induces a major change in the microbiota [281,282]. The 
microbiota starts to resemble that in the adult gastrointestinal tract by 1 year of age and almost 
completely by 3 years of age [21,23,262,268,277,283]. However, at 2 years of age, facultative 
anaerobes are more often found in children compared to healthy adults, and complete 
resemblance to the adult microbiota in level of diversity does not occur until later in childhood 
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[268,277]. Differences in microbiota composition soon after birth could have effects in the 
intestine for up to 7 years [21]. 
Other factors influencing microbiota composition early in life include genetic factors, 
geography, breastfeeding and diet, health and microbiota of the mother, gestational age, family 
structure, and exposure to antibiotics [21,23,262,264,268,279–281,283–286]. Preterm infants 
have immature gastrointestinal tracts and colonization of the intestine is delayed, resulting in 
lower diversity of the microbiota [23,263,284]. The differences in microbiota composition of 
breastfed infants compared to older children (no longer exclusively breastfed) and adults were 
initially described using culture techniques in the late 1960s [287]. Oligosaccharides abundant in 
breast milk are unable to be fully digested by infants and instead are consumed by and enrich the 
microbiota, especially Bifidobacterium [288–290]. Correspondingly, the predominant bacteria in 
the microbiota of breastfed infants are Bifidobacterium and Lactobacillus [22,277], while infants 
fed with formula milk have a more complex microbiota that is more similar to the microbiota of 
adults [23,270,271,277]. Taken together, the determinants of the microbiota suggest full-term 
infants born vaginally and who are exclusively breastfed have the “most beneficial” microbiota 
composition, with many Bifidobacterium and fewer E. coli and C. difficile [23,280,291].  
Diet following the cessation of breastfeeding is also an important determinant of 
microbiota composition. Diets high in plant carbohydrates favor colonization by bacteria that are 
able to ferment dietary fiber [292]. Children from Burkina Faso with a high-fiber diet showed 
increases in Bacteroidetes and decreases in Firmicutes in comparison to European children with 
a modern western diet. An abundance of Prevotella and Xylanibacter, which contain genes that 
ferment cellulose and xylan, in the children from Burkina Faso suggests their high-fiber diet may 
have influenced the composition of their microbiotas to maximize energy intake from ingested 
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food [293]. It is likely that only long-term changes in diet (over months or years) are able to 
substantially shift the composition of the microbiota [294]. 
While the microbiota of infants are individualized and dynamic, the microbiota in adults 
is more stable and less modifiable by exposures and life events [295]. However, microbial 
populations are highly variable across populations and within populations over time [296]. The 
main bacterial phyla of the adult gastrointestinal microbiota are Bacteroidetes and Firmicutes, 
comprising over 90% of the total microorganisms [20,279,297,298]. Minor constituents include 
Actinobacteria (specifically Bifidobacterium), Proteobacteria, and Verrucomicrobia bacteria as 
well as methanogenic archaea, eukaryotes (mostly yeasts), and viruses/phages [296,298]. Most 
of the bacteria in the adult intestine are strict anaerobes, with aerobic and facultative anaerobes at 
much lower prevalences [272]. Adult human intestinal microbiota can be classified into three 
enterotypes which describe the three observed patterns of dominating taxa: Bacteroides in 
enterotype 1, Prevotella in enterotype 2, and Ruminococcus in enterotype 3. Prevalence of 
enterotypes is highly associated with diet; for example, diets heavy in protein and animal fat are 
associated with enterotype 1, while diets composed of mostly carbohydrates are associated with 
enterotype 2 [264]. However, other factors such as age, gender, nationality, and body mass index 
are not associated with enterotype. While the composition of organisms is different between 
enterotypes, they form similar functions and each create homeostasis [270]. Some speculate that 
the classification of enterotypes is artificial and they are not distinct, but instead lie on a 
continuum. Corresponding enterotypes among children have not yet been described [20].  
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Microbiota function 
The importance of the microbiota in human health was first postulated by Élie 
Metchnikoff in 1907, who thought certain gut bacteria poisoned the body. He associated longer 
lifespan with consumption of fermented milk containing beneficial lactic acid bacteria 
(Lactobacillus bulgaricus and Streptococcus thermophiles) [281,299,300]. In his book, The 
Prolongation of Life, he writes, “I think, therefore, that lactic bacteria can render a great service 
in the fight against intestinal putrefaction” [300].  
Research following Metchnikoff’s observations has demonstrated that the microbiota is 
important during early development for intestinal structure, metabolism, nutrition, and normal 
immune system development [21]. The functionality of the microbiota is encoded in 
approximately 20,000 microbial genes, a third of which are well-characterized [301]. While 
microbiota composition in terms of bacteria species can vary greatly, taxonomic diversity is not 
correlated with functional diversity, and the functions performed by the microbiota are similar 
across individuals suggesting there is functional redundancy across bacteria [296,301]. In 
addition, bacterial species exist in an interrelated network and rely on other bacteria for 
complementary functions which leads to correlated fluctuations in the abundances of 
functionally related species [301]. 
Most conclusions about the function of the microbiota are derived from studies of germ-
free mice, which have no intestinal microbes and can be functionally compared to normal mice 
[279]. The microbiota plays a role in developing the normal intestinal layer by affecting gene 
expression associated with angiogenesis and maturation of the intestine [22]. Germ-free mice do 
not fully develop intestinal blood vessels, and villus capillaries remain underdeveloped through 
adulthood [279,302]. In addition, germ-free mice have intestinal structural abnormalities 
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including enlarged cecum, dysfunctional gut-associated lymphoid tissue (GALT), and reduced 
intestinal surface area, epithelial cell turnover, and Peyer’s Patches [22,303]. The proliferation 
and differentiation of epithelial cells as well as the maturation of the intestinal mucosa and 
GALT requires signaling from the intestinal microbiota for complete development and 
recruitment of mature immune cells [265,301]. The microbiota therefore plays a role in intestinal 
barrier function, and aberrant microbial colonization early in life may increase permeability of 
the intestine and mucosal inflammation [22]. 
The microbiota also supports normal digestion and metabolic functions by affecting 
nutrient absorption and energy storage in the host [22,23]. A large number of novel genes are 
found in the microbiota which supplement the limited enzymes encoded in the human genome 
that metabolize complex carbohydrates and proteins [265,304]. For example, bacteria ferment 
remaining energy substrates from ingested foods to short chain fatty acids, breakdown proteins 
into their essential amino acids, and facilitate the extraction and storage of calories into host fat 
tissue [22,23]. Children from Burkina Faso were found to have more Bacteroidetes compared to 
European children, corresponding to more short-chain fatty acids, which provide beneficial anti-
inflammatory functions [293,305]. The microbiota also provides and metabolizes vitamins and 
other non-nutrient factors which are essential for human health [265,306]. Finally, the microbiota 
contributes to healthy sensory and motor gut functions by contributing to intestinal propulsive 
activity [302] and through the brain-gut- microbiota axis, which allows the microbiota to interact 
with the brain through neuronal cells and epithelial-cell and receptor-mediated signaling 
[22,267]. Recent evidence even suggests the microbiota plays a role in brain development and 
can subsequently influence adult behavior [301]. 
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The changes and development of the microbiota in the first few years of life coincide 
with a critical period of immune system maturation, such that the microbiota contributes to 
developing the immune system, and the composition of the microbiota and its access to body 
sites is reciprocally controlled by the immune system [279,303]. The microbiota contributes to 
the balance of T cell subsets, including regulatory T (Treg) cells and those involved TH1 and TH2 
type immune responses, which influences recognition of microbes by gut immune cells to initiate 
appropriate immune responses [22,303]. Deviations in microbiota composition have been 
associated with allergic and autoimmune diseases, such as inflammatory bowel disease (IBD), 
type 1 diabetes mellitus, and asthma, which are associated with pathological TH1 and TH2 
responses [23]. By stimulating lymphoid tissue in the gut mucosa, the commensal bacteria direct 
the immune system to recognize and produce antibodies (especially secretory IgA) against 
pathogens while not harming helpful bacteria, a process termed immune tolerance. This activity 
is mediated by the production of Treg cells and expression of toll-like (pattern recognition) 
receptors in the intestines which discriminate between commensal bacteria and pathogens 
[23,246,269,279,305,307]. In addition, the microbiota aids in the development of oral tolerance, 
in which the immune system does not respond to ingested food or self-antigens [22,269]. Germ-
free mice show reduced IgA antibody concentrations and lower concentrations of circulating B 
and T lymphocytes compared to normal mice, and correspondingly respond to infection and 
injury with ineffective immune responses [246,265,279]. 
 
The microbiota and diarrhea 
The first hypothesis that the intestinal flora protects against infection was proposed in 
1916 by the German scientist Alfred Nissle, and supporting evidence for this hypothesis 
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continues to grow [308]. In addition to the beneficial effects of the microbiota on immune system 
homeostasis described above, a healthy microbiota may protect against diarrheal disease through 
a barrier effect called competitive exclusion, such that members of the microbiota occupy 
intestinal mucosal sites which inhibits the attachment and growth of pathogens 
[14,299,301,309,310]. This process has also been referred to as colonization resistance or a 
barrier effect, in which the normal microbes are a barrier against colonization of pathogens and 
overgrowth of yeasts [302,308,311]. Commensal bacteria also discourage growth of pathogens 
by competing for nutrients, directly releasing inhibitory molecules, and impairing flagellar 
motility [14,302,308,309]. Because resident microorganisms are well-adopted to the intestinal 
environment, generally inhabit available metabolic and physical niches, and have established 
robust networks through biofilms, healthy microbiotas resist the establishment of pathogens that 
might cause diarrhea [265]. 
The role of the microbiota in affecting susceptibility to infection has been well-studied in 
mouse models, and early studies from the 1960s and 1970s showed the intestinal flora was 
antagonistic against Salmonella, Shigella, and Vibrio cholera infection [308]. Several other 
recent studies have found that a normal microbiota in mice successfully prevents colonization by 
Salmonella enterica serovar Typhimurium, likely through competitive exclusion. Conversely, 
mice with altered microbiotas due to antibiotic administration are more susceptible to intestinal 
infection and disease due to Salmonella and other enterobacteria such as E. coli [247,249,312]. 
One study showed a dose-response such that greater alterations to the microbiota led to higher 
colonization by S. enterica serovar Typhimurium, and more severe inflammation and intestinal 
pathology. Because the microbiota-modified mice did not have reduced total bacterial numbers, 
the alteration in bacterial composition appears to be responsible for the increased susceptibility 
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[312,313]. Further, modification of the microbiota through the antibiotic treatment of mice 
increased susceptibility to infection by vancomycin-resistant Enterococcus and C. difficile [312]. 
Increased susceptibility to pathogens may be partially due to reduced host-produced 
antimicrobial molecules when the microbiota is disrupted [247]. The clear association between 
the microbiota and susceptibility to infection has led some researchers to suggest that people 
with an altered microbiota are functionally immunocompromised and less resilient against new 
and opportunistic pathogens and recurrent infections [312].  
The association between the microbiota and susceptibility to viral infection and disease is 
not as well-understood. Studies have found examples both where intestinal bacteria are 
antagonistic to viral infection and where they promote viral infection [247,314,315]. For 
example, Bacteroides thetaiotaomicron and Lactobacillus casei have been shown to prevent 
infection of the intestinal epithelial cells by rotavirus in vitro. Similarly, mice with depleted 
microbiotas through antibiotic treatment or development in germ-free conditions are more 
susceptible to influenza compared to normal mice [247,314]. In this case, the microbiota appears 
to initiate, and may be required, for the immune response against influenza since mice with 
altered microbiotas showed reduced antibody titers and T cell responses [314,315].  
On the other hand, the GI microbiota has been shown to enhance replication and infection 
of other viruses [314,316,317]. Antibiotic-treated mice were less susceptible to poliovirus 
compared to mice with normal microbiotas, resulting in a mortality rate among normal mice 
twice that among antibiotic-treated mice. When bacteria were reintroduced to the antibiotic-
treated mice, the pathogenesis of poliovirus increased. Similarly, the pathogenesis of reovirus 
(another enteric virus) was enhanced in mice with normal microbiotas. The authors conclude that 
antibiotic-disruption of the microbiota may have anti-viral effects despite no direct action against 
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viruses [316]. A similar study demonstrated that mouse mammary tumor virus, a retrovirus, was 
more efficiently transmitted in the presence of a rich microbiota, and correspondingly virus 
transmission to offspring was reduced in antibiotic-treated mice and germ-free mice [317]. In 
vitro studies in mouse and human cell lines confirm that components of both Gram-positive and 
Gram-negative bacteria increase the infectivity of viruses [315]. 
Further, viral infections can enhance secondary bacterial infections suggesting a close 
interconnected relationship between the microbiota, bacteria, and viruses [314]. Astroviruses and 
rotaviruses increase the permeability of the gut mucosa, which compromises the immune 
response to a wide range of pathogens [249]. Recent evidence suggests that other disorders 
associated with the microbiota, such as IBD and Crohn’s disease, are mediated not only by the 
commensal bacteria, but also by enteric viruses [249]. Finally, the role of the microbiota in 
resistance to fungal infections has been demonstrated by the association of antibiotic treatment 
with fungal infections by Candida albicans [247,308]. 
The potential for dysbiosis of the microbiota to specifically cause acute infectious 
diarrhea in humans, in addition to infection more generally, has been less well-studied. Several 
researchers have documented changes in the microbiota during diarrhea. Most studies are cross-
sectional and compare the microbiotas of diarrhea cases and healthy controls. These studies 
excluded subjects who had recently taken antibiotics to ensure changes in the microbiota were 
associated with diarrhea alone. The first studies were conducted in the 1970s and 1980s and 
relied on bacterial culture to describe microbiota composition. Mata, in 1972, found that in the 
neonatal period, the microbiotas of children with severe diarrhea with dehydration showed a 
substantial decrease in anaerobes, especially Bifidobacterium and Bacteroides. E. coli and other 
enterobacteria comprised the majority of the flora, and Shigella was found in high numbers 
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[318]. Two studies from Vellore, India in the 1970s similarly documented that the proportion of 
aerobic to anaerobic bacteria was unusually high in diarrhea cases. Subjects with diarrhea had 
more enterobacteria and Staphylococcus, while healthy controls had more Bifidobacterium, 
Bacteroides, and Veillonella [319,320]. These studies suggest diarrhea may induce a more 
aerobic environment in the gastrointestinal tract, which promotes growth of aerobes over 
anaerobes. 
Since the advent of highly sophisticated bacterial DNA detection techniques, researchers 
have been able to identify large numbers of organisms in the microbiota that could not be readily 
cultured in earlier studies. These techniques have implicated the dysbiosis of the microbiome in 
many chronic gastrointestinal diseases in humans including enteric infections, especially C. 
difficile infection, small intestinal bacterial overgrowth, inflammatory gastrointestinal disorders 
such as irritable bowel syndrome (IBS) and IBD, and colorectal cancer [246]. DNA sequencing 
of the 16S rRNA gene (highly conserved across bacterial species) in fecal samples from patients 
with diarrhea-predominant IBS showed the microbiotas of IBS patients were less diverse and 
more instable over time compared to healthy controls [321,322]. Specifically, IBS patients had 
more enterobacteria, Veillonella, Prevotella, and Lactobacillus, and less Faecalibacterium, 
Bifidobacterium, and Verrucomicrobia compared to controls [321,323]. Similarly, patients with 
C. difficile-associated diarrhea (CDAD) and infants with C. difficile colonization had reduced 
diversity and high variability in fecal bacterial communities. Patients with C. difficile infection 
also showed reduced Firmicutes and Bacteroidetes populations [246]. Again, the ratio of 
facultative anaerobes to strict anaerobes was higher in patients with CDAD, and prevalence of 
Bifidobacterium was inversely associated with C. difficile [324–328]. Among a small sample of 
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men with diarrhea induced by an osmotic laxative, microbiota diversity was reduced and a shift 
in prevalent phyla was documented from Bacteroidetes and Firmicutes to Proteobacteria [329].  
Variations in the microbiota associated with acute (presumably infectious) diarrhea have 
also been demonstrated using molecular techniques in both high and low-income country 
settings. Diarrhea patients presenting to a hospital or clinic in the United States showed 
decreased diversity and overgrowth of selected organisms in fecal samples compared to healthy 
clinic controls [330]. Among children in Bangladesh, acute diarrhea was associated with 
decreased microbiota diversity, and cholera patients had reductions in Bacteroidetes, Firmicutes, 
and Actinobacteria, with an increase in harmful Proteobacteria [331,332]. Similarly, Colombian 
children who had diarrhea in the past 2 weeks had a reduced copy number for total bacteria in 
fecal samples and fewer Bifidobacterium and Lactobacillus. However, relative concentrations of 
bacterial species in diarrheal fecal samples varied across study sites [333]. The microbiotas of 
adult patients in China with viral diarrheas caused by adenovirus, norovirus, rotavirus, and 
astrovirus were less diverse and more variable compared to healthy controls. The dominant 
phylum in diarrhea cases was Firmicutes instead of Bacteroidetes, and Bacteroides, 
Bifidobacterium, and Lactobacillus were found in lower copy numbers among patients with 
diarrhea [334]. Children aged 3 months to 5 years with acute diarrhea and mild dehydration in 
Vellore, India had lower levels of Bacteroides-Prevotella group bacteria during diarrhea 
compared to 3 months after diarrhea, while no disturbance of Bifidobacterium was observed 
[335]. The same researchers showed asymptomatic rotavirus in neonates in the first month of life 
did not alter Bifidobacterium or enterobacteria counts in stool samples [336]. 
These studies have consistently documented changes in the microbiota during diarrhea, 
but do not establish temporality. It is not clear from fecal samples collected during the diarrhea 
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episode if diarrhea causes the modifications in the microbiome, if dysbiosis of the microbiome 
instead is a risk factor for diarrhea, or if both processes are possible. However, the evidence 
described above from animal models suggest dysbiosis of the microbiota increases susceptibility 
to infection and could therefore be an important risk factor for diarrhea.  
The role of the microbiota in diarrhea, susceptibility to infection, and other GI disorders 
is also supported by the success of fecal microbiota transplantation (FMT) in ameliorating GI 
disease. FMT involves introducing an entire microbial community to a patient through 
administration of a healthy donor fecal sample by enema, transcolonic infusion, or nasoduodenal 
or nasogastric infusion. The goal of FMT is to replace an unhealthy microbiota with a healthy 
one, and has been associated with increases in richness and diversity of the microbiota [328,337]. 
Few adverse events have been reported, and FMT has shown to be effective most commonly in 
treating C. difficile infection, but also in treating ulcerative colitis and IBS [337,338]. 
Supplementation of the microbiota with the probiotics, Bifidobacterium bifidum and 
Streptococcus thermophilus, in infant formula also resulted in reduced diarrhea incidence in a 
small study of children under 2 years of age [339]. The ability for a supplemented or replaced 
microbiota to improve GI disorders indicates the role of the microbiota in gastrointestinal 
pathogenesis. 
 
Antibiotics and the microbiota 
Antibiotic treatment is a major cause of disturbances to the microbiota that may induce 
diarrhea and predispose to other diseases. Because many commonly-used antibiotics target a 
broad range of bacteria, antibiotics are effective in killing not only pathogenic bacteria, but also 
beneficial commensal microorganisms in the gut [18]. By targeting a subset of the bacteria in the 
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microbiota based on drug activity, antibiotic treatment affects the relative abundance of 
organisms in addition to their absolute numbers. The substantial reduction of beneficial bacterial 
populations provides the opportunity for overgrowth of opportunistic pathogens and increase in 
disease severity [14,340]. Specifically, drug resistant bacteria are able to flourish under antibiotic 
selective pressure while sensitive bacteria are depleted [17,292,341,341]. For example, C. 
difficile is often found in low prevalences and is non-pathogenic until the normal flora is 
depleted by antibiotics and C. difficile is able to occupy newly available ecological niches 
[17,340]. Further, even if not directly targeted by the antibiotic, bacteria may be depleted due to 
dependences on targeted bacteria for nutrients, secondary metabolites, or waste product removal. 
For example, treatment with vancomycin reduced the abundance of Gram-negative organisms 
despite the restriction of antibiotic activity to Gram-positive bacteria [14,19]. 
The collateral damage from antibiotics to the healthy microbiota has been repeatedly 
shown to cause dramatic short-term changes to microbiota composition, wherein reduces in 
microbial diversity occur in the first few days of antibiotic exposure. Bacteria resistant to the 
antibiotic increase in numbers and dominate the microbiota until antibiotic pressure is removed 
and sensitive bacteria are found again in increased numbers. However, antibiotics can also cause 
lasting effects such that the microbiota does not fully recover to its pre-treatment state [18,20]. 
The magnitude and type of changes induced in the microbiota depends on the spectrum of 
bacteria covered by the antibiotic, the dosage, duration, and route of administration of treatment, 
and the pharmacokinetic and pharmacodynamic properties of the antibiotic [17,20,247,311]. 
While many studies of the effects of antibiotics on the microbiota have been completed in 
mice and other animal models, studies of the effects of antibiotics in humans have been more 
unusual. These studies often involve a small number of subjects and are complicated by baseline 
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variability in microbiota composition [248,286]. Because responses to antibiotics are 
individualized (large among-subject variability) and are influenced by prior exposure to 
antibiotics, aggregation of microbiota composition data across subjects may not produce valid 
results. Comparison of samples taken from the same individual before and after treatment are 
likely to be more interpretable [17,286,340]. Further, studies among sick patients with clinical 
indications for antibiotic treatment are confounded by effects the indicating illness may have on 
the microbiota [286]. However, results from human studies are consistent in that in nearly all 
studies across specific antibiotic exposures, antibiotics caused a sharp reduction in the abundance 
and diversity of organisms in the microbiota [17,18,292]. Antibiotic use has also been repeatedly 
associated with reductions in Firmicutes and Bacteroidetes and a concurrent increase in 
Proteobacteria [18]. 
Because the majority of bacteria in the human gastrointestinal tract are anaerobic, 
antibiotics that are active against anaerobic bacteria, such as clindamycin, may have the largest 
effects on the microbiota and normal GI functioning [17]. Broad spectrum antibiotics also have a 
larger impact compared to narrow-spectrum antibiotics active against few bacteria [251]. 
Because the microbiota of infants and young children is underdeveloped, relatively unstable, and 
highly susceptible to disturbances, antibiotic exposures early in life may delay normal intestinal 
colonization and have the largest and longest-term effects on the microbiota. Specifically, 
microbiota modifications are pronounced among infants under 1 year of age, and changes to 
microbiota composition last longer in neonates exposed to antibiotics compared to 10-month old 
exposed infants [20,251,280,291,340].  
Antibiotic use in infants has been associated with decreased numbers of Bifidobacterium 
and Bacteroides, and increased numbers of Clostridium, Enterococcus, Staphylococcus, and 
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enterobacteria in stool samples [19,247,268,280,283,297,340,342]. For example, one week of 
amoxicillin treatment for acute bronchitis among infants aged 1-2 years resulted in decreased 
total fecal bacteria and increased abundance of E. coli [343]. Antibiotic treatment of over 600 
European infants in the first 6 weeks of life was associated with higher relative proportions of 
enterobacteria (16.6% of total bacteria in infants treated with antibiotics versus 6.8% in untreated 
infants) [344]. Similarly, neonates given parenteral ampicillin and gentamicin with 48 hours of 
birth had more Proteobacteria and less Actinobacteria, including Bifidobacterium and 
Lactobacillus, than untreated neonates 4 weeks after treatment [345]. 
The evidence concerning long-term effects of antibiotics on the microbiota is mixed. The 
response of the microbiota over time to disturbances due to antibiotic exposure has been studied 
within an ecological framework, specifically assessing ecosystem stability and resilience 
[286,346]. The complexity of the microbiota community and the functional redundancy therein 
may contribute to the long-term resiliency of the microbiota in response to disturbances by 
antibiotics or other interventions [301]. Correspondingly, studies demonstrate that the majority 
of bacterial species return to their pre-treatment abundances relatively quickly. However, some 
species may not recolonize for an extended period of time (> 4 years) or not at all. Therefore, the 
recovery of the microbiota following antibiotic exposure is often incomplete 
[16,296,297,341,347–353]. For example, the composition of the microbiota of healthy volunteers 
almost fully returned to its pre-treatment abundances 4 weeks after oral treatment with 
ciprofloxacin for 5 days, but some bacterial taxa did not recover at 6 months post-treatment [16]. 
Similarly, alterations of some species in the microbiota persisted for up to 2 years following 
treatment with clindamycin for 7 days [292,352] and remained for up to 4 years after treatment 
with clarithromycin, metronidazole, and omeprazole for Helicobacter pylori  [354]. In infants, 
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overgrowth of enterobacteria after antibiotic treatment persisted to at least 1 month after 
treatment with cephalexin in the first 4 days of life [342]. Similarly, higher levels of 
Proteobacteria and reduced diversity of Bifidobacterium species due to parenteral treatment with 
ampicillin and gentamicin within 48 hours of birth persisted at 8 weeks of life [345].  
In addition to affecting the types and numbers of bacteria in the gastrointestinal tract, 
antibiotics further alter metabolic activities, vitamin absorption, and immune system 
development and functioning in the gut [17,251,280,355].  Antibiotic use resulted in altered 
amounts of metabolites found in mouse fecal samples, suggesting antibiotics affect pathways 
associated with sugar, nucleotide, and fatty acid metabolism in addition to bile acid, eicosanoid, 
and steroid hormone synthesis [14,356]. Alterations to the microbiota may also change our 
ability to metabolize drugs, resulting in differences in activation or inactivation, prolonged 
circulation, and increased toxicity of drugs [340,355]. Antibiotic exposure in the perinatal period 
has been shown to result in changes in gene expression associated with the developing GI tract, 
which may result in impaired GI functioning, intestinal inflammation, increased intestinal 
permeability, and increased risk of systemic infections [301,340,357]. Loss of bacterial signals 
and bacterial components that are recognized by the immune system impacts inflammatory and 
other immune responses, especially the development of regulatory lymphocytes [14,251]. Mice 
treated with antibiotics have shown reduced lymphoid tissue, neutrophil activity, TH1 responses, 
and interferon, cytokine, and IgG serum levels [19,251]. Antibiotics may even inhibit the 
development of protective responses after exposure to vaccines, while probiotics that enhance 
the microbiota may increase the immunogenicity of vaccines [315,358]. Finally, by selecting for 
resistant bacteria, antibiotic treatment increases the reservoir of resistance genes present in the 
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microbiota that could be transferred between species, potentially reducing the effectiveness of 
future antibiotic treatment in the individual [14,248,341,359]. 
 
Maternal antibiotic use and the infant microbiota 
The hypothesized mechanism for the effect of maternal antibiotic use on infant diarrhea 
also involves modification of the infant microbiota due to exposure to antibiotics in breast milk. 
Maternal antibiotic use during the perinatal period alters the developing microbiota in the 
neonate and may cause overgrowth of potential pathogens [251]. Changes in the microbiota may 
also mediate the effect of perinatal exposure to antibiotics on increased risk of necrotizing 
enterocolitis, cerebral palsy, and IBD [23]. The microbial diversity of infant stool samples was 
reduced in infants of mothers who were given antibiotics soon before delivery in one study 
[340], and antibiotic treatment of mothers prenatally or during breastfeeding was associated with 
lower total numbers of bacteria and lower proportions of Bacteroides and Atopobium in another 
[268,344]. However, the effects of antibiotic exposure in the infant due to treatment of the 
mother are likely to be weaker compared to direct antibiotic exposure. Cesarean section babies 
with mothers who were treated intravenously with broad-spectrum cefotiam hydrochlorlide in 
the first 4 days of life had similar types of alterations to the microbiota as babies directly 
administered antibiotics in terms of reductions in diversity and Bifidobacterium and overgrowth 
of Enterococcus, but the alterations were less pronounced [342]. Several studies have found 
antibiotic use during pregnancy has no effect on the infant microbiota [268,297].  
In sum, the evidence for substantial effects of antibiotic exposure on the microbiota, and 
the corresponding association between microbiota dysbiosis and increased susceptibility to 
infection, suggest a highly plausible mechanism for an effect of antibiotics on diarrheal risk. 
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However, the contribution of antibiotic treatment to diarrheal risk in young children in LMICs is 
unknown. 
 
Antibiotics, the microbiota, and growth 
Antibiotics may indirectly affect growth by increasing the number, duration, and severity 
of diarrhea episodes, which would in turn increase the risk for growth shortfalls as described 
previously.  However, antibiotics may also have a more direct effect on malnutrition and growth 
outcomes mediated by the changes in the microbiota. The hypothesis that antibiotics and the 
microbiota may affect growth originated in the food animal industry, where antibiotics are 
administered to animals at low doses for an extended period time in drinking water and 
commercial feeds [74,360,361]. The ability for antibiotics to promote growth in livestock has 
been documented since the 1950s. Antibiotic use for growth promotion increases the rates of 
weight gain, especially in poultry and swine, by up to 16% [74,360]. Although the specific 
mechanism is unknown, modification of the microbiota by antibiotics and alteration of the 
animals’ immune responses likely play a role in the growth promoting effect. Antibiotics have 
been shown to influence the diversity of the microbiota in chickens [362], and do not promote 
growth in germ-free animals, suggesting the microbiota is a necessary mediator of this 
phenomenon [361]. Because a variety of antibiotics increase growth, including macrolides, 
tetracyclines, penicillins, and glycopeptide, the effects do not appear to be specific to a certain 
drug class or type [360,363,364]. 
Analogous treatment to increase weight gain in malnourished children with long-term 
daily administration of antibiotics produced conflicting results in studies during the 1950s. 
Severely undernourished African children given aureomycin for 2-7 weeks had higher weight 
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gains than children given a placebo. Similarly, Guatemalan children fed 50 mg of aureomycin 
daily for 6 months grew larger in weight and height compared to children given placebos. 
However, there was no long-term height and weight advantage at 2 years after treatment, and 
penicillin had no effects on either height or weight gain. The authors of a review of these studies 
conclude that there was no evidence that prolonged treatment with antibiotics increased growth 
in children [74].  
However, short-term courses of antibiotics are widely used to treat acute malnutrition, 
and the WHO recommends that all severely malnourished children receive broad-spectrum 
antibiotics, such as gentamicin and ampicillin, for several days if admitted to a hospital [10]. 
Antibiotic use in this setting is thought to treat or prevent disease which allows children to regain 
weight as they recover. A study of malnourished Guatemalan children in 1972 found that 
children with protein-calorie malnutrition had more enterobacteria in the small intestine and an 
altered fecal flora compared to normal children [365]. Lack of dietary protein was linked to 
overgrowth of intestinal bacteria in the guts of children with kwashiorkor [366], and differences 
were found in microbiota composition between twins discordant for kwashiorkor [367]. 
Similarly, analysis of the microbiota from a malnourished child from an urban slum in Kolkata 
showed evidence of infection by gastrointestinal pathogens belonging to the 
Campylobacteraceae and Helicobacteraceae families, which may respond to antibiotics [368]. 
Correspondingly, amoxicillin and cefdinir have been associated with increased weight gain in 
undernourished Malawian children [360]. In a randomized trial of 7-day courses of amoxicillin 
or cefdinir for severe acute malnutrition among Malawian children under 5 years of age, 
recovery rates were 3.6-5.8% higher and mortality rates were 2.6-3.3% lower among children 
receiving antibiotics. The rate of weight gain was also faster among children receiving antibiotics 
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[369]. Antibiotic treatment likely affects the microbiota, which could contribute to the 
pathogenesis and recovery from undernutrition, through its impact on both nutrient metabolism 
and immune system functioning [370]. 
Antibiotics have also been associated with weight gain in children without malnutrition. 
Erythromycin increased daily weight gain in preterm infants with feeding intolerance [371]. 
Administration of sulfonamides and cotrimoxazole to prevent pneumonia and other 
complications after measles also increased weight gain among children in Guinea-Bissau [372]. 
Several other studies have linked tetracyclines, macrolides (especially azithromycin), and 
clarithromycin to weight gain in infants, older children, and adults [363]. Antibiotics in different 
settings may contribute to weight gain by preventing or treating infection and by causing changes 
in the composition of the microbiota, or both [363].  
Antibiotics given to infants in the first 6 months of life may have the largest effects on 
growth given antibiotic use at this age has been associated with being overweight later in 
childhood, while antibiotic use at 6-23 months was not shown to impact later growth 
[11,360,363]. However, this association is likely more nuanced, as antibiotics during the first 6 
months of life increased risk of overweight among Danish children of normal weight mothers, 
while it decreased the risk of overweight among Danish children of overweight mothers [373]. In 
a trial of annual versus biannual mass oral azithromycin distributions for trachoma in Niger, no 
significant difference in anthropometric measurements of preschool children were found, though 
biannually treated children had slightly lower odds of underweight, stunting, and wasting [374]. 
A recent meta-analysis of 10 randomized control trials of oral antibiotics in low or middle 
income countries concluded that antibiotics improved growth, though the summary effect sizes 
were likely not clinically significant (less than 1 mm/month difference in height and 24 g/month 
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in weight) [375]. These trials included the early studies mentioned above and therefore were 
conducted over a 60 year period and varied broadly in terms of indication for treatment, 
eligibility, and antibiotic intervention. An international cross-sectional study of antibiotic 
exposures in the first year of life also reported an adjusted increase in body mass index (BMI) 
associated with antibiotics at age 5-8, but only among males (+0.104 kg/m2). The effects varied 
across sites and a decrease in BMI was found in all countries classified as non-affluent except 
Thailand [376].  
The impact of antibiotics and the microbiota on growth, and specifically on weight gain 
and loss, has recently garnered renewed interest in light of the growing problem of obesity. 
Because the functional repertoire of the microbiota includes energy harvest and fat deposition, 
different compositions of the microbiota may be more efficient in energy uptake than others and 
therefore contribute to excessive weight gain in humans [377–379]. Recent studies have shown 
consistent differences in the microbiotas between lean and obese mice, specifically a shift in the 
ratio of Firmicutes:Bacteroidetes with a higher than normal abundance of Firmicutes in obese 
mice [363,380,381]. Germ-free mice have lower body fat content than normally raised mice even 
when the germ-free mice consume more food [382]. The body fat content of germ-free mice 
when colonized with the microbiota from a conventionally raised mouse increases by 60% 
within two weeks, even with reduced food intake [383]. When germ-free mice were colonized 
with the microbiotas from obese mice, they showed higher weight gain compared to germ-free 
mice colonized with microbiotas from lean mice. These mice had higher abundances of 
Firmicutes and correspondingly had increased energy extraction from food and up regulation of 
genes in the microbiome involved with carbohydrate and lipid metabolism [363,379]. 
Conversely, when the microbiotas from human infants with kwashiorkor were transplanted into 
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germ-free mice and the mice were given a diet similar to the infants’ diet, these mice lost 
significant weight, mirroring the phenotype of kwashiorkor [367]. These studies suggests that the 
microbiota in interaction with diet was responsible for the overweight and underweight 
phenotypes respectively.  
Because there are more genes involved in lipid and carbohydrate metabolism in 
Firmicutes compared to Bacteroidetes, researchers speculate that Firmicutes may contribute to 
greater energy harvest [382,384]. This hypothesis has been supported by concurrent increases in 
Firmicutes, increases in weight gain, and alterations of carbohydrate, lipid, and cholesterol 
metabolism, including an increase in fatty acids, in the guts of mice treated with antibiotics 
[382]. However, differences in metabolic function at the family and species levels indicate that 
there is not a uniform separation among species within the two phyla [363]. The 
Firmicutes:Bacteroidetes ratio may be an oversimplification and is likely modified by diet [380]. 
This conclusion is supported by human studies wherein the Firmicutes:Bacteroidetes 
ratio has been shown to be both increased and decreased among obese humans in different 
settings [363,380]. Among healthy adults in India, there was no clear association between the 
Firmicutes:Bacteroidetes ratio and obesity [385]. Actinobacteria, Lactobacillus species, and 
several other bacteria species have also been associated with obesity in different studies 
[363,381,386]. Among infants, higher levels of Bacteroides the first year of life was associated 
higher body mass index in the 2nd and 3rd years of life, taking into account several important risk 
factors for body mass index. In another study, increased body mass index associated with 
microbiota composition differences in the first year of life persisted to affect risk of overweight 
at 7 years of age [379].  
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These studies indicate large variation in the effects of specific bacterial species on weight 
gain, and some of these differences are likely due to methodological challenges. Cross-sectional 
studies prohibit the conclusion of a temporal relationship between microbiota composition and 
obesity, while observational longitudinal studies may be confounded by common risk factors for 
the microbiota and growth. In addition, sampling of the microbiota from the large intestine or in 
fecal samples may be misleading since most metabolic activities associated with the microbiota 
occur in the small intestine [361].  
 Recent epidemiologic studies from high-income countries have reported associations 
between antibiotic use and obesity. In a large study of Danish children, antibiotics in the first 6 
months of life were associated with increased risk of overweight at 7 years of age, but only 
among normal weight mothers [373]. Among overweight mothers, antibiotics slightly reduced 
risk for overweight in their children. However, antibiotic exposures were captured only for ear 
and lung infections, and the very low prevalence of antibiotic use under 6 months (7%) reported 
[373] compared to other studies in Denmark [387] and other high-income countries suggests 
antibiotic use may have been heavily under-reported. 
In a study of UK children, exposure to antibiotics under 6 months of age was associated 
with increased BMI and risk of overweight and obesity at 3 years, but the effect did not persist at 
7 years. Also, exposures between 6 and 23 months did not have a consistent effect on body mass 
[11]. In Philadelphia, antibiotic exposure in the first 2 years of life was associated with a minimal 
increase in overall risk for obesity from 2-5 years (Rate ratio: ~1.05), but the effect was larger in 
magnitude (Rate ratio: ~1.1) for greater number of antibiotic courses received, broad-spectrum 
antibiotics compared to narrow-spectrum and for earlier age (below 6 months) of first exposure 
compared to later age at exposure [228]. 
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These human studies of the effects of antibiotic use on growth are complicated by the 
diverse indications for treatment across studies. In a small study of patients receiving long-term 
treatment with doxycycline for Q fever endocarditis, a quarter of treated patients showed 
abnormal weight gain [388]. Similar studies of patients with infective endocarditis also showed 
increases in BMI associated with long-term antibiotic treatment, but only among those receiving 
vancomycin [389,390]. It is unclear if these effects are specific to patients with endocarditis or if 
they are relevant to a general population. 
Evidence that the microbiota affects growth is also supported by studies in which 
probiotic administration affects weight gain. Probiotics supplement the gut microbiota with 
organisms that are beneficial to the human host to create a healthier microbial community. The 
probiotics, Lactobacillus acidophilus, Lactobacillus fermentum, and Lactobacillus ingluviei, 
have been associated with weight gain in both animals and humans, while Lactobacillus 
plantarum and Lactobacillus gasseri have been associated with weight loss [391]. Several 
combinations of probiotics, sometimes in combination with milk formula or highly nutritious 
ready-to-use therapeutic food (RUTF), have also induced weight and/or height gain in children 
[360]. For example, a trial of infant formula supplemented with Bifidobacterium breve and 
Lactobacillus rhamnosus increased body weight and height in healthy infants [392]. On the other 
hand, different combinations of probiotics have also shown to reduce rates of weight gain and 
induce weight loss, suggesting the effects of probiotics on growth are complicated and likely 
organism-specific [360].  
Because the functional repertoire of the microbiota includes energy harvest and fat 
deposition, different compositions of the microbiota may be more efficient in energy uptake than 
others and therefore contribute to weight change in humans [377–379]. However, while the 
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microbiota likely plays a role in growth, it is not clear which compositions or specific species in 
the microbiota are most beneficial, and it is difficult to predict the effects of alterations of the 
microbiota due to antibiotics or probiotics. The interaction of the microbiota with metabolism 
may be modulated by antibiotic use to cause either weight gain or weight loss [24]. The effects 
of antibiotic use on growth in association with treatment for common childhood illnesses are 
unknown. 
 
Summary and rationale 
Diarrhea is a universal and recurring disease during childhood that causes high morbidity 
and substantial mortality. The negative effects of diarrhea on malnutrition, growth, and cognition 
indicate the need for improved strategies for prevention and greater coverage of effective 
treatment. Inappropriate and ineffective antibiotic treatment for diarrhea and other childhood 
illnesses is widespread in India despite national and international recommendations against 
routine treatment with antibiotics. Antibiotics cause modifications in the gastrointestinal 
microbiota which may increase susceptibility to future infection and modify nutrient absorption 
and growth. However, longitudinal studies of childhood diarrhea have not considered the effects 
of antibiotics on diarrheal risk. While studies of diarrhea associated with antibiotic use have been 
completed, most focus on diarrhea occurring concurrently or soon after antibiotic use (AAD), 
and longer term effects of antibiotics on diarrheal risk have not been studied. In addition, these 
studies are often focused on hospitalized adults in high-income countries, and few studies have 
been completed among children in low-resource settings. Further, recent human studies of the 
effects of antibiotics on growth, and specifically obesity, have not consistently shown an effect 
or identified key components to explain this phenomenon. The effect of antibiotic treatment in 
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early childhood on growth has not been studied in a prospective observational study among 
children from LMICs. 
To address these knowledge gaps, we aimed to assess the impact of antibiotic treatment 
among young children on diarrheal risk (Specific Aim 1) and growth outcomes (Specific Aim 2) 
before 3 years of age. We investigated the effects of antibiotic treatment of diarrhea, and any 
antibiotic exposures in the first 6 months of life, on future diarrhea, and estimated the impact of 
interventions that would prevent unnecessary antibiotic exposures. We also studied the effects of 
early life antibiotic exposures on both short and long-term growth. We hypothesized that the GI 
microbiota likely mediates the potential associations between antibiotics, diarrhea, and growth, 
as diagramed in Figure 2.1. Specifically, diarrhea or other illnesses result in antibiotic treatment, 
which modifies the microbiota and in turn affects immune system functioning. These changes 
may lead to increased susceptibility to subsequent diarrhea and result in poor growth. Microbiota 
modifications associated with antibiotic exposures may conversely also promote growth, given 
the established growth promoting effects of antibiotics in livestock and the association of 
antibiotics with obesity in humans.  
Laboratory and epidemiologic studies support the hypothesized biological mechanism for 
the effect of antibiotics on diarrheal risk through modification of the microbiota. Antibiotic use 
causes dramatic reductions in diversity of the microbiota and alters the composition of bacterial 
species, especially during infancy when the developing microbiota is most susceptible to 
perturbations [24]. This corresponds to an important period in early childhood when a healthy 
microbiota is critical for gastrointestinal tract and immune system development. The microbiota 
of patients with diarrhea have altered compositions, suggesting that the microbiota plays a role in 
diarrhea and that diarrheal risk could be affected by perturbations through antibiotic exposure. 
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Similarly, the microbiotas differ between malnourished versus normal children, and lean versus 
obese adults. Small-scale studies have shown mixed results concerning the duration of the effect 
of antibiotics on the microbiota [18] such that some suggest the microbiota returns to a pre-
treatment state within days or weeks of antibiotic exposure [286], while others show that 
antibiotics can cause long-lasting changes in the composition of the microbiota [17]. Therefore, 
it is plausible that antibiotic treatment could affect diarrheal risk and growth among children in 
both the short and long-term through modification of the microbiota, especially in a setting with 
high diarrhea incidence and overuse of antibiotics. 
We focused on antibiotic treatment for diarrhea specifically (Aims 1A and 1C) and any 
antibiotic exposure regardless of clinical indication in the first 6 months of life (Aims 1B and 2). 
The first exposure is directly relevant to the effects of potential interventions concerning diarrhea 
treatment. Our observational (non-randomized) study is analogous to a hypothetical clinical trial 
in which children are randomized to treatment with antibiotics or not at each time a diarrhea 
episode arises. Since we are unable to recommend changes in all antibiotic prescription practices 
because many illnesses require treatment with antibiotics, focus on only unnecessary antibiotic 
exposures for diarrhea treatment in Aim 1C better corresponds to potential public health 
interventions.  
On the other hand, because antibiotics for diarrhea may comprise a minority of total 
antibiotic exposures in children, an exploration of the effects of antibiotics regardless of clinical 
indication was also important to understand the basic etiology of the effects of antibiotics on 
diarrheal risk and growth. We focused on antibiotic use in the first 6 months since early life 
antibiotic exposure has the greatest impact on microbiota development and is likely to cause 
long-term changes in the microbiota [20,251,280,291,340]. Similarly, diarrhea during this time 
63 
 
causes longer-term growth deficits compared to diarrhea episodes at older ages, which suggests 
antibiotic exposures at this time may have the largest effect on growth outcomes. These two 
exposure definitions answer distinct yet complementary questions, one directly applicable to 
interventions and the other related to understanding general etiology. 
Understanding the effects of antibiotic treatment for diarrhea will help inform policy 
makers, physicians, and public health professionals to improve treatment guidelines and rational 
antibiotic use. While rational use of antibiotics has been advocated to reduce the development of 
pathogen resistance to antibiotics, evidence of direct harm to children who are given antibiotics 
may accelerate the adoption of policies and practices to reduce inappropriate use. Such evidence 
would counter a commonly held assumption among doctors and caregivers that even if 
antibiotics are not strictly indicated, “at least they can’t hurt.” This impact could occur at 
multiple levels: 1) the results may provide an evidence base needed by policy makers to enforce 
regulations that control the sale of antibiotics; 2) physicians could incorporate this evidence into 
their cost-benefit equation when deciding whether to give children antibiotics, reducing 
prescription rates, and 3) mothers and caregivers, who rarely respond to appeals about the future 
development of pathogen resistance, would have an easily understood and logical reason to avoid 
giving antibiotics to their children. Reduction of inappropriate antibiotic use in these ways would 
benefit not only the individual children, but also society as a whole. The efficacy of antibiotics 
would be preserved for the treatment of more serious human infections, and the prevalence of 
drug-resistant bacteria may decrease [393,394]. This is of critical importance given the potential 
for the loss of the ability to treat more serious infections as bacteria become multidrug-resistant.  
In addition, epidemiologic evidence that antibiotics increase risk for diarrhea will 
substantiate the rapidly accumulating laboratory-based evidence supporting a mechanism 
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through modifications of the microbiota. Further evidence of the effects of antibiotics on growth 
outcomes contributes to our understanding of the impact of inappropriate antibiotic treatment on 
long-term morbidity. Future follow-up studies may be developed from this study to assess the 
diversity and composition of the gut microbiota in stored stool samples from the children to 
better understand underlying biological mechanisms. These results may contribute in the future 
to the development of therapeutic and preventive interventions for diarrhea, such as those 
involving probiotics, that may stabilize and strengthen the microbiota.  
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Figure 2.1. Conceptual diagram showing the hypothesized biological mechanisms for the causal 
pathways between antibiotic treatment, subsequent diarrhea, and growth. Potential confounders 
are omitted from this diagram for simplicity. 
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CHAPTER III: RESEARCH METHODS 
 
Study design 
We completed secondary analyses of existing data collected in three cohort studies of 
452, 176, and 497 children respectively from semi-urban slums of Vellore, Tamil Nadu, India 
from 2002 to 2013 [28,395,396]. These cohorts provided highly detailed existing data on 
diarrhea incidence, duration, and severity, as well as record of antibiotics and other treatments 
for diarrhea. In two of the three studies, field workers visited enrolled children’s homes twice-
weekly from birth to 3 years of age and captured diarrhea incidence data based on a 3-day recall 
period. In the third study, children were followed weekly from birth to 2 years of age with 7-day 
recall. Study personnel recommended the children attend the study clinic when ill, and clinic 
records from these visits were linked to community follow-up data. Additional characteristics of 
each study are shown in Table 3.1.  
All three studies were supervised under one principal investigator using the same 
protocols with minor adjustments. There was consistent quality control of data collection and 
management. Because all three cohort studies were completed in the same source population by 
the same investigators, data were comparable across studies. The three cohorts had a high 
incidence of diarrhea (approximately half had 4 or more episodes in the first 3 years of life), and 
approximately one-quarter of episodes were treated with antibiotics. By using existing data from 
a population with high incidence of diarrhea, the study was practical, feasible, and inexpensive to 
conduct. 
67 
 
Source population 
 The source population was all children born in geographically adjacent, semi-urban slums 
on the western side of the city of Vellore, in the state of Tamil Nadu, India (Figure 3.1). Tamil 
Nadu is a state with high immunization coverage and good public health care delivery 
infrastructure [397]. The slums of Vellore cover 2.2 km2 and have approximate population 
densities of 17,000 per km2. The rainy season occurs between August and November, and peak 
temperatures during the summer months reach above 40°C.  
Residents form a relatively homogeneous population, and many families are long-term residents 
of the slums, which have less than 4% annual migration. Half of the households are Hindu, 45% 
are Muslim, and 5% are Christian. Manual production of tobacco-based cigarette-like products 
(beedis) for a daily wage is the most common occupation, while employment in unskilled work, 
domestic servitude, sweeping, and small trading is also common. Most households rely on the 
earnings from daily wages, without regular salaries or other benefits such as pensions and health 
insurance [395–397]. 
Rapid migration to urban areas in India in recent years has resulted in urban slum 
populations that are overcrowded, have poor housing conditions, and lack of clean water and 
sanitation infrastructure [396]. Tenancy and ownership of property is not secure, and houses are 
closely clustered with open drains and trash disposal [398]. Firewood is the primary cooking fuel 
in the slums of Vellore, and piped drinking water is supplied by the local municipality irregularly 
(at intervals of 2-28 days). This water is collected and stored in wide-mouthed containers and is 
often consumed without further treatment. Bore-wells and water tank trucks supplied by the 
Vellore Municipal Corporation provide alternative sources of drinking water when water is 
scarce [396]. Microbial contamination of the Vellore municipal water supply is common [399].  
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Residents have access to free government health services, including a physician-run 
urban health center (UHC) in the area and a government hospital ~5 km away. They can also 
access non-profit private health care providers, including the Christian Medical College Hospital 
(CMC) and its two outreach units—the Community Health and Development Hospital (CHAD) 
and the Low Cost Effective Care Unit (LCECU) [395]. Other private facilities, clinics, nursing 
homes, and traditional medicine and faith healers are also located in the vicinity. In addition, a 
physician-run clinic was established in the study area which provides free health care to study 
children. CMC study personnel have periodically completed health education campaigns in the 
study areas concerning the causes and outcomes of diarrhea in children and available treatment 
and prevention strategies. The infant mortality rate in this population estimated through 
community-based surveillance conducted by the UHC from 2008 to 2011 was 18.2 deaths per 
1000 live births per year, and 38% of infant deaths were attributed to diarrhea from 1995-2003 
[395,396]. 
This identified source population of young children was ideal for the proposed analyses 
since diarrhea incidence is highest in the first few years of life [2,40] and poor outcomes are 
associated with young age [30]. Regulation of antibiotics is low and correspondingly access to 
antibiotics is high in the slums of Vellore. Therefore, a substantial proportion of diarrhea 
episodes among children in this population experience were treated with antibiotics.  
 
Study population 
Information on study population, data collection, and laboratory analyses is summarized 
from published articles from the three cohorts and has been supplemented by discussions with 
the Principal Investigator and study team at CMC [28,62,171,395–410]. The study populations 
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consisted of children born in the study areas between March 2002 and August 2003, July 2008 
and May 2009, and April 2009 and May 2010, for the three studies respectively. Women of 
child-bearing age were visited through repeated household surveys and identified at local 
antenatal clinics in the study areas to identify pregnancies (or pregnancies and children who were 
being exclusively breastfed for Study 2). Children of pregnant women were enrolled through 
consecutive recruitment following written informed consent obtained from each child’s parent or 
guardian. Study 2 was a quasi-experimental study in which families received either bottled 
(n=90) or municipal (n=86) drinking water based on the street on which they lived. This cohort 
was not a birth cohort since children were recruited at birth or while they were still being 
exclusively breastfed. Inclusion and exclusion criteria across the three studies are compared in 
Table 3.2. 
 
Collection of clinical and demographic data 
Baseline information on demography (family size, number of siblings, sex, religion), 
socioeconomic indicators (socioeconomic status, maternal education, education and occupation 
of the head of the household), health-seeking behavior, environment, diet, and characteristics of 
delivery were collected within 45 days of birth. A score from the Kuppuswamy scale was 
assigned to each household as a measure of socioeconomic status (SES) based on educational 
and occupational level of the family, house ownership, total number of rooms in the house 
(excluding kitchen and bathroom), and household possessions. The scale ranges from 0-5; a 
score of 0 or 1 was considered low SES, 2 or 3 was considered middle SES, and 4 or 5 was 
considered high SES. 
70 
 
An assessment of water, food, and personal hygiene for each household was completed 
every six months through self-reported information and observation of: 1) treatment and storing 
of drinking water; 2) use of dedicated dippers to consume stored drinking water; 3) washing of 
foods, cooking vessels, and the breast prior to feeding; 4) hand washing before feeding the child 
and after defecation; 5) periodicity of bathing; and 6) details of toilets or other places of 
defecation. A household hygiene score ranging from 0-18, which has been previously validated 
in this population, was assigned based on inputs from the structured questionnaire. Households 
with scores at or above the upper tertile (≥12) were considered to have good household hygiene. 
For our analyses, the hygiene measurement of each child recorded closest to their time of 
weaning was considered representative of hygiene across the follow-up period since variability 
in hygiene scores over time was low and hygiene at the time of weaning is most critical to 
diarrheal risk. Children who dropped out of the studies before weaning occurred were assigned 
the hygiene score recorded at baseline (Study 1 and 3) or closest to the time of drop-out (Study 
2).  
Birth weight and length were obtained from delivery records if available at the first home 
visit. Thereafter, heights and weights were measured each month of follow-up at the study clinic 
using single measurements. Weight was measured using a Salter weighing scale to the nearest 
100 grams. Recumbent length was measured using a standard infantometer for the first year of 
life or until the child was able to stand, and subsequently height was measured with a 
stadiometer, both to the nearest millimeter. Relevant data types collected for each study are 
compared in Table 3.3.  
At each twice-weekly visit (once-weekly for Study 2) to the households of enrolled 
children, field workers interviewed the caregiver about any illnesses on each day since the last 
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visit. If an episode of diarrhea was identified during the visit or through self-referral by the 
mother, the field worker visited the home daily to assess diarrhea severity details including the 
number of stools passed per day, consistency and color of stools, any associated fever or 
vomiting, treatment given, and diarrhea among other members of the family. Because accurate 
temperature measurements were not possible in the field, temperatures were recorded as normal, 
low-grade fever, and high-grade fever as reported by the caregivers. Details of hospitalization if 
applicable and medications given were also recorded, including the name of antibiotics given 
(recorded as free-response). The family was instructed to collect stool samples when diarrhea 
developed, and samples were collected every other day until three samples were collected or the 
episode ended (1-3 stool samples per diarrhea episode). A window period of 15 days (7 days 
before and 7 days after diarrhea) was allowed for collection of stool samples.  
Regular home visits were also used as an opportunity to collect information on the 
incidence of other illnesses reported by the caregiver. Field workers encouraged the family to 
take the child to the study clinic for assessment of severity and appropriate treatment for diarrhea 
or for any illness caregivers felt might be serious. Field workers were also trained to identify 
other common morbidities by using standard definitions and to refer infants to a health facility if 
necessary. Children were referred to CHAD or CMC hospital when symptoms were severe, and 
illnesses were managed by physicians according to routine practice. The costs of care were 
covered by the study. Visits to other public and private healthcare facilities and physician-
recorded diagnoses in prescription or discharge summaries were recorded if available at home 
visits.  
Breastfeeding details were collected every two weeks until breastfeeding was stopped 
completely including the number of feeds per day and if liquid food, semi-solid food, and solid 
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food were given. In addition to samples collected during diarrhea, stool samples were collected 
from all children every 15 days (or monthly for Study 2). Exclusive breastfeeding was defined 
according to the standard WHO definition [411] as feeding with breast milk only with the 
exception of vitamins, mineral supplements, and medicines (no liquid, semisolid, or solid food). 
Field workers were retrained and study protocols were standardized periodically over the 
study period. Anthropometric instruments were calibrated at least once a week. The data 
collected by field workers were validated in a 10% random subsample on revisits by the study 
supervisor and/or physician. Morbidity data at the study clinic were also used to validate the 
information gathered by the field workers. Missing data was monitored through completion of a 
missing data form by field workers at each time data were not collected. Dates and types of 
missing data, reasons for missing data, and information on whether the child had diarrhea at the 
time of missing data were recorded. Drop outs were accompanied by an assessment of reason for 
drop out and details of death if applicable.  
Data were collected in standardized paper forms by field workers and double entered 
concurrently with data collection. Quality checks were completed at the time of data entry and 
through electronic logical checks before validation [397]. Because the proportion of missing data 
for baseline covariates was 5% or less, we imputed the median value for individuals with missing 
data. We assumed single imputation would result in negligibly over-precise confidence intervals 
given the proportion of missing values for these variables was small.  
 
Case definitions 
Assessment of diarrheal outcomes for Aim 1 was based on caregiver-reported diarrhea at 
home visits and by self-referral of caregivers to study personnel. We defined diarrhea as at least 
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three watery or loose stools in a 24-hour period. The episode ended on the day that the child’s 
bowel movements returned to normal. Duration of a diarrhea episode was defined as the number 
of days from the first day of watery stools until the last day of watery stools inclusive. We 
defined a new episode of diarrhea as occurring only after at least 48 hours from the last episode 
during which bowel movements were normal. Person-time at risk was defined as all days during 
follow-up excluding days with diarrhea and the 48 hours after diarrhea during which a new 
episode of diarrhea could not be defined. 
 Severity of diarrhea was assessed at each day of illness using a modified version of the 
Vesikari scale, which was designed to assess severity of acute watery diarrhea caused by 
rotavirus in children. The scale was modified such that fever was reported by the mother instead 
of measured by a thermometer, and symptom inputs for the scale were assessed throughout the 
episode instead of solely at admission. This modified version has been used in this population 
previously for rotavirus-associated diarrhea and cryptosporidiosis [412]. The 20-point score is 
determined by the total duration of diarrhea, the maximum number of stools passed in 24 hours, 
the duration of vomiting (if present), the maximum number of vomiting episodes in 24 hours, 
fever (in °C), the degree of dehydration, and treatment. An episode was classified as mild if the 
score was between 1 and 5, moderate if the score was between 6 and 10, severe if the score was 
between 11 and 15, and very severe if the score was between 16 and 20. 
The assessment of growth outcomes for Aim 2 was based on monthly anthropometrics 
taken at the study clinic. Steps to reduce bias due to measurement error were taken during data 
review completed at CMC. The standard deviation (SD) of the two measurements taken before 
and after each anthropometric measurement was calculated. Any measurements more than three 
SDs from these four measurements were recoded as missing. We also individually checked the 
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plausibility of measurements associated with the largest growth velocities between two 
measurements (top 1% of all such intervals). Implausibly large height or weight gains or losses 
in an interval resulted in the outlying measurement to be recoded as missing.  
We used the 2006 WHO child growth standards as the reference population to calculate 
height-for-age (HAZ), weight-for-height (WHZ) and weight-for-age (WAZ) z-scores from the 
growth measurements. Children were classified as stunted (HAZ <−2 SD from the growth 
reference), wasted (WHZ <−2 SD), underweight (WAZ <−2 SD), or normal.  
 
Exposure assessment 
Assessment of antibiotic treatment for diarrhea as the exposure for Aim 1A was based on 
self-reported treatment information given by caregivers. Fieldworkers asked caregivers at the 
time of the current diarrhea episode to report all medications given during that specific episode. 
Questions were asked specifically about ORS, antimotility drugs, and antibiotics. The name of 
the drug(s) was recorded and a copy of prescription(s) was attached to the data collection form if 
available for reimbursement purposes. Field workers also asked about traditional medicines, 
including herbal, Homeopathic, and Unani medicines. Antibiotic exposures were classified by 
reviewing drug names reported and categorizing them by generic name and class of antibiotic. 
Because exposure information was reported at the time of the diarrhea episode (presumably 
during treatment), it is unlikely that the exposure was affected by recall bias. However, 
respondents may not have known the type or name of the specific drug given, resulting in 
misclassification. 
While incidences of other illnesses among study children were recorded, treatments for 
these illnesses were not originally collected in the study protocols, and therefore antibiotic 
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exposures due to treatment for other illnesses were not available in the cohort datasets. For Aims 
1B and 2, to assess the impact of any antibiotic exposures (regardless of clinical indication), we 
obtained antibiotic exposures for other illnesses from antibiotic prescriptions in study clinic 
records for Study 2 and 3. We reviewed clinic records for study children during the study period 
to record all treatments for diarrhea (including antibiotics and others) and all antibiotic 
prescriptions for non-diarrheal illnesses assessed at the study clinic. We extracted the date of 
clinic visit, diagnoses given, drug prescriptions including dosage and prescribed duration if 
available, and any other relevant treatment information. Complete record of antibiotic 
prescriptions was available only for Study 3 since one-third of prescriptions to children in Study 
2 were not associated with a recorded Study ID number. We therefore restricted the analyses in 
Aims 1B, 1C, and 2 to Study 3. Exposure classification was derived from a combination of self-
reported treatment information given by caregivers during diarrhea episodes and drug 
prescriptions for all illnesses from clinic records. 
 
Sample size and participation rates 
 In Study 1, 914 pregnant women were identified and 452 children were sequentially 
found eligible and enrolled (Figure 3.2A). The most common inclusion criteria violation was that 
the mother did not intend to stay in the study area for 3 years, often because of a common 
cultural practice to relocate to the maternal village for several months after the birth of a child. 
Of 452 children enrolled, 391 children completed the first year of follow-up, 380 completed 2 
years of follow-up, and 373 completed the study at 3 years. Five deaths occurred, including 3 
that were associated with diarrhea and dehydration in the first year of life. The drop-out rate 
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across the three years was 17.5% and the median age at time of leaving the study was 4.4 months 
(interquartile range (IQR): 2.5, 33.6).  
In Study 2, 193 pregnant women and exclusively breastfed children were identified and 
eligible for participation (Figure 3.2B). After the attrition and refusal of 17 subjects during the 
antenatal follow-up period, 176 children were enrolled. Because Study 2 allowed enrollment of 
children after birth while still exclusively breastfeeding, the median age at baseline was 22 days 
(IQR: 12.5, 56). Of 176 children enrolled, 170 children completed 1 year of follow-up and 160 
completed two years of follow-up. The drop-out rate was 9.1% with a median age at dropout of 
16.3 months (IQR: 7.7, 19.4). None of the study children died during the two year follow-up 
period. 
In Study 3, 561 pregnant women were identified and eligible for participation (Figure 
3.2C). Following attrition during the antenatal follow-up period due to refusal, migration, and 
adverse pregnancy outcomes, 497 children were enrolled in the study. Of these, 443, 420, and 
410 children completed the first, second, and third study year respectively, resulting in a drop-
out rate of 17.5% and median age at time of leaving the study at 7.8 months (IQR: 4.1, 15.5). 
Nine children died during follow-up; 3 deaths were associated with diarrhea. In all three studies, 
the most common reason for dropout was migration from the study area.  
The total length of follow-up for the three cohorts was 1166.9, 311.6, and 1290.9 person-
years respectively. The total numbers of diarrhea episodes reported during this follow-up time 
were 1955, 807, and 2295 episodes, of which 27.5%, 6.6%, and 23.5% were treated with 
antibiotics in the three studies respectively. Children in Study 1 had on average 28.9 weight 
measurements and 28.1 height measurements over the three years of follow-up. Children in 
Study 2 had on average 21.6 height and weight measurements over 2 years of follow-up, and 
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children in Study 3 had on average 30.6 height and weight measurements over 3 years of follow-
up. 
 
Ethical approval 
The study was approved by the Institutional Review Boards of the Christian Medical 
College, Vellore, India, Tufts University Health Sciences campus, Boston, USA, and University 
of North Carolina – Chapel Hill, USA. 
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Table 3.1. Study design of three cohort studies of children in Vellore, Tamil Nadu, India 2002-
2013. 
 Study 1 Study 2 Study 3 
Study period 2002-2006 2008-2011 2009-2013 
Length of follow-up 3 years 2 years 3 years 
Type of cohort Birth Quasi-experimental 
(Open cohort) 
Birth 
Frequency of follow-up Twice weekly Weekly Twice weekly 
No. of children enrolled 452 176 497 
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Table 3.2. Inclusion and exclusion criteria for three cohort studies of children in Vellore, Tamil 
Nadu, India 2002-2013. 
 Study 1 Study 2 Study 3 
Semi-urban slum 
areas  
(total population of 
study area) 
Ramnaickanpalayam, 
Chinnallapuram, Kaspa 
(35,000) 
Ramnaickanpalayam, 
Chinnallapuram, 
Kaspa, Vasanthapuram 
(40,000) 
Ramnaickanpalayam, 
Chinnallapuram, 
Kaspa, Vasanthapuram 
(40,000) 
Dates of 
identification of 
pregnant women* 
November 2001-
August 2002 
September 2008-April 
2009 
March 2009-May 2010 
Birth dates of 
enrolled children 
March 2002-August 
2003 
July 2008-May 2009 April 2009-May 2010 
End of follow-up August 2006 May 2011 May 2013 
Inclusion criteria - Mother pregnant - Mother pregnant or 
child exclusively 
breastfed  
- Mother pregnant 
Exclusion criteria - Mother does not 
intend to remain in 
the area for 3 years  
- Birth weight <1500 g 
- Gross congenital 
anomalies  
- Residence in a brick-
built house with five 
or more rooms 
- Mother does not 
intend to remain in 
the area for 2 years  
- Birth weight <1500 g 
- Gross congenital 
anomalies 
- Mother does not 
intend to remain in 
the area for 3 years  
- Birth weight <1500 g 
- Gross congenital 
anomalies  
- Serologically positive 
for HIV 
*And recruitment of exclusively breastfed children in Study 2 
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Table 3.3. Clinical and demographic data collected from three cohorts of children in Vellore, 
Tamil Nadu, India 2002-2013. 
Data Type Study 1 Study 2 Study 3 
Demographics and 
socioeconomic 
indicators 
At baseline At baseline At baseline 
Delivery details At baseline At baseline At baseline 
Anthropometrics Monthly Monthly Monthly 
Hygiene practices* Monthly for first 6 
months, then every 3 
months 
Every 3 months for 
first year, then 
every 6 months 
Every 6 months 
Breastfeeding 
practices 
Every 2 weeks Every 2 weeks Every 2 weeks 
Diarrhea incidence, 
duration, and 
severity; active 
surveillance for other 
illnesses  
Twice weekly  
(3-day recall) 
Weekly  
(7-day recall) 
Twice weekly  
(3-day recall) 
Antibiotic treatment 
for diarrhea 
Yes Yes Yes 
Type of antibiotic No No Yes 
Duration and dosage 
of antibiotic use 
No No No 
*Sanitation practices were collected less frequently in later cohorts due to low variability of 
responses over time 
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Figure 3.1. Map [413] indicating the geographic residence of the study population in Vellore 
(black point) in the state of Tamil Nadu (dark gray), India (white).  
  
82 
 
 
 
Figure 3.2. Summary enrollment and participation flowchart of the three study cohorts in 
Vellore, Tamil Nadu, India 2002-2013. A – Study 1; B – Study 2; C – Study 3. Sum of 
individual exclusions does not equal total exclusions where individuals were excluded for more 
than one reason.  
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CHAPTER IV: ANALYTIC METHODS 
 
The statistical analysis methods varied for each aim to best answer the corresponding 
scientific questions of interest. In some cases, we applied relatively novel methods (Aim 1C) or 
adapted methods so that the results would be more interpretable with respect to our study 
questions (Aim 1A). In Aim 1A, we used inverse probability-weighted Kaplan-Meier (KM) 
curves to estimate differences in the time to subsequent diarrhea among children who received 
antibiotics for their most recent episode and those who did not. In Aim 1B, we used negative 
binomial regression to estimate the effect of any antibiotic exposure in the first 6 months of life 
on rates of diarrhea up to 3 years of age. In Aim 1C, we used the parametric g-formula with the 
same negative binomial model to estimate the impact of hypothetical interventions to reduce 
antibiotic use on diarrheal rates. To understand the effects of antibiotics on growth in Aim 2, we 
used longitudinal generalized linear regression with generalized estimating equations (GEE) and 
robust variance to account for within-subject correlation of the growth measurements. In short-
term analyses, we also compared results from this model to those from the fixed-intercept model. 
We assessed both continuous (WAZ, HAZ, and WHZ z-scores) and binary (underweight, 
stunted, and wasted) growth outcomes with linear regression and the Poisson approximation to 
log-binomial regression respectively. The cohort data from Study 3 was used in the primary 
analyses for Aim 1A, and exclusively for Aims 1B, 1C, and 2, since this was the only cohort 
with complete information on antibiotic treatment for non-diarrheal illnesses.  
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Aim 1A 
Analyses of the effect of antibiotic treatment for diarrhea on risk of subsequent diarrhea 
episodes was restricted to children who experienced at least one episode of diarrhea and 
therefore had the opportunity to be exposed. We included 434 of 497 (87.3%) children in Study 
3, 160 of 176 (90.9%) in Study 2, and 390 of 452 (86.3%) in Study 1 who had at least one 
diarrhea episode. We focused the analyses on Study 3, which was the most recent cohort and had 
complete information on antibiotic treatment for non-diarrheal illnesses. Because Study 1 and 2 
lacked complete records of antibiotics, and the type of antibiotics given for diarrhea were 
unknown, we presented the results from these cohorts as sensitivity analyses. 
The primary exposure was antibiotic treatment for diarrhea based on caregiver-report 
during the episode. To validate caregiver-report, we also used alternative definitions of exposure 
to antibiotics. First, we restricted the exposed group to only those children whose caregivers 
reported the name of a confirmed antibiotic in the free-response section of the questionnaire. 
Second, we considered children exposed if either their caregiver reported antibiotics were given 
(by indicating yes/no) or if an antibiotic prescription was recorded in clinic records during the 
diarrhea episode. Finally, we considered children exposed only if a confirmed antibiotic name 
was reported or if a prescription was recorded in the clinic records. 
We used logistic regression to calculate inverse probability of exposure weights 
stabilized by the marginal probability of exposure [414]. Confounding variables for the exposure 
model were chosen by causal directed acyclic graph (DAG; Figure 4.1) [415] to account for 
baseline characteristics and indications for treatment. Continuous variables were modeled 
flexibly with restricted quadratic splines [416], and covariate specifications were compared by 
Akaike’s information criterion. Final covariates selected and their specifications are shown in 
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Table 4.1. To remove extreme weight values [417], weights were censored at the 0.5th and 99.5th 
percentiles by resetting the value of weights greater than the 99.5th percentile and less than the 
0.5th percentile to the values of the 99.5th and 0.5th percentiles respectively. 
We estimated inverse probability-weighted KM curves [414,418] for the time to next 
diarrhea episode comparing children who did and did not receive antibiotics for the previous 
episode. The time scale [418] was from 48 hours after the previous diarrhea episode to the 
incident day of the next episode. Children were censored at drop-out, death, or the end of follow-
up at 3 years of age. We assumed person-time during which children were temporarily 
unreachable was missing at random and drop-out was non-informative given the small 
proportion of drop-outs (n=50, 11.5% overall; n=18, 4.1% between the first and second diarrhea 
episode). We calculated the time difference and time ratio at 50% diarrhea-free survival, the 
median survival time, from the weighted KM curves. Confidence intervals were constructed by 
bootstrap [419] with 200 resamples at the level of the individual to account for clustering of 
episodes within children.  
We also estimated hazard ratios comparing the same exposure groups using marginal 
structural Cox models [418] with the same inverse probability weights. These models were 
estimated by pooled logistic regression with adjustment for time using a restricted quadratic 
spline [416]. Correlation between outcomes from the same child was accounted for using 
generalized estimating equations with a robust variance estimator. 
We assessed modification of the effect of antibiotics by age at exposure by stratification. 
We also considered the effect of specific antibiotics commonly given (cotrimoxazole and 
cefixime) by comparing children receiving each drug with children given no antibiotics. To 
assess the impact of long episode duration contributing to shorter time between episodes, we 
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repeated the main analyses excluding all episode pairs where the first episode lasted for more 
than 7 days. 
To assess whether antibiotics were associated with the severity of subsequent diarrhea 
when another episode occurred, we estimated the effects of antibiotic treatment for the previous 
episode on the severity and duration of the next episode. In models weighted for the same 
covariates as in above analyses, we used inverse probability-weighted linear regression with the 
Vesikari score and number of days with diarrhea as continuous outcomes. We also estimated the 
adjusted relative risk for a severe (Vesikari ≥ 11) and prolonged/persistent (≥7 days) next 
episode using inverse probability-weighted log-binomial regression. 
 
Aim 1B 
To assess whether any antibiotic exposure in the first 6 months of life affected subsequent 
rates of diarrhea from 6 months to 3 years of age, we restricted analyses to Study 3, which had 
complete information on antibiotics given for non-diarrheal illnesses. We included 465 of 497 
(93.6%) children in Study 3 who remained in the study for more than 6 months and were 
therefore at risk for diarrhea after 6 months of age. We did not restrict to children with at least 
one diarrhea episode since diarrhea was not a prerequisite of antibiotic exposure in this analysis.  
The main exposures were any antibiotic exposure in the first 6 months of life, as well as 
the total number of antibiotic courses in the first 6 months of life, both based on antibiotic 
prescriptions recorded in clinic records and caregiver-reported antibiotic treatment at birth and 
for diarrhea. We excluded all topical antibiotics (neosporin, neomycin, soframycin, and gentian 
violet). Rates of diarrhea after 6 months of age per child were defined by the total number of 
incident episodes divided by the total time that child remained in the study. We excluded from 
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person-time denominators days with diarrhea (when a child was not at risk of incident diarrhea), 
periods during which the child was unreachable, and any time after loss to follow-up or death.  
We used Poisson and negative binomial regression to model the rates of diarrhea from 6 
months to 3 years of age. Crude and adjusted incidence rate ratios (IRRs) for diarrhea were 
estimated comparing children who were exposed to early life antibiotics to those who were not. 
Confounding variables were chosen using the DAG [415] (Figure 4.1), and optimal variable 
coding was determined by likelihood ratio test (α=0.1) and Akaike’s information criterion. Final 
covariates selected and their specifications are shown in Table 4.2. We assessed effect measure 
modification by exclusive breastfeeding, sex, Cesarean section birth, age at first diarrhea, and 
growth status (underweight, stunted, wasted) in first 6 months by reporting stratum-specific 
estimates and testing homogeneity by likelihood ratio test (α=0.1). We further explored the role 
of breastfeeding by assessing the crude association between exclusive breastfeeding and 
antibiotic treatment using log-risk and linear regression.  
To assess potential misclassification of the exposure, we repeated main analyses with 
more restricted definitions of antibiotic exposure that included caregiver-reported antibiotics 
only if an antibiotic name was recorded. To determine if the effect of antibiotics on diarrheal 
rates differed by antibiotic type, we repeated analyses separately comparing children who 
exclusively received one of the most commonly used antibiotics, amoxicillin and cotrimoxazole, 
to children who received no antibiotics. We further assessed if the effect of antibiotics differed 
depending on 1) the indication for which antibiotic treatment was given; 2) the number of 
diarrhea episodes experienced in the first 6 months of life; and 3) the time period for diarrheal 
outcomes (6-18 months of age compared to 18-36 months). 
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Aim 1C 
To estimate the effect of hypothetical interventions to reduce unnecessary antibiotic use, 
we used the same data and model structure as in Aim 1B (Table 4.2). We classified potentially 
unnecessary antibiotic use by characterizing antibiotic treatments under 6 months of age by 
indicating diagnosis: non-bloody diarrhea, URI, non-diarrheal acute gastroenteritis (AGE; i.e. 
vomiting), and other, which included bloody diarrhea. We considered antibiotics for non-bloody 
diarrhea as “not indicated” according to clinical guidelines given our confidence in the diarrhea 
case definition. We considered antibiotics for URI and non-diarrheal AGE as “likely not 
indicated” to reflect the potential variability and uncertainty in diagnoses from the study clinic 
records. Antibiotics given for all other illnesses, including cases of bloody diarrhea, were 
considered necessary. We considered two interventions: (i) removing all antibiotics that were not 
indicated, and (ii) removing all antibiotics that were not indicated or likely not indicated. All 
other antibiotic exposures were not affected by the interventions. Given our binary exposure 
classification (exposed to at least one course of antibiotics versus none), children remained 
exposed to antibiotics if they had any necessary antibiotic exposures. Children who received only 
unnecessary antibiotics moved from exposed to unexposed after the interventions. The targeted 
interventions were applied only to children who had already stopped exclusive breastfeeding. 
We used the parametric g-formula [420–425] to estimate contrasts associated with the 
effect of antibiotic use on diarrheal rates. The general procedure was as follows:  
1. Estimate beta coefficients for the observed exposure and covariates using the negative 
binomial model with rates of diarrhea from 6 months to 3 years as the outcome 
2. Use the estimated coefficients to predict the outcome in all individuals under the index 
exposure and again under the referent exposure 
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3. Average the predicted outcomes across individuals in the exposure groups 
4. Compare the average outcomes to estimate the adjusted rate difference  
5. Estimate the number needed to treat (NNT) as the reciprocal of the rate difference 
6. Construct confidence intervals by bootstrap with 200 replicates [419]  
Using this method, we estimated the population average causal effect, population attributable 
contrast, generalized impact contrast, and the targeted impact contrast. In sensitivity analyses, we 
also estimated the population average and generalized impact contrasts in the exposed population 
only (commonly termed the “effect of treatment in the treated”). We also expanded our models 
to estimate separate coefficients for the effects of necessary and unnecessary antibiotics and 
included the interaction between them to account for any differences in effect by indicating 
condition. 
 
Aim 2 
To assess whether antibiotic exposure affects growth in the first 3 years of life, we 
restricted analyses to Study 3, which had complete information on antibiotics given for non-
diarrheal illnesses. We included all 497 children in the parent cohort for short-term analyses of 
effects in the first 6 months of life. In the long-term analyses, we included 456 (91.8%) children 
who remained in the study until at least 6 months of age and had one or more growth 
measurements after 6 months of age. Growth z-scores were considered the primary outcomes of 
interest since they vary linearly with age and account for growth differences by age and sex. 
These models were simpler to fit compared to modeling absolute height and weight, which 
requires the inclusion of higher order terms for age to capture the non-linearity of growth curves. 
To improve the interpretability of effects, we also translated the effects on z-scores to their age 
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and gender-specific equivalents in height and weight using the one standard deviation differences 
in weight/height from the expanded z-score tables provided by the WHO [426,427]. 
 
Short-term effects 
We considered growth measurements taken within one week before or after a child’s 
monthly birth anniversary as their weight/height at that month of age. Growth measurements for 
months during which a child was not measured during this two week period were considered to 
be missing for that child (6.5% of child-months overall).  
We used longitudinal general linear regression to model WAZ, HAZ, and WHZ in 
monthly intervals from 0 through 5 months of age. We estimated the effects of antibiotic 
exposures in a given month on WAZ, HAZ, and WHZ at the end of the following month 
(conceptually depicted in Figure 4.2A), and accounted for correlation between outcomes from 
the same child using GEE with a robust variance estimator. To assess the sensitivity of results to 
the time period between antibiotic exposure and outcome, we repeated the monthly analyses with 
outcomes both at the end of the exposure month (Figure 4.2B) and at two months following the 
exposure month (Figure 4.2C). 
Confounding variables for the exposure model were chosen using the DAG [415] (Figure 
4.1) to account for baseline growth status, other baseline characteristics, and indications for 
treatment, which are the most important determinants of antibiotic use and also affect child 
growth. Optimal variable coding was determined by the quasi-likelihood under the independence 
model criterion (QIC), which is appropriate for GEE models [428]. Final covariates selected and 
their specifications are shown in Table 4.3. We stratified effects by month of antibiotic exposure, 
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gender, exclusive breastfeeding in the exposure month, baseline malnutrition status of the child 
(underweight, stunted, or wasted), and illness burden.  
To validate our results with an alternate model that eliminates potential unmeasured 
child-level confounding, we used a fixed-intercept model in which the effects of antibiotic use in 
monthly intervals were estimated within-child (a child’s exposed and unexposed months served 
as the index and reference exposures respectively), and between-child heterogeneity was 
captured in fixed child-specific effects (not estimated in the model) [429]. We again estimated 
the effect of antibiotic exposure in a given month on WAZ, HAZ, and WHZ at the end of the 
following month and stratified effects by gender. We used the robust variance estimator to 
account for correlation between observations within-child and necessarily included only the 
time-varying covariates [429] listed above.  
 
Long-term effects 
We used longitudinal general linear regression with GEE to model all WAZ, HAZ, and 
WHZ measurements after 6 months of age as a function of antibiotic use in the first 6 months of 
life. Each child’s exact age in days at the growth measurement was retained in the longitudinal 
models. We included the growth z-score corresponding to the outcome at 6 months as a covariate 
to ensure the estimation of long-term effects of antibiotics on growth rates following 6 months of 
age. Baseline confounding variables were again chosen by using the DAG [415] (Figure 4.1) and 
were largely the same as those in the short-term analysis, but also included Cesarean section 
birth. Final covariates selected and their specifications are shown in Table 4.3. We stratified 
effects by sex, number of antibiotic courses received, and age period of growth (6 months-1 year, 
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1-2 years, 2-3 years). We further assessed modification of effects by exclusive breastfeeding, 
illness burden, and malnutrition status.  
For both short and long-term analyses, we estimated the effects of antibiotics on the 
relative risk of underweight, stunting, and wasting with the same exposure groups and covariates 
as the linear regression models. We used Poisson regression with the robust variance estimator as 
an approximation of log-binomial regression [430] since the log-binomial regression models did 
not converge. We also validated results by repeating analyses with the same alternative definition 
of antibiotic exposure used in Aim 1 analyses. 
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Table 4.1. Covariate specification in final adjusted models for Aim 1A. 
Covariate Model specification 
Diarrhea episode number Indicator variables for episode 2, 3, 4, and 5+ 
Child sex Dichotomous 
Socioeconomic status Indicator variables for low and medium/high 
based on the Kuppuswamy scale [431] 
Maternal education Linear continuous 
Cesarean birth Dichotomous 
Low birth weight (<2.5 kg) Dichotomous 
Preterm birth (<37 weeks) Dichotomous 
Hospitalization at birth Dichotomous 
Antibiotics given at birth Dichotomous 
Age at previous episode Restricted quadratic spline [416] with knots at the 
20th, 40th, 60th, and 80th percentiles 
Vesikari score[412] of the previous 
episode 
Restricted quadratic spline with knots at the 25th, 
50th, 75th percentiles 
Duration of previous episode Restricted quadratic spline with knots at the 5th, 
50th, 95th percentiles 
Hospitalization during previous episode Dichotomous 
Fever during previous episode Linear continuous 
Dehydration during previous episode Dichotomous 
Bloody diarrhea during previous 
episode 
Dichotomous 
Zinc given during previous episode Dichotomous 
Underweight at previous episode 
(weight-for-age z-score <−2 SD)  
Dichotomous 
Stunted at previous episode (height-for-
age z-score <−2 SD) 
Dichotomous 
Wasted at previous episode (weight-for-
height z-score <−2 SD) 
Dichotomous 
Exclusive breastfeeding at previous 
episode 
Dichotomous 
Any breastfeeding at previous episode Dichotomous 
Number of previous antibiotic courses 
for any illnesses 
Linear continuous 
Number of sick days between episodes Restricted quadratic spline with knots at the 25th, 
50th, and 75th percentiles 
Other antibiotics given between 
episodes 
Dichotomous 
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Table 4.2. Covariate specification in final adjusted models for Aims 1B and 1C. 
Covariate Specification 
Child sex Dichotomous 
Socioeconomic status Indicator variables for low, medium, and high 
based on the Kuppuswamy scale [431] 
Maternal education Linear continuous 
Household hygiene Restricted quadratic spline [416] for continuous 
hygiene score [432] with knots at the 25th, 50th, 
75th percentiles 
Household crowding (number of 
household members/number of rooms) 
Linear continuous 
Low birth weight (<2.5 kg) Dichotomous 
Exclusive breastfeeding at 6 months of 
age 
Dichotomous 
Number of diarrhea episodes in first 6 
months 
Disjoint indicators for 1, 2, 3, 4, and 5+ episodes 
Total number of days with diarrhea in 
first 6 months 
Restricted quadratic spline [416] with knots at the 
25th, 50th, 75th percentiles 
Maximum Vesikari score[412] of any 
diarrhea episode in first 6 months 
Linear continuous 
Number of severe episodes in first 6 
months (Vesikari ≥ 11) 
Linear continuous 
Prolonged or persistent diarrhea episode 
in first 6 months 
Dichotomous 
Hospitalization for diarrhea in the first 6 
months 
Dichotomous 
Fever during diarrhea in first 6 months Dichotomous 
Dehydration during diarrhea in first 6 
months 
Disjoint indicators for 0, 1, and 2+ diarrhea 
episodes with dehydration 
Underweight (average weight-for-age z-
score under 6 months of age <−2 SD) 
Dichotomous 
Stunted (average height-for-age z-score 
under 6 months of age <−2 SD) 
Dichotomous 
Wasted (average weight-for-height z-
score under 6 months of age <−2 SD) 
Dichotomous 
Any severe illness in first 6 months Dichotomous 
Number of other infections in first 6 
months 
Linear continuous 
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Table 4.3. Covariate specification in final adjusted models for Aim 2. 
Short-term models 
Covariate Specification 
Month of age corresponding to exposure 
period 
Indicator variables for months 0, 1, 2, 3, 4, and 5 
Baseline z-score (at beginning of 
exposure month) 
Continuous 
Child sex Dichotomous 
Socioeconomic status Indicator variables for low and medium/high 
based on the Kuppuswamy scale [431] 
Maternal education Dichotomous: 0-12 years (no formal education, 
primary/middle) vs. 13+ years 
(college/polytechnic/professional) 
Household hygiene Linear continuous hygiene score [432]  
Household crowding (number of 
household members/number of rooms) 
Dichotomous: 0-<5 people/room vs. ≥5 
people/room 
Low birth weight (<2.5 kg) Dichotomous† 
Preterm birth (<37 weeks) Dichotomous§ 
Cesarean birth Dichotomous*§ 
Total number of days with diarrhea in 
exposure month 
Indicator variables for 0 days, 1-3 days, and >3 
days* 
Severe diarrhea in exposure month 
(Vesikari ≥ 11) 
Dichotomous§ 
Hospitalization in exposure month Dichotomous 
Dehydration during diarrhea in exposure 
month 
Dichotomous 
Prolonged or persistent diarrhea episode 
in exposure month 
Dichotomous 
ORS received during diarrhea in 
exposure month 
Dichotomous 
Exclusive breastfeeding in exposure 
month 
Indicator variables for none, part of the month, 
full month*† 
Total days severely ill or with other 
infections in exposure month 
Indicator variables for 0 days, 1-7 days, and >7 
days 
Total number of days with of diarrhea in 
previous month 
Indicator variables for 0 days, 1-3 days, and >3 
days 
Including interaction term with month of age for:  
*WAZ model, †HAZ model, §WHZ model 
Fixed-intercept model 
Baseline z-score Continuous 
Total number of days with in exposure 
month 
Indicator variables for 0 days, 1-3 days, and >3 
days 
Severe diarrhea in exposure month 
(Vesikari ≥ 11) 
Dichotomous 
Hospitalization in exposure month Dichotomous 
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Dehydration during diarrhea in exposure 
month 
Dichotomous 
Prolonged or persistent diarrhea episode 
in exposure month 
Dichotomous 
ORS received during diarrhea in 
exposure month 
Dichotomous 
Exclusive breastfeeding in exposure 
month 
Indicator variables for none, part of the month, 
full month 
Total days severely ill or with other 
infections in exposure month 
Indicator variables for 0 days, 1-7 days, and >7 
days 
Duration of diarrhea in previous month Indicator variables for 0 days, 1-3 days, and >3 
days 
Long-term models 
Baseline z-score (at 6 months of age) Continuous 
Child sex Dichotomous 
Socioeconomic status Indicator variables for low and medium/high 
based on the Kuppuswamy scale [431] 
Maternal education WAZ/WHZ models: Dichotomous: 0-12 years 
(no formal education, primary/middle) vs. 13+ 
years (college/polytechnic/professional) 
HAZ model: Indicator variables for 0 years (no 
formal education), 1-8 years (primary/missle), 
and 9+ years (higher secondary/college/ 
polytechnic/professional) 
Household hygiene Dichotomous: Poor (hygiene score <12) vs. good 
(hygiene score ≥12 [432]) 
Household crowding (number of 
household members/number of rooms) 
WAZ/HAZ models: Dichotomous: ≤2 
people/room vs. >2 people/room 
WHZ model: Indicator variables for ≤2 
people/room, 2.1-4.9 people/room, and ≥5 
people/room 
Low birth weight (<2.5 kg) Dichotomous 
Preterm birth (<37 weeks) Dichotomous 
Cesarean birth Dichotomous 
Exclusive breastfeeding until at least 3 
months of age 
Dichotomous 
Total number of days with diarrhea in 
first 6 months 
Indicator variables for 0 days, 1-14 days, and >14 
days 
Prolonged or persistent diarrhea episode 
in first 6 months 
Dichotomous 
Maximum Vesikari score [412] of any 
diarrhea episode in first 6 months 
Quadratic 
Fever during diarrhea in first 6 months Dichotomous 
Dehydration during diarrhea in first 6 
months 
WAZ/WHZ models: Dichotomous 
HAZ model: Indicator variables for 0, 1, and 2+ 
diarrhea episodes with dehydration 
97 
 
Days with other infections in first 6 
months 
Indicator variables for 0 days, 1-14 days, and >14 
days 
Any severe illness in first 6 months Dichotomous 
Underweight (average weight-for-age z-
score under 6 months of age <−2 SD) 
Dichotomous (HAZ model only) 
Stunted (average height-for-age z-score 
under 6 months of age <−2 SD) 
Dichotomous (WAZ model only) 
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Figure 4.1. Directed acyclic graph (DAG) for the effects of antibiotics on diarrhea and growth. 
Bold indicates main exposure or outcome; heavy black lines indicate causal paths of interest; 
variables shaded in grey are unmeasured. Birth characteristics include cesarean birth, pre-term 
birth, low birth weight, hospitalization, and antibiotics at birth. Other treatments include zinc and 
oral rehydration salts (ORS). 
 
99 
 
 
Figure 4.2. Schematic of exposure period and age of outcome assessment for short term growth 
analyses. Also indicated are the age of baseline growth measurement included in the models and 
the average time between exposure and growth outcome. The analyses included the analogous 
scheme for all months through 6 months of age. A – Primary analysis; B & C – Sensitivity 
analyses.  
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CHAPTER V: ANTIBIOTIC TREATMENT OF DIARRHEA IS ASSOCIATED WITH 
DECREASED TIME TO THE NEXT DIARRHEA EPISODE AMONG YOUNG CHILDREN 
IN VELLORE, INDIA 
 
Abstract 
Background 
Antibiotics are commonly given for the treatment of childhood diarrhea, but are not 
indicated in most cases. Antibiotics modify the gastrointestinal microbiota, which may have 
unanticipated effects on the risk of subsequent diarrhea. 
Methods 
In a prospective observational cohort study, we assessed the effect of caregiver-reported 
antibiotic treatment for diarrhea on the timing of a child’s next episode among 434 children 
followed from birth to 3 years of age in Vellore, India. We estimated median time differences 
and time ratios from inverse probability of exposure-weighted Kaplan-Meier curves for the time 
to next diarrhea episode comparing children who did and did not receive antibiotics for the 
previous episode. 
Results  
Study children had more than 5 diarrhea episodes on average in the first 3 years of life, 
and more than a quarter of all episodes were treated with antibiotics. Children who received 
antibiotics for their first diarrhea episode had their second episode on average 8 weeks earlier 
(median time difference: -8, 95% CI: -10, -3) than children who did not receive antibiotics. The 
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effects of antibiotics on subsequent diarrhea were greatest at earlier episodes and younger ages, 
and cefixime had a slightly larger effect compared to cotrimoxazole. 
Conclusions 
Antibiotic treatment of diarrhea was associated with reduced time to a subsequent 
diarrhea episode, especially among younger infants. While rational use of antibiotics has been 
advocated to reduce antimicrobial resistance in a population, we show that overuse of antibiotics 
may also have a direct adverse effect on individual patients. 
 
Introduction 
 Diarrhea is a universal and recurring disease during childhood with the highest burden in 
low and middle-income countries. In 2010, the global incidence of diarrhea before age 5 was 
estimated to be 2.7 episodes per child-year, which corresponds to approximately 1.7 billion total 
episodes and resulted in 700,000 deaths [30].  
Antibiotics are widely accessible and commonly used for the treatment of childhood 
diarrhea in India. However, international and Indian organizations, including the World Health 
Organization, recommend against routine use of antibiotics to treat diarrhea [10,188]. Antibiotics 
are generally contraindicated for non-bloody diarrheas because they are ineffective against non-
bacterial and resistant pathogens, and most episodes of diarrhea are self-limiting [189,191]. 
Despite these arguments, several healthcare facility-based studies in India have reported 
antibiotic prescription rates for acute childhood diarrhea from 50-90% [9,199,203,204]. In a 
nationwide community-based survey, 16% of children under 5 who had diarrhea in the two 
weeks preceding survey reported treatment with antibiotics, and another 30% reported treatment 
with unknown drugs that may have included antibiotics [8].  
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While major concerns about inappropriate antibiotic use often focus on the development 
of pathogen resistance to antibiotics, direct harm to patients is also possible and often overlooked 
[15]. Specifically, antibiotics may disrupt the GI microbiota—the complex community of 
microorganisms inhabiting the human GI tract—by causing a sharp reduction in the abundance 
and diversity of organisms [14,20]. This disruption can be prolonged, and the recovery of the 
microbiota following antibiotic exposure is often incomplete [16,17]. The microbiota is 
important for the development of the immune system [265,279], and may protect against 
diarrheal disease by occupying intestinal mucosal sites and inhibiting the attachment and growth 
of pathogens [296,433,434]. 
Studies of the impact of antibiotics on diarrhea most often focus on the incidence of AAD 
occurring within 8 weeks of antibiotic exposure [229,230], and often among hospitalized adults 
in high-income countries [235]. Longitudinal investigation of the effects of antibiotics on 
diarrheal risk has not been completed among children in resource-poor settings. In a birth cohort 
of children from Vellore, India, we assessed the effect of antibiotic treatment for diarrhea on the 
timing of a child’s next diarrhea episode.  
 
Methods 
 We analyzed data from a prospective observational cohort study on immune responses to 
cryptosporidiosis in 497 children followed from birth to 3 years of age from 2009 to 2013. The 
study population, enrollment strategy, and data collection methods have been described 
previously [28]. Briefly, baseline information on demography, socioeconomic indicators, health-
seeking behavior, environment, diet, and characteristics of delivery were collected within 45 
days of birth. Fieldworkers interviewed caregivers twice per week about any illnesses since the 
last visit. Clinical characteristics of the diarrhea episodes were recorded including the number of 
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stools per day, consistency and color of stools, fever or vomiting, associated hospitalization, and 
treatments given. Heights and weights were measured monthly at the study clinic, and 
breastfeeding histories (exclusive, non-exclusive, none) were collected every two weeks until 
breastfeeding was stopped completely. 
 
Data and definitions 
Diarrhea was defined using the standard WHO definition as at least three loose or watery 
stools in a 24-hour period [10]. Duration of a diarrhea episode was defined as the number of days 
from the first day of watery stools until the last day of watery stools inclusive. A new episode of 
diarrhea was defined only after at least 48 hours of normal bowel movements since the previous 
episode. Person-time at risk was defined as all days during follow-up excluding days with 
diarrhea and 48 hours after an episode of diarrhea during which a new episode of diarrhea could 
not be defined.  
Severity of diarrhea was assessed using the 20-point Vesikari scale [412]. Episodes were 
classified as mild (1-5), moderate (6-10), severe (11-15), and very severe (16-20). Episodes were 
classified as acute if lasting 0-6 days or prolonged/persistent if lasting for 7 or more days. 
The primary exposure was antibiotic treatment for diarrhea based on caregiver-report 
during the episode. A yes-no question was asked specifically about whether antibiotics were 
given and the name of the drug(s) was recorded if known (available for 64.0% of antibiotic 
reports). We also extracted antibiotic prescriptions from clinic records for all illnesses (most 
commonly respiratory, skin, and ear infections) assessed at the study clinic. 
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Children were classified according to standard definitions as underweight (weight-for-age 
z-score < −2 SD from the 2006 WHO growth reference [435]), stunted (height-for-age z-score < 
−2 SD), and/or wasted (weight-for-height z- score < −2 SD).  
 
Data analysis 
We restricted this analysis to children who had at least one diarrhea episode and therefore 
had the opportunity to be treated with antibiotics for diarrhea. Because the proportion of missing 
data for baseline and diarrhea severity-related covariates was 5% or less for all variables, we 
imputed the median values of variables for individuals and episodes with missing data (indicated 
in Table 5.1 footnote). 
Logistic regression was used to calculate inverse probability of exposure weights 
stabilized by the marginal probability of exposure [414]. Confounding variables for the exposure 
model were chosen by a causal DAG [415] to account for baseline characteristics and indications 
for treatment. We were particularly concerned about confounding by diarrhea episode severity, 
which was associated with higher antibiotic use rates and might also predict future diarrheal risk. 
We therefore included multiple characteristics of the diarrhea episode to capture the multifaceted 
concept of illness severity. The final exposure model included episode number, socioeconomic 
status defined from the modified Kuppuswamy scale [431,436], maternal education, child sex, 
Cesarean birth, low birth weight, preterm birth, hospitalization at birth, antibiotics given at birth, 
and characteristics of the last diarrhea episode: age, Vesikari score [412], duration, 
hospitalization, fever, dehydration, bloody diarrhea, underweight, stunted, wasted, exclusive and 
any breastfeeding, zinc given, number of previous antibiotic courses for any illnesses, number of 
sick days between episodes, and other antibiotics given between episodes. Continuous variables 
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were modeled flexibly with restricted quadratic splines [416], and covariate specifications were 
compared by Akaike’s information criterion. To remove extreme weight values [417], weights 
were censored at the 0.5th and 99.5th percentiles by resetting the value of weights greater than the 
99.5th percentile and less than the 0.5th percentile to the value of the 99.5th and 0.5th percentile 
respectively. 
We estimated inverse probability-weighted Kaplan-Meier (KM) curves [414,418] for the 
time to next diarrhea episode comparing children who did and did not receive antibiotics for the 
previous episode. The time scale [418] was from 48 hours after the previous diarrhea episode to 
the incident day of the next episode. Children were censored at drop-out, death, or the end of 
follow-up at 3 years of age. We assumed person-time during which children were temporarily 
unreachable was missing at random and drop-out was non-informative given the small 
proportion of drop-outs (n=50, 11.5% overall; n=18, 4.1% between the first and second diarrhea 
episode). We assessed each episode pair separately and then collapsed across episodes. 
We calculated the time difference and time ratio at 50% diarrhea-free survival, the 
median survival time, from the weighted KM curves. Confidence intervals were constructed by 
bootstrap [419] with 200 resamples at the level of the individual to account for clustering of 
episodes within children.  
We also estimated hazard ratios comparing the same exposure groups using marginal 
structural Cox models [418] with the same inverse probability weights. These models were 
estimated by pooled logistic regression with adjustment for time using a restricted quadratic 
spline [416]. Correlation between outcomes from the same child was accounted for using 
generalized estimating equations with a robust variance estimator. 
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Effect measure modification 
We assessed modification of the effect of antibiotics by age at exposure by stratification. 
We also considered the effect of specific antibiotics commonly given, 
trimethoprim/sulfamethoxazole (cotrimoxazole) and cephalosporins (97.4% of which were 
cefixime), by comparing children receiving each drug with children given no antibiotics. 
 
Sensitivity analyses 
To validate caregiver-report of antibiotic treatment, we repeated analyses with alternative 
definitions of antibiotic exposure. First, we restricted the exposed group to only those children 
whose caregivers reported the name of a confirmed antibiotic in the free-response section of the 
questionnaire. Second, we considered children exposed if either their caregiver reported 
antibiotics were given (by indicating yes/no) or if an antibiotic prescription was recorded in 
clinic records during the diarrhea episode. Finally, we considered children exposed only if a 
confirmed antibiotic name was reported or if a prescription was recorded in the clinic records. 
To assess the impact of long episode duration contributing to shorter time between 
episodes, we repeated the main analyses excluding all episode pairs where the first episode lasted 
for more than 7 days (n=194, 8.6% total; n=42, 9.8% among first episodes). 
To assess whether antibiotics were associated with the severity of subsequent diarrhea 
when another episode occurred, we estimated the effects of antibiotic treatment for the previous 
episode on the severity and duration of the next episode. In models weighted for the same 
covariates as in above analyses, we used inverse probability-weighted linear regression with the 
Vesikari score and number of days with diarrhea as continuous outcomes. We also estimated the 
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adjusted relative risk for a severe (Vesikari ≥ 11) and prolonged/persistent (≥7 days) next 
episode using inverse probability-weighted log-binomial regression. 
Last, we compared the results from the main study with two earlier cohorts of children 
from the same study area [396,397]. The earlier cohorts lacked complete records of antibiotics 
given to treat non-diarrheal illnesses, and the type of antibiotics given for diarrhea were 
unknown. In addition, the most recent earlier study was a smaller quasi-experimental study, in 
which children were followed once-weekly for only 2 years and enrolled after birth if still 
exclusively breastfed [396]. Despite these limitations, we present the results from these cohorts 
for completeness. 
 
Results 
 Almost all children in the birth cohort (434 of 497, 87.3%) had at least one diarrhea 
episode and were included in the analysis. Of these, 412, 393, and 384 children completed the 
first, second, and third study year of follow-up respectively (drop-out rate of 11.5%). Six 
children died during follow-up; two deaths were associated with diarrhea. Most children were of 
low socioeconomic status (n=282, 65%, Table 5.1) and approximately half had poor household 
hygiene (n=210, 48.4%). By six months of age, most children had stopped exclusive 
breastfeeding (n=370, 85.3%) and had their first episode of diarrhea (n=307, 70.7%). Children 
who received antibiotics were slightly more likely to be from households with poor hygiene. 
These children stopped all breastfeeding on average one month earlier, and had their first 
diarrhea episode at younger ages (Table 5.1). 
The total accumulated follow-up was 1013.3 person-years, including 981.8 diarrhea-free 
person-years included as person-time at risk in analyses. Incidence of diarrhea was highest 
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around 6 months of age, with an incidence of 32.4 episodes per 100 person-months among 
children between 5 and 7 months of age (Figure 5.1).   
A total of 2,295 diarrhea episodes were reported, of which 658 (28.9%) were treated with 
antibiotics. We excluded 16 diarrhea episodes (0.7%) due to missing antibiotic treatment 
information. More than half of children (n=268, 61.8%) reported at least one antibiotic course for 
diarrhea, and 154 (35.5%) reported two or more antibiotic courses for diarrhea in the first 3 years 
of life. Antibiotic treatment of diarrhea was associated with older age at the time of the episode 
and increased episode severity and duration (Table 5.2). The most common antibiotic given was 
cotrimoxazole, accounting for 50.3% of caregiver-reported antibiotics and 57.8% of antibiotics 
prescribed at the study clinic for diarrhea. Cefixime accounted for another 24.6% of caregiver-
reported antibiotics and 34.5% of antibiotic prescriptions at the clinic. All other antibiotics, such 
as fluoroquinolones, penicillins, and macrolides, were reported for less than 5% of cases. 
 
Effect on diarrhea incidence 
Of 434 children experiencing a first diarrhea episode, we excluded 3 children with 
missing antibiotic treatment and one child who dropped out on the first day following their first 
episode. Among children who had a second diarrhea episode (n=375, 87.2%), the median time to 
second diarrhea episode was 10 weeks (IQR: 3, 20). The crude difference in median time to 
second diarrhea episode among children who were treated with antibiotics for their first episode 
(n=84) compared to children who were not treated (n=289) was 2 weeks (median time difference 
(MTD): -2, 95% CI: -8, 3). The crude hazard ratio from a Cox proportional hazards model was 
1.15 (95% CI: 0.77, 1.72). 
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Figure 5.2A shows inverse probability of treatment-weighted KM curves for time to 
second diarrhea episode among children who were (n=93) and were not (n=337) treated with 
antibiotics for their first episode. Based on the weighted curves, children who received 
antibiotics for their first diarrhea episode had their second episode on average 8 weeks earlier 
(MTD: -8, 95% CI: -10, -3) or twice as soon (median time ratio (MTR): 0.50, 95% CI: 0.38, 
0.79) as children who did not receive antibiotics (Table 5.3). In a Cox proportional hazards 
model weighted for the same covariates, the adjusted hazard ratio was 1.38 (95% CI: 1.05, 1.82). 
The effect of antibiotic treatment of the second diarrhea episode on time to third diarrhea 
was similar, while effects in later episode pairs were smaller (Figure 5.2B-E, Table 5.3). The 
overall adjusted time difference and ratio when collapsing all episode pairs were -4 weeks (95% 
CI: -9, 0) and 0.71 (95% CI: 0.44, 0.96) respectively (Figure 5.2F, Table 5.3). 
 
Effect measure modification 
The effect of antibiotics on time to next diarrhea was greatest among children who were 
treated with antibiotics for diarrhea under 6 months of age compared to antibiotic treatment 
between 6 months and 1 year and after 1 year of age (Figure 5.3, Table 5.3). A shorter time to 
next diarrhea was observed for both cotrimoxazole (MTD: -1, 95% CI: -7, 2) and cephalosporins 
(MTD: -3, 95% CI: -9, 0) compared to no antibiotics, though the effect was smaller for 
cotrimoxazole (Figure 5.4, Table 5.4).  
 
Sensitivity analyses 
Results under alternative exposure definitions were consistent with the main analyses, 
though the effect size diminished as the definitions became less sensitive and more specific 
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(Figure 5.5, Table 5.4). When excluding all previous episodes with greater than 7 days duration, 
diarrhea-free survival curves were similar to main analyses, and time differences and ratios were 
slightly larger in magnitude (Figure 5.6, Table 5.5).  
When subsequent diarrhea occurred, the average Vesikari score and duration of the 
second episode were slightly lower among children who were treated with antibiotics during 
their first episode compared to those who were not (Table 5.6). Correspondingly, the risks for a 
severe or prolonged/persistent second diarrhea episode were lower among these children. 
However, the absolute differences in severity and duration were small (less than one point on the 
Vesikari scale and less than one day, respectively) and imprecise since few episodes were severe 
(10.4%) or of long duration (11.5%). The results were consistent when restricting to episodes 
which occurred under 6 months of age and when including all episode pairs (Table 5.7).  
To validate our findings, we analyzed data from two previous cohorts conducted at this 
site [395–397]. One study [396] was conducted from 2008-2011 and included 160 children with 
at least one diarrhea episode. Prevalence of antibiotic treatment of diarrhea was lower, at 6.4% 
(50 of 785 total episodes with antibiotic treatment information). The second study [395,397], 
conducted from 2002-2006, included 390 children who had at least one diarrhea episode. Of 
1,812 diarrhea episodes with known antibiotic treatment, 27.7% (n=502) were treated with 
antibiotics. Information on antibiotic treatment for other illnesses was missing. The weighted 
KM curves including all episode pairs from these earlier studies were consistent with the results 
from the main study. Combining all three cohorts, children who were treated with antibiotics for 
their first diarrhea episode had their second episode 3 weeks (MTD: -3, 95% CI: -7, 1) or 20% 
(MTR: 0.80, 95% CI: 0.53, 1.07) earlier than children who were not treated with antibiotics 
(Figure 5.7). 
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Discussion 
This study provides the first evidence that antibiotic treatment of diarrhea may shorten 
the time between episodes, especially among younger infants. These results are directly 
applicable to diarrhea treatment decisions since antibiotic treatment is not essential for most 
cases of diarrhea. Specifically, according to Integrated Management of Childhood Illness (IMCI) 
protocols [437], antibiotic treatment was likely not indicated for a majority of cases in this study 
since only few episodes (0.9%) were associated with bloody stools. While antibiotics are a well-
known cause of AAD [229], we provide further support for a sustained impact of antibiotics on 
diarrheal risk. These results, which focus on antibiotic treatment of diarrhea specifically, are 
consistent with our recent work demonstrating that any antibiotic exposure early in life is 
associated with increased diarrheal rates [438].  
Antibiotic treatment of diarrhea had the greatest impact on time to next episode during 
the first two diarrhea episodes. This difference in effect may be due to young age at earlier 
episodes and high overall antibiotic exposure by the time of later episodes. The substantial 
increases in magnitude of the adjusted effects compared to the crude effect are largely due to 
removing confounding by age. Because the microbiota is underdeveloped and more susceptible 
to disturbances during infancy, antibiotic exposures at the youngest ages may have the largest 
impact on the microbiota, and correspondingly on diarrheal risk [20,280].  In addition, because 
of the high rates of antibiotic use in this population, four-fifths (83%) of the population had prior 
exposure to antibiotics by the third diarrhea episode. We hypothesize that antibiotics for diarrhea 
are likely to have the largest impact when they represent a majority of total antibiotic exposures, 
which occurs at earlier episodes and younger ages. 
112 
 
The difference in effect on diarrheal risk between cotrimoxazole and cefixime may result 
from their different spectrums of activity. Cotrimoxazole is broad-spectrum, but notably does not 
affect anaerobes [439], which dominate the gut microbiota [272]. Conversely, anaerobes are 
sensitive to cefixime, and this drug is also more effective against Gram-negative bacteria 
(especially Enterobacteriaceae) common in the gut [439]. Correspondingly, diarrhea as a drug-
related adverse event is more commonly reported for cefixime (15-20%) compared to 
cotrimoxazole (<1-10%) [439,440]. Similarly, cephalosporins are one of the predominant drug 
classes noted to cause AAD [13,236]. The activity of cefixime against intestinal anaerobes may 
result in greater disruption of the gut microbiota and increased susceptibility to diarrheal 
pathogens. 
In the minority of diarrhea episodes of bacterial etiology and for which antibiotics may 
have been indicated, the reduction in time to subsequent diarrhea may alternatively have been 
due to a temporary benefit of antibiotics followed by the recrudescence of the causative and 
antibiotic-susceptible agents, resulting in a second diarrhea episode. 
As in any observational study, there is the potential for bias due to uncontrolled 
confounding, including by local environmental factors associated with force of transmission and 
pathogen-specific effects on the microbiome. However, this cohort has the advantage of a 
detailed record of illness characteristics that were likely the main indications for treatment. This 
study was limited by potential misclassification of exposure due to caregiver-reported treatment 
information. However, we also incorporated antibiotic prescriptions from clinic records, which 
likely captured the majority of antibiotic exposures since the clinic was located in the study area 
and provided free care and medicines. There was concordance between caregiver-reported and 
antibiotic prescriptions for diarrhea: 78% of antibiotic prescriptions during diarrhea episodes 
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were associated with caregiver-reported antibiotic treatment. Further, our results were consistent 
when we used alternative definitions of antibiotic exposure in sensitivity analyses. 
Because there were few severe illnesses in our cohort, we considered diarrhea incidence 
the main outcome of interest. Antibiotic treatment was associated with slightly lower severity 
and duration of subsequent diarrhea episodes, but the differences were small and imprecise. 
Antibiotic treatment of diarrhea may also have unintended consequences for other illnesses such 
as respiratory infections, and other potential effects should be taken into account when making 
treatment decisions.  
By providing evidence that antibiotics may cause direct harm to children through an 
association with decreased time to future diarrhea episodes, these findings will counter a 
commonly held assumption among doctors and caregivers that even if antibiotics are not strictly 
indicated, “at least they can’t hurt ” [15]. While rational use of antibiotics has been advocated to 
reduce antimicrobial resistance at the population level, rational use might also decrease future 
diarrheal risk among treated patients. 
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Table 5.1. Demographic characteristics of 434 children with at least one diarrhea episode in a 
birth cohort in Vellore, Tamil Nadu, India 2009-2013. 
 
 0 antibiotics reported 
for diarrhea (n=166) 
1+ antibiotics reported 
for diarrhea (n=268) 
 No. (%) children No. (%) children 
Household characteristics   
Socioeconomic status*   
Low 114 (68.7) 168 (62.7) 
Medium 50 (30.1) 94 (35.1) 
High 2 (1.2) 6 (2.2) 
Maternal education   
No formal education 67 (40.4) 93 (34.7) 
Primary/middle school 52 (31.3) 97 (36.2) 
Higher secondary school 42 (25.3) 69 (25.7) 
College/polytechnic/professional 
school 
5 (3.0) 9 (3.4) 
Poor household hygiene† 75 (45.2) 149 (55.6) 
Crowding   
High (>4 people/room) 52 (31.3) 78 (29.1) 
Medium (3.1-4 people/room) 63 (38.0) 103 (38.4) 
Low (≤ 3 people/room) 51 (30.7) 87 (32.5) 
Child characteristics   
Sex of child   
Male 87 (52.4) 147 (54.9) 
Female 79 (47.6) 121 (45.1) 
Cesarean section 29 (17.5) 45 (16.8) 
Low birth weight‡ 33 (20.3) 43 (16.3) 
Preterm birth‡ 19 (11.7) 26 (9.9) 
Baby kept in ICU at birth 9 (5.4) 23 (8.6) 
Antibiotics at birth‡ 3 (1.9) 8 (3.1) 
Age at first diarrhea   
<6 months 103 (62.0) 204 (76.1) 
6 months – 1 year 44 (26.5) 52 (19.4) 
>1 year 19 (11.4) 12 (4.5) 
Age (months) at stopping exclusive 
breastfeeding (mean, SD) 
4.2 (2.0) 3.8 (2.1) 
Age (months) at stopping all 
breastfeeding (mean, SD) 
17.4 (8.7) 16.2 (8.3) 
*Socioeconomic status categories defined from the modified Kuppuswamy scale [431,436] 
†Poor household hygiene was based a score of less than 12 on a scale developed from an assessment of 
water, food, and personal hygiene [432] 
‡7 missing values for low birth weight; 9 missing values for preterm birth; 13 missing values for 
antibiotics at birth; SD – standard deviation 
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Table 5.2. Characteristics of diarrhea episodes and their association with antibiotic treatment 
among 434 children in a birth cohort in Vellore, Tamil Nadu, India 2009-2013. 
 
No. (%) total 
episodes 
(n=2279*) 
No. (%) episodes 
treated with antibiotics 
(n=658) 
Crude OR†  
(95% CI) 
Age at episode    
< 6 mo. 589 (25.8) 110 (16.7) 1. 
6 mo. – 1 year 701 (30.8) 213 (32.4)  1.90 (1.46, 2.47) 
1 – 2 years 596 (26.2) 209 (31.8) 2.35 (1.80, 3.07) 
2 – 3 years 393 (17.2) 126 (19.1) 2.05 (1.53, 2.76) 
Severity (Vesikari score)   
Mild (2-5) 1125 (49.4) 235 (35.7) 1. 
Moderate (6-10) 900 (39.5) 302 (45.9) 1.91 (1.57, 2.33) 
Severe (11-15) 221 (9.7) 104 (15.8) 3.37 (2.49, 4.55) 
Very severe (16-20) 33 (1.4) 17 (2.6) 4.02 (2.00, 8.08) 
Duration (days)     
Acute (1-6) 2011 (88.2) 549 (83.4) 1. 
Prolonged (7-13) 234 (10.3) 93 (14.1) 1.76 (1.33, 2.32) 
Persistent (≥14) 34 (1.5) 16 (2.4) 2.37 (1.20, 4.67) 
Bloody stools    
No 2231 (97.9) 634 (96.4) 1. 
Yes 48 (2.1) 24 (3.7) 2.52 (1.42, 4.47) 
Fever‡    
No 1990 (87.3) 518 (78.7) 1. 
Yes 289 (12.7) 140 (21.3) 2.67 (2.08, 3.43) 
Dehydration    
No 1652 (72.5) 410 (62.3) 1. 
Yes 627 (27.5) 248 (37.7) 1.98 (1.63, 2.41) 
Hospitalization    
No 2219 (97.4) 623 (94.7) 1. 
Yes 60 (2.6) 35 (5.3) 3.59 (2.13, 6.04) 
*Excludes 16 episodes for which antibiotic treatment was unknown. 
†Odds ratio for antibiotic treatment of diarrhea episode by diarrhea characteristic 
‡Caregiver-reported 
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Table 5.3. Estimated effect of antibiotic treatment for the previous diarrhea episode on time to 
next episode by episode pair and age at first episode among 430 children in a birth cohort in 
Vellore, Tamil Nadu, India 2009-2013. 
 
Episode 
pair 
Antibiotics 
for previous 
episode 
No. of 
children 
Median time 
difference 
(weeks; 
95% CI)* 
Median time 
ratio (95% CI)* 
Hazard ratio† 
(95% CI)* 
1st to 2nd No 337 0. 1. 1. 
 Yes 93 -8 (-10, -3) 0.50 (0.38, 0.79) 1.38 (1.05, 1.82) 
2nd to 3rd No 273 0. 1. 1. 
 Yes 94 -7 (-11, 1) 0.46 (0.29, 1.10) 1.53 (1.05, 2.23) 
3rd to 4th No 234 0. 1. 1. 
 Yes 75 1 (-11, 11) 1.07 (0.37, 1.90) 0.79 (0.54, 1.16) 
4th to 5th No 174 0. 1. 1. 
 Yes 71 1 (-11, 12) 1.06 (0.40, 2.00) 1.70 (0.98, 2.97) 
>5th No 588 0. 1. 1. 
 Yes 322 -3 (-7, 4) 0.79 (0.53, 1.33) 1.24 (0.93, 1.64) 
All No 1606 0. 1. 1. 
 Yes 655 -4 (-9, 0) 0.71 (0.44, 0.96) 1.35 (1.11, 1.64) 
Age at first 
episode      
< 6 mo. No 472 0. 1. 1. 
 Yes 108 -4 (-6, 0) 0.60 (0.40, 1.00) 1.72 (1.27, 2.32) 
6 – 12 mo. No 491 0. 1. 1. 
 Yes 212 -4 (-9, 3) 0.76 (0.53, 1.22) 1.42 (1.14, 1.76) 
≥ 12 mo. No 643 0. 1. 1. 
 Yes 335 -2 (-10, 6) 0.91 (0.55, 1.32) 1.12 (0.82, 1.54) 
*Weighted for episode number, socioeconomic status [431,436], maternal education, child sex, Cesarean 
birth, low birth weight, preterm birth, hospitalization at birth, antibiotics given at birth, and characteristics 
of the last diarrhea episode: age, Vesikari score [412], duration, hospitalization, fever, dehydration, 
bloody diarrhea, underweight, stunted, wasted, exclusive and any breastfeeding, zinc given, number of 
previous antibiotic courses for any illnesses, number of sick days between episodes, and other antibiotics 
given between episodes. The mean weight was 1.01 with range 0.29-16.18; after censoring at the 0.05th 
and 99.5th percentiles, the mean was 0.99 with range 0.31-5.77. 
CI – confidence interval 
†Assumes proportional hazards 
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Table 5.4. Estimated effect of antibiotic treatment for the first diarrhea episode on time to 
second episode using alternative definitions for antibiotic treatment among 434 children in a 
birth cohort in Vellore, Tamil Nadu, India 2009-2013. 
 
Antibiotic exposure 
definition 
Antibiotics 
for previous 
episode 
No. of 
children 
Median time 
difference 
(weeks; 95% CI)* 
Median time 
ratio (95% CI)* 
Cotrimoxazole§ No 1417 0. 1. 
 Yes 384 -1 (-7, 2) 0.92 (0.50, 1.17) 
Cephalosporins§ No 1417 0. 1. 
 Yes 180 -3 (-9, 0) 0.79 (0.43, 1.00) 
Caregiver-report yes No 337 0. 1. 
 Yes 93 -8 (-10, -3) 0.50 (0.38, 0.79) 
Caregiver-report 
antibiotic name No 380‡ 0. 1. 
 Yes 53 -4 (-10, 2) 0.71 (0.41, 1.17) 
Caregiver-report yes or 
prescription from clinic No 302 0. 1. 
 Yes 128 -2 (-7, 4) 0.86 (0.56, 1.33) 
Caregiver-report 
antibiotic name or 
prescription from clinic No 335 0. 1. 
 Yes 98 1 (-7, 5) 1.08 (0.55, 1.40) 
*Weighted for episode number, socioeconomic status, maternal education, child sex, Cesarean birth, low 
birth weight, preterm birth, hospitalization at birth, antibiotics given at birth, and characteristics of the last 
diarrhea episode: age, Vesikari score, duration, hospitalization, fever, dehydration, bloody diarrhea, 
underweight, stunted, wasted, exclusive and any breastfeeding, zinc given, number of previous antibiotic 
courses for any illnesses, number of sick days between episodes, and other antibiotics given between 
episodes; CI – confidence interval 
†Assumes proportional hazards 
‡Includes missing antibiotic use as not exposed 
§Includes all episodes due to small sample size per episode pair 
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Table 5.5. Estimated effect of antibiotic treatment for the previous diarrhea episode on time to 
second episode excluding previous episodes >7 days duration among 434 children in a birth 
cohort in Vellore, Tamil Nadu, India 2009-2013. 
 
Episode 
pair 
Antibiotics 
for previous 
episode 
No. of 
children 
Median time 
difference 
(weeks; 95% CI)* 
Median time 
ratio (95% CI)* 
1st to 2nd No 306 0. 1. 
 Yes 82 -8 (-10, -2) 0.50 (0.38, 0.83) 
2nd to 3rd No 246 0. 1. 
 Yes 81 -7 (-12, 2) 0.50 (0.25, 1.22) 
All No 1488 0. 1. 
 Yes 579 -4 (-9, -1) 0.71 (0.44, 0.93) 
*Weighted for episode number, socioeconomic status, maternal education, child sex, Cesarean birth, low 
birth weight, preterm birth, hospitalization at birth, antibiotics given at birth, and characteristics of the last 
diarrhea episode: age, Vesikari score, duration, hospitalization, fever, dehydration, bloody diarrhea, 
underweight, stunted, wasted, exclusive and any breastfeeding, zinc given, number of previous antibiotic 
courses for any illnesses, number of sick days between episodes, and other antibiotics given between 
episodes; CI – confidence interval 
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Table 5.6. Estimated effect of antibiotic treatment for the first diarrhea episode on the severity 
and duration of subsequent diarrhea among 373 children who had a second episode from Vellore, 
Tamil Nadu, 2009–2013. 
 Second diarrhea episode 
 Mean 
Vesikari 
score (SD)  
Severe 
episode*  
N (%) Total 
Vesikari score Severe episode* 
First diarrhea 
episode aβ† (95% CI) aRR§ (95% CI) 
No antibiotics  7.0 (3.3) 46 (15.9) 289 0. 1. 
Antibiotics 7.0 (3.5) 14 (16.7) 84 -0.20 (-1.13, 0.73) 0.71 (0.37, 1.37) 
 
Mean 
duration 
(days; SD)  
Prolonged/
persistent 
episode‡ 
N (%) 
 Duration (days)  
Prolonged/ 
persistent episode‡ 
 Total aβ# (95% CI)  aRR§ (95% CI) 
No antibiotics  4.3 (3.7) 42 (14.5) 289 0. 1. 
Antibiotics 3.4 (2.2) 10 (11.9) 84 -0.66 (-1.36, 0.03) 0.91 (0.41, 1.99) 
*Vesikari score ≥ 11 
†Difference in Vesikari score adjusted for episode number, socioeconomic status [431,436], maternal 
education, child sex, Cesarean birth, low birth weight, preterm birth, hospitalization at birth, antibiotics 
given at birth, and characteristics of the last diarrhea episode: age, Vesikari score [412], duration, 
hospitalization, fever, dehydration, bloody diarrhea, underweight, stunted, wasted, exclusive and any 
breastfeeding, zinc given, number of previous antibiotic courses for any illnesses, number of sick days 
between episodes, and other antibiotics given between episodes. 
‡Duration ≥ 7 days 
§Risk ratio adjusted for covariates listed in † 
#Difference in diarrhea duration (days) adjusted for covariates listed in † 
SD – Standard deviation; CI – confidence interval 
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Table 5.7. Estimated effect of antibiotic treatment for the previous diarrhea episode on the 
severity and duration of the next diarrhea episode among 430 children from Vellore, Tamil 
Nadu, 2009–2013. A – Restricting to children under 6 months of age at previous episode; B – 
Including all episode pairs. 
A Next diarrhea episode 
 
Mean 
Vesikari 
score (SD)  
Severe 
episode* 
N (%) Total 
Vesikari score Severe diarrhea 
Previous 
diarrhea 
episode aβ† (95% CI) aRR§ (95% CI) 
No antibiotic  7.2 (3.2) 72 (16.4) 440 0. 1. 
Antibiotic 7.4 (3.5) 18 (16.8) 107 -0.26 (-1.04, 0.49) 0.63 (0.35, 1.13) 
 
 Prolonged/
persistent 
episode‡ 
N (%) 
 Duration (days) 
Prolonged or 
persistent diarrhea 
 
Mean 
duration 
(days; SD)  Total aβ# (95% CI) aRR§ (95% CI) 
No antibiotic  4.3 (3.4) 76 (17.3) 440 0. 1. 
Antibiotic 3.9 (2.5) 19 (17.8) 107 -0.46 (-1.01, 0.06) 0.87 (0.50, 1.51) 
 
B Next diarrhea episode 
 
Mean 
Vesikari 
score (SD)  
Severe 
episode* 
N (%) Total 
Vesikari score Severe diarrhea 
Previous 
diarrhea 
episode aβ† (95% CI) aRR§ (95% CI)  
No antibiotic  6.5 (2.9) 136 (10.5) 1308 0. 1. 
Antibiotic 6.5 (3.1) 57 (10.4) 541 -0.26 (-0.58, 0.05) 0.78 (0.56, 1.08) 
 
 Prolonged/
persistent 
episode‡ 
N (%) 
 Duration (days)  
Prolonged or 
persistent diarrhea 
 
Mean 
duration 
(days; SD)  Total aβ# (95% CI)  aRR§ (95% CI)  
No antibiotic  3.8 (3.4) 165 (12.6) 1308 0. 1. 
Antibiotic 3.3 (2.3) 47 (8.7) 541 -0.45 (-0.72, -0.18) 0.67 (0.46, 0.98) 
*Vesikari score ≥ 11 
†Difference in Vesikari score adjusted for same covariates as in Table 5.6 
§Risk ratio adjusted for same covariates as in Table 5.6 
‡Duration ≥ 7 days 
#Difference in diarrhea duration (days) adjusted for same covariates as in Table 5.6 
SD – Standard deviation; CI – confidence interval 
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Figure 5.1. Incidence of diarrhea by age (using restricted quadratic splines [416]) among 434 
children in a birth cohort in Vellore, Tamil Nadu, India 2009-2013. 
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Figure 5.2. Inverse probability of treatment-weighted Kaplan-Meier curves for time to next 
diarrhea episode by antibiotic treatment for the previous diarrhea episode among 430 children 
from Vellore, Tamil Nadu, 2009–2013. Weighted diarrhea-free survival from: A – first to second 
episode; B – second to third episode; C – third to fourth episode; D – fourth to fifth episode; E –
previous to next episode including episodes ≥6; F – all episode pairs. 
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Figure 5.3. Stratified by age at first diarrhea episode, inverse probability of treatment-weighted 
Kaplan-Meier curves for time to next diarrhea episode among 430 children from Vellore, Tamil 
Nadu, 2009–2013. A – first diarrhea and antibiotic treatment below 6 months of age; B – first 
diarrhea and antibiotic treatment between 6 months and 1 year of age; C – first diarrhea and 
antibiotic treatment after 1 year of age. 
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Figure 5.4. Stratified by antibiotic type given for the previous diarrhea episode, inverse 
probability of treatment-weighted Kaplan-Meier curves for time to next diarrhea episode among 
430 children from Vellore, Tamil Nadu, 2009–2013. A – Antibiotic treatment with a 
cephalosporin versus no antibiotics; B – Antibiotic treatment with cotrimoxazole versus no 
antibiotics. 
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Figure 5.5. Inverse probability of treatment weighted Kaplan-Meier curves for time to second 
diarrhea episode using alternative definitions for antibiotic treatment of the first diarrhea episode 
among 430 children from Vellore, Tamil Nadu, 2009–2013. A –Children exposed only if 
caregivers reported the name of an antibiotic; B – Children exposed if either their caregiver 
reported antibiotics were given or if an antibiotic prescription was recorded in clinic records 
during the diarrhea episode; C – Children exposed if an antibiotic was listed in the free-response 
section of the questionnaire or if a prescription was recorded in the clinic records. 
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Figure 5.6. Inverse probability of treatment-weighted Kaplan-Meier curves for time to next 
diarrhea episode by antibiotic treatment for the previous diarrhea episode excluding previous 
episodes >7 days duration among 430 children from Vellore, Tamil Nadu, 2009–2013. A – 
Weighted diarrhea-free survival from first to second episode; B – Weighted diarrhea-free 
survival from second to third episode; C – Weighted diarrhea-free survival for all episode pairs. 
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Figure 5.7. Inverse probability of treatment-weighted Kaplan-Meier curves for time to next 
diarrhea episode by antibiotic treatment for the previous diarrhea episode in alternative cohorts. 
A – All episodes among a cohort of 160 children from Vellore, Tamil Nadu, 2008–2011; B – All 
episodes among a cohort of 390 children from Vellore, Tamil Nadu, 2002–2006; C – From first 
to second episode among all three cohorts of 390 (2002-2006), 160 (2008-2011), and 430 (2009-
2013) children from Vellore, Tamil Nadu. 
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CHAPTER VI: THE EFFECT OF EARLY LIFE ANTIBIOTIC EXPOSURES ON 
DIARRHEAL RATES AMONG YOUNG CHILDREN IN VELLORE, INDIA 
 
Abstract 
Background 
Antibiotic treatment of childhood illnesses is common in India. In addition to 
contributing to antimicrobial resistance, antibiotics may result in increased susceptibility to 
diarrhea through interactions with the gastrointestinal microbiota. Breast milk, which enriches 
the microbiota early in life, may increase the resilience of the microbiota against perturbations by 
antibiotics. 
Methods 
In a prospective observational cohort study, we assessed whether antibiotic exposures 
from 0-5 months affected rates of diarrhea up to age 3 among 465 children from Vellore, India. 
Adjusting for treatment indicators, we modeled diarrheal rates among children exposed and 
unexposed to antibiotics using negative binomial regression. We further assessed whether the 
effect of antibiotics on diarrheal rates was modified by exclusive breastfeeding at 6 months. 
Results 
More than half of children (n=267, 57.4%) were given at least one course of antibiotics in 
the first 6 months of life. The adjusted relative incidence rate of diarrhea was 33% higher among 
children who received antibiotics under 6 months of age compared to those who did not 
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(incidence rate ratio: 1.33, 95% confidence interval: 1.12, 1.57). Children who were exclusively 
breastfed until 6 months of age did not have increased diarrheal rates following antibiotic use. 
Conclusions 
Antibiotic exposures early in life were associated with increased rates of diarrhea in early 
childhood, but exclusive breastfeeding may protect against this negative impact. While 
antibiotics must be used for treatment when necessary, the potential for increased susceptibility 
to diarrhea should be further explored.  
 
Introduction 
Antibiotics are frequently used to treat childhood illnesses, especially respiratory tract 
infections, otitis media, and diarrhea. However, many of these infections are viral and/or self-
limiting, such that antibiotics are not necessary [189,191,213]. The overuse of antibiotics among 
children has been reported around the world [213,219,220], and antibiotic over-prescribing by 
primary care physicians [9,208] in India is further compounded by the ability to purchase 
antibiotics over the counter without a prescription [210] in spite of government regulations [209].  
Often, the primary rationale given for restricting antibiotic use is to slow the development 
of antimicrobial resistance [15,211]. However, recent evidence has suggested antibiotics may 
also have a direct negative impact on the patients prescribed the drugs, primarily through 
interactions with the GI microbiota [15]. The development of the GI microbiota in the first few 
months of life coincides with a critical period of intestinal structure and immune system 
maturation [265,279,303]. A healthy microbiota is important in the early life defense against 
gastrointestinal infections by providing a barrier effect that inhibits the attachment and growth of 
pathogens [433,434]. Antibiotics impact the diversity and composition of the GI microbiota, and 
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some of these effects can persist long after treatment is completed [17,351], especially among 
infants [20,251,280,291,340]. These exposures have been further associated with impaired GI 
functioning, intestinal inflammation, increased intestinal permeability, and increased risk of 
systemic infections [301,340,357]. 
Given the potential negative impact of antibiotics on the developing microbiota, we 
assessed whether antibiotic exposure in the first 6 months of life affected subsequent rates of all-
cause diarrhea from 6 months to 3 years of age in a birth cohort from Vellore, India. We also 
explored the impact of exclusive breastfeeding, which may modify this effect given the 
beneficial role of breast milk on the microbiota [288,290,441]. 
 
Methods 
We performed an analysis of data from a prospective observational cohort study of 
immune responses in cryptosporidiosis in 497 children followed from birth to 3 years of age. The 
parent study population consisted of all children born in four geographically adjacent, semi-
urban slums of Vellore, in the state of Tamil Nadu, India between April 2009 and May 2010. The 
study population, enrollment strategy, and data collection methods have been previously 
described [28]. The study was approved by the Institutional Review Boards of the Christian 
Medical College, Vellore, India, Tufts University Health Sciences campus, Boston, USA, and 
University of North Carolina – Chapel Hill, USA. 
Briefly, baseline information on maternal demographic characteristics, socioeconomic 
indicators, health-seeking behavior, environment, diet, and characteristics of delivery were 
collected within 45 days of birth. Fieldworkers visited households of all enrolled children twice 
per week until 3 years of age to collect information on incidence, duration, and hospitalization 
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for all illnesses as well as specific severity and treatment details for reported diarrhea. Caregivers 
were asked specifically if any antibiotics were given for diarrhea (yes/no) and if so, to report the 
name of the antibiotic (available for 64.0% of antibiotic reports). Breastfeeding history 
(exclusive, non-exclusive, none) was collected every two weeks until breastfeeding was stopped 
completely. Height and weight were measured monthly at the study clinic. Antibiotic 
prescriptions and corresponding diagnoses were also extracted from records at the physician-run 
study clinic that was established in the study area to provide free health care to study children. 
 
Data and definitions 
The main exposures were any antibiotic exposure in the first 6 months of life, as well as 
the total number of antibiotic courses in the first 6 months of life, both based on a combination of 
antibiotic prescriptions recorded in clinic records and caregiver-reported antibiotic treatment at 
birth and for diarrhea. We excluded all topical antibiotics (neosporin, neomycin, soframycin, and 
gentian violet). This clinical definition of antibiotic exposure was used in all primary analyses. 
Exclusive breastfeeding was defined according to the standard WHO definition [411] as feeding 
with breast milk only with the exception of vitamins, mineral supplements, and medicines (no 
liquid, semisolid, or solid food). 
Diarrhea outcomes were based on caregiver-reported diarrhea at twice-weekly home 
visits. Diarrhea was defined using the standard WHO definition as at least three loose or watery 
stools in a 24-hour period [10]. A new episode was defined as diarrhea that occurred after at least 
2 days of normal bowel movements. Rates of diarrhea after 6 months of age per child were 
defined by the total number of incident episodes divided by the total time that child remained in 
the study. We excluded from person-time denominators days with diarrhea (when a child was not 
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at risk of incident diarrhea, 0.3% of total person-time from 6 months to 3 years), periods during 
which the child was unreachable (0.6% of person-time from 6 months to 3 years), and any time 
after loss to follow-up or death (8.2% of person-time). Because the proportion of missing data 
was less than 3% for all baseline variables (see footnote in Table 6.1), we imputed the median 
values of variables for individuals with missing data. 
 
Data analysis 
We used Poisson and negative binomial regression to model the rates of diarrhea from 6 
months to 3 years of age. The negative binomial model was preferred over the Poisson model by 
likelihood ratio test (p<0.0001) and was used in final analyses to correct for over-dispersion 
[442]. Crude and adjusted incidence rate ratios (IRRs) for diarrhea were estimated comparing 
children who were exposed to early life antibiotics to those who were not. Confounding variables 
were chosen by a causal DAG [415] based on the substantive literature, and optimal variable 
coding was determined by likelihood ratio test (α=0.1) and Akaike’s information criterion (AIC).  
Using the causal DAG, we identified the following demographic characteristics and 
measures of illness in the first 6 months for adjustment in the models: child sex, socioeconomic 
status based on the Kuppuswamy scale [431]), maternal education, household hygiene [432], 
household crowding, low birth weight (<2.5 kg), number of diarrhea episodes in first 6 months, 
total number of days with diarrhea in first 6 months, maximum Vesikari score [412] of any 
diarrhea episode in first 6 months, number of severe episodes in first 6 months (Vesikari ≥ 11), 
prolonged or persistent diarrhea episode in first 6 months, hospitalization for diarrhea in the first 
6 months, fever during diarrhea in first 6 months, dehydration during diarrhea in first 6 months, 
underweight (average weight-for-age z-score under 6 months of age <−2 SD from the 2006 
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WHO growth reference [435]), stunting (average height-for-age z-score <−2 SD), and wasting 
(average weight-for-height z-score <−2 SD) in the first 6 months, any severe illness in first 6 
months, and number of other infections in first 6 months. 
 
Effect measure modification 
We assessed whether the effect of early life antibiotic exposure on diarrheal risk after 6 
months was modified by exclusive breastfeeding at 6 months of age or at first antibiotic exposure 
by reporting stratum-specific estimates and testing homogeneity by likelihood ratio test (α=0.1). 
We further explored the role of breastfeeding by assessing the crude association between 
exclusive breastfeeding and antibiotic treatment (both any exposure under six months, using log-
risk regression, and age at first exposure, using log-transformed age with linear regression). We 
further assessed effect measure modification by sex, Cesarean section birth, age at first diarrhea, 
and growth status (underweight, stunted, wasted) in first 6 months. 
 
Sensitivity analyses 
To assess potential misclassification of the exposure, we repeated main analyses with 
more restricted definitions of antibiotic exposure that included caregiver-reported antibiotics 
only if an antibiotic name was recorded. To determine if the effect of antibiotics on diarrheal 
rates differed by antibiotic type [443,444], we repeated analyses separately comparing children 
who exclusively received one of the most commonly used antibiotics, amoxicillin and 
cotrimoxazole, to children who received no antibiotics. We were unable to assess other major 
classes of antibiotics due to few children receiving other drugs. We further assessed if the effect 
of antibiotics differed depending on 1) the indication for which antibiotic treatment was given; 2) 
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the number of diarrhea episodes experienced in the first 6 months of life; and 3) the time period 
for diarrheal outcomes (6-18 months of age compared to 18-36 months). 
 
Results 
We included 465 of 497 children in the parent cohort (93.6%) who remained in the study 
for more than 6 months and were therefore at risk for diarrhea after 6 months of age. An 
additional 11.8% of children were lost to follow-up over the remaining study period; 21, 24, and 
10 children dropped out before 1, 2, and 3 years of age respectively. All person-time during 
which these children remained in the study was included in the analysis, and differential follow-
up times were accounted for in the analytic models. Six children died after 6 months of age, and 
two of these deaths were associated with diarrhea. Two-thirds of children were of low 
socioeconomic status (n=308, 66.2%, Table 6.1). Children living in crowded households with 
more than 4 people per room were common (n=149, 32.0%), and approximately half of mothers 
reported poor household hygiene (n=221, 47.5%). By six months of age, most children had 
stopped exclusive breastfeeding (n=394, 84.7%) and had their first episode of diarrhea (n=300, 
64.5%). Demographic characteristics of the children by exclusive breastfeeding to at least 6 
months of age are shown in Table 6.2. 
Rates of diarrhea were highest between 3 and 9 months of life, with crude incidence rates 
of 28.1 cases per 100 person-months among children aged 3-6 months and 30.3 cases per 100 
person-months among children aged 6-9 months. After 6 months of age, diarrhea rates decreased 
to an average rate of 13.4 cases per 100 person-months from 6 months to 3 years, corresponding 
to a total of 1,693 episodes, or an average of 3.6 episodes per child in that period. The median 
number of diarrhea episodes after 6 months of age was 2 (interquartile range: 1, 5; Figure 6.1).  
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Antibiotic exposure in the first 6 months of life was common. More than half (n=267, 
57.4%) of children were given at least one course of antibiotics in the first 6 months (Table 6.1). 
At the study clinic, antibiotic prescriptions in this age group were most frequently associated 
with diagnoses for upper respiratory infections (n=160, 36.5% of total prescriptions), acute 
gastroenteritis (including diarrhea; n=111, 25.3%), lower respiratory infections (n=71, 16.2%), 
and acute otitis media (n=18, 4.1%). Almost all children (n=415, 89.2%) also received 
antibiotics after 6 months of age, and children who were given antibiotics under 6 months were 
more likely to receive antibiotics after 6 months compared to children who were not given 
antibiotics under 6 months (Table 6.1). 
Amoxicillin and sulfamethoxazole/trimethoprim (cotrimoxazole) were the most 
commonly given antibiotics. Children were generally given amoxicillin for respiratory illnesses, 
and cotrimoxazole for gastrointestinal illnesses. Approximately one-third of children received 
either or both of these antibiotics before 6 months of age. Less common antibiotic exposures 
were cefixime (4.3% of children received cefixime under 6 months of age), fluoroquinolones 
(ciprofloxacin, norfloxacin, and levofloxacin; 2.4%), and azithromycin (1.7%). 
 
Effect of antibiotics on diarrheal rates 
Antibiotic exposure under 6 months of age was crudely associated with an increase in 
diarrhea rates from 6 months to 3 years (Table 6.3). After multivariable adjustment, the relative 
incidence rate of diarrhea was 33% higher among children who had at least one course of 
antibiotics under 6 months of age compared to those who did not (IRR: 1.33, 95% CI: 1.12, 
1.57). There was no significant difference in the effect by the number of antibiotic courses 
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received. Children who received three or more courses of antibiotics had a slightly lower relative 
increase compared to one or two courses, though this estimate was less precise (Table 6.3).  
 
Effect measure modification 
The effect of early antibiotic exposure differed by exclusive breastfeeding practices in the 
first 6 months of life (p for heterogeneity = 0.003). Children who were exclusively breastfed 
until at least 6 months of age (n=71) did not show an increase in diarrheal rates associated with 
antibiotic exposure (Table 6.4). Conversely, among children who had discontinued exclusive 
breastfeeding before 6 months (n=394), any early antibiotic exposure was associated with a 48% 
relative increase in diarrheal rates (IRR: 1.48, 95% CI: 1.23, 1.78). Results were qualitatively 
similar when restricting to exclusive breastfeeding at the first antibiotic exposure: the relative 
increase in diarrheal rates among children who were exclusively breastfed at their first antibiotic 
exposure was less than that among children who were not exclusively breastfed at their first 
antibiotic exposure (Table 6.5).  
While breastfeeding modified the effect of antibiotics, duration of exclusive 
breastfeeding was not crudely associated with antibiotic use in the first 6 months of life. Children 
who were exclusively breastfed until at least 6 months were equally likely to be exposed to early 
life antibiotics as children who stopped exclusive breastfeeding before 6 months (crude risk 
ratio: 0.94, 95% CI: 0.76, 1.15). There was also no crude linear relationship between age at 
stopping exclusive breastfeeding and age at first antibiotic use (β = -0.0000, 95% CI: -0.0013, 
0.0012).  
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There was no evidence of effect measure modification of the impact of antibiotics on 
diarrheal rate by sex, Cesarean section birth, age at first diarrhea, or growth status in the first 6 
months of life.  
 
Sensitivity analyses 
In an alternative definition of antibiotic exposure, we included caregiver-report only if an 
antibiotic was named. Adjusted effects were qualitatively similar, but slightly closer to the null, 
for both overall effects and effects stratified by exclusive breastfeeding (Table 6.6). 
There were no differences in the effect on diarrheal rates by antibiotic drug type. A 
sufficient number of children received amoxicillin (n=145) and cotrimoxazole (n=158) for 
multivariate analyses. The adjusted IRR comparing children exposed to only amoxicillin to 
children who received no antibiotics was 1.46 (95% CI: 1.12, 1.90), which was similar to the rate 
ratio comparing children exposed to only cotrimoxazole to unexposed children: 1.32 (95% CI: 
1.04, 1.69; Table 6.7).  
There was no difference in the effect of antibiotics on diarrheal rates depending on the 
indicating illness for antibiotic treatment. Children treated with antibiotics for only diarrheal and 
only non-diarrheal illnesses had similar increases in diarrhea rates after 6 months of age (Table 
6.8). The effect was also the same regardless of the number of diarrhea episodes experienced 
during the first 6 months (Table 6.9), and the time period for diarrheal outcomes (6-18 months of 
age compared to 18-36 months; Table 6.10).  
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Discussion 
Our study provides the first evidence that antibiotic treatment early in life is associated 
with increased rates of all-cause diarrhea from 6 months to 3 years of age, even when controlling 
for indications for treatment such as illness burden and severity. Further, we found that exclusive 
breastfeeding during antibiotic exposure may be protective against the effects of antibiotics since 
antibiotic exposure was not associated with increased diarrheal rates among children who were 
exclusively breastfed for at least the first 6 months of life.  
The effect of antibiotic treatment on diarrheal risk may be mediated by a prolonged effect 
of the antibiotics on microbiota composition [17] or through collateral effects on intestinal 
structure and function relating to inflammation, permeability, and intestinal immunity [247,357]. 
In this way, antibiotics could affect susceptibility to diarrhea due to diverse causes. The strong 
effect modification by exclusive breastfeeding may also be explained by interactions with the 
microbiota. Bacteria such as Lactobacillus are present in breast milk and are thought to be 
beneficial: in a randomized trial of a Lactobacillus strain present in breast milk, infants given the 
probiotic demonstrated reduced incidence of gastrointestinal infections [441,445]. The protective 
effect of breastfeeding suggests the microbiota enriched by breast milk may be more resistant to 
perturbations by antibiotics. 
Antibiotic treatment in the first 6 months of life was common among study children 
(57.4%). In the US and UK, the proportion of children treated under 6 months of age based on 
caregiver-report is reported to be lower, at approximately one third of children [11,12]. Higher 
rates of antibiotic use in our study population may be due to higher rates of infection, better 
capture of antibiotic prescriptions in clinic records, and greater availability of antibiotics without 
prescriptions.  
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 The main limitation of this study was potential under-ascertainment of antibiotic 
exposures for antibiotics obtained outside of the study clinic for non-diarrheal illnesses. 
However, we expect almost all antibiotic exposures to be captured in clinic records since the 
study clinic was conveniently located in the residential area where study children lived and 
provided clinical care and medicines free of charge. High concordance between caregiver-
reported and antibiotic prescriptions for diarrhea supports our assumption that most antibiotic 
exposures were recorded in clinic records (78% of antibiotic prescriptions during diarrhea 
episodes were associated with caregiver-reported antibiotic treatment). The validity of caregiver-
reported antibiotics was supported in sensitivity analyses by consistent results when using a more 
restricted definition of antibiotic exposure that required caregivers to list an antibiotic name.  
We also did not have information on the duration of antibiotic exposures. Length of 
therapy may be an important component of the effect of antibiotics on diarrheal risk given the 
potential for longer antibiotic exposure periods to have increased impact on the microbiota 
[17,351,443]. While we were unable to assess the potential dose-response relationship between 
duration of exposures and increased diarrheal rates, we do not expect that this more detailed 
information would alter our overall conclusions of an effect of antibiotics on diarrheal rates. 
While we cannot ensure the absence of confounding in this observational study, we have 
adjusted for detailed treatment indications associated with disease severity that also predict 
diarrheal risk. As well, because a clinical trial which randomized all antibiotic treatment in this 
setting would be unethical, we believe this evidence from a well-conducted prospective 
observational cohort study with good follow-up provides important preliminary evidence 
towards understanding the impact of antibiotics on diarrheal risk. Antibiotics are commonly 
given during infancy at a time in which the developing gastrointestinal microbiota is most 
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sensitive to perturbations. While these drugs are lifesaving and should be used for treatment 
when necessary, the possibility for antibiotics to increase risk of future diarrheal disease should 
be further explored and potentially considered when making treatment decisions. 
  
141 
 
Table 6.1. Demographic characteristics of 465 children in a birth cohort in Vellore, Tamil Nadu, 
India 2009-2013.  
 
No antibiotics 
 0-5 months 
(n=198) 
Antibiotics 
0-5 months  
(n=267) 
 
No. children 
(%) No. children (%) 
Household characteristics   
Socioeconomic status*   
Low 139 (70.2) 169 (63.3) 
Medium 56 (28.3) 93 (34.8) 
High 3 (1.5) 5 (1.9) 
Maternal education   
No formal education 71 (35.9) 99 (37.1) 
Primary/middle school 72 (36.4) 86 (32.2) 
Higher secondary school 50 (25.3) 73 (27.3) 
College/polytechnic/professional school 5 (2.5) 9 (3.4) 
Poor household hygiene† 89 (45.0) 135 (50.6) 
Crowding   
Low (≤ 3 people/room) 39 (19.7) 96 (36.0) 
Medium (3.1-4 people/room) 90 (45.5) 91 (34.1) 
High (>4 people/room) 69 (34.9) 80 (30.0) 
Child characteristics   
Sex of child   
Male 97 (49.0) 149 (55.8) 
Female 101 (51.0) 118 (44.2) 
Cesarean section 32 (16.2) 50 (18.7) 
Low birth weight‡ 36 (18.2) 42 (15.7) 
Baby kept in ICU at birth 10 (5.1) 23 (8.6) 
Antibiotics at birth‡ 0 12 (4.5) 
Age at first diarrhea   
<6 months 100 (50.5) 200 (74.9) 
6 months – 1 year 58 (29.3) 38 (14.2) 
>1 year 17 (8.6) 14 (5.2) 
No diarrhea 23 (11.6) 15 (5.6) 
Number of diarrhea episodes 0-5 months   
0 98 (49.5) 67 (25.1) 
1 52 (26.3) 75 (28.1) 
2 34 (17.2) 68 (25.5) 
3+ 14 (7.1) 57 (21.4) 
Age (months) at stopping exclusive 
breastfeeding (mean, SD) 
4.0 (2.20) 3.9 (1.98) 
Age (months) at stopping all breastfeeding 
(mean, SD) 
16.8 (7.95) 16.7 (8.57) 
Underweight in first 6 mo. 50 (25.3) 74 (27.7) 
Stunted in first 6 mo. 34 (17.2) 67 (25.1) 
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Wasted in first 6 mo. 34 (17.2) 38 (14.2) 
Antibiotic use in first 6 mo.   
1 – 135 (50.6) 
2 – 74 (27.7) 
3+ – 58 (21.7) 
Antibiotic use 6 mo.-3 years.   
1 23 (11.6) 16 (6.0) 
2 27 (13.6) 22 (8.2) 
3+ 118 (59.6) 209 (78.3) 
*Socioeconomic status categories defined from the Kuppuswamy scale based on educational and 
occupational level of the family, house ownership, total number of rooms in the house, and household 
possessions [431] 
†Poor household hygiene was based on a score of less than 12 on a scale developed from an assessment 
of water, food, and personal hygiene [432] 
‡7 missing values for low birth weight; 14 missing values for antibiotics at birth; SD – standard deviation; 
ICU – intensive care unit 
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Table 6.2. Demographic characteristics of 465 children by exclusive breastfeeding at 6 months 
of age in a birth cohort in Vellore, Tamil Nadu, India 2009-2013. 
 
Exclusively 
breastfed until at 
least 6 mo. (n=71) 
No longer exclusively 
breastfed at 6 mo. 
(n=394) 
 No. children (%) No. children (%) 
Household characteristics   
Socioeconomic status*   
Low 53 (74.7) 255 (64.7) 
Medium 17 (23.9) 132 (33.5) 
High 1 (1.4) 7 (1.8) 
Maternal education   
No formal education 30 (42.3) 140 (35.5) 
Primary/middle school 23 (32.4) 135 (34.3) 
Higher secondary school 17 (23.9) 106 (26.9) 
College/polytechnic/professional 
school 
1 (1.4) 13 (3.3) 
Poor household hygiene† 36 (50.7) 208 (52.8) 
Crowding   
Low (≤ 3 people/room) 19 (26.8) 116 (29.4) 
Medium (3.1-4 people/room) 27 (38.0) 154 (39.1) 
High (>4 people/room) 25 (35.2) 124 (31.5) 
Child characteristics   
Sex of child   
Male 39 (54.9) 207 (52.5) 
Female 32 (45.1) 187 (47.5) 
Cesarean section 10 (14.1) 72 (18.3) 
Low birth weight‡ 11 (15.5) 67 (17.0) 
Baby kept in ICU at birth 4 (5.6) 29 (7.4) 
Antibiotics at birth‡ 3 (4.2) 9 (2.3) 
Age at first diarrhea   
<6 months 41 (57.8) 259 (65.7) 
6 months – 1 year 17 (23.9) 79 (20.1) 
>1 year 6 (8.5) 25 (6.4) 
No diarrhea 7 (9.9) 31 (7.9) 
Number of diarrhea episodes 0-5 months   
0 30 (42.3) 135 (34.3) 
1 17 (23.9) 110 (27.9) 
2 18 (25.4) 84 (21.3) 
3+ 6 (8.5) 65 (16.5) 
Age (months) at stopping exclusive 
breastfeeding (mean, SD) 
7.0 (1.34) 3.4 (1.67) 
Age (months) at stopping all 
breastfeeding (mean, SD) 
19.9 (7.45) 16.2 (8.33) 
Antibiotic use in first 6 mo.   
0 28 (39.4) 170 (43.2) 
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1 20 (28.2) 115 (29.2) 
2 17 (23.9) 57 (14.5) 
3+ 6 (8.5) 52 (13.2) 
*Socioeconomic status categories defined from the Kuppuswamy scale based on educational and 
occupational level of the family, house ownership, total number of rooms in the house, and household 
possessions 
†Poor household hygiene was based on a score of less than 12 on a scale developed from an assessment 
of water, food, and personal hygiene 
‡7 missing values for low birth weight; 14 missing values for antibiotics at birth; SD – standard deviation  
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Table 6.3. Estimated effect of antibiotic exposure in the first 6 months of life on incident rates of 
diarrhea from 6 months to 3 years of age among 465 children in a birth cohort in Vellore, Tamil 
Nadu, India 2009-2013. 
    Incidence rate ratio (95% CI) 
 
  
No. of 
children  
Rate of 
diarrhea* Crude Adjusted† 
Antibiotics <6 
months 
No 198 10.1 1.  1. 
Yes 267 15.9 1.58 (1.33, 1.88) 1.33 (1.12, 1.57) 
      
Number of 
antibiotic 
courses 
0 198 10.1 1.  1. 
1 135 15.0 1.49 (1.22, 1.83) 1.36 (1.12, 1.64) 
2 74 16.7 1.66 (1.30, 2.11) 1.35 (1.07, 1.70) 
3+ 58 17.0 1.69 (1.28, 2.22) 1.17 (0.89, 1.55) 
*Rate per 100 person-months 
†Incident rate ratio adjusted for covariates listed in the methods and specified in the supplemental 
material. 
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Table 6.4. Estimated effect of antibiotic exposure in the first 6 months of life on rates of diarrhea 
from 6 months to 3 years of age by exclusive breastfeeding at 6 months of age among 465 
children in a birth cohort in Vellore, Tamil Nadu, India 2009-2013. 
 
  
No. of 
children 
Adjusted IRR* 
(95% CI) 
Exclusively breastfed at 6 mo. (n=71)   
Antibiotics <6 months No 28 1.  
Yes 43 0.76 (0.50, 1.13) 
Number of antibiotic courses† 0 28 1.  
1 20 0.73 (0.45, 1.19) 
2+ 23 0.77 (0.48, 1.23) 
Not exclusively breastfed at 6 mo. (n=394)   
Antibiotics <6 months No 170 1.  
 Yes 224 1.48 (1.23, 1.78) 
Number of antibiotic courses† 0 170 1.  
 1 115 1.53 (1.24, 1.88) 
 2+ 109 1.42 (1.14, 1.77) 
*Incident rate ratio adjusted for covariates listed in the methods and specified in the supplemental 
material. 
†Categorization reduced to 0, 1, and 2+ courses because of small sample size (reduced model is supported 
by AIC). 
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Table 6.5. Estimated effect of antibiotics in the first 6 months of life and exclusive breastfeeding 
at first antibiotic exposure on rates of diarrhea from 6 months to 3 years of age among 465 
children in a birth cohort in Vellore, Tamil Nadu, India 2009-2013. 
 
No. of 
children 
Adjusted IRR*  
(95% CI) 
No antibiotic exposure 198 1. 
Exclusively breastfed at 
first antibiotic exposure 163 1.28 (1.06, 1.54) 
Not exclusively breastfed at 
first antibiotic exposure 104 1.40 (1.14, 1.74) 
*Incident rate ratio adjusted for child sex, socioeconomic status, maternal education, household hygiene, 
household crowding, low birth weight, number of diarrhea episodes in first 6 months, total number of 
days with diarrhea in first 6 months, maximum Vesikari score of diarrhea episodes in first 6 months, 
number of severe (Vesikari ≥ 11) episodes in first 6 months, prolonged or persistent diarrhea episode in 
first 6 months, hospitalization for diarrhea in the first 6 months, fever during diarrhea in first 6 months, 
dehydration during diarrhea in first 6 months, underweight, stunted, and wasted in the first 6 months, any 
severe illness in first 6 months, number of other infections in first 6 months 
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Table 6.6. Estimated effect of antibiotic exposure in the first 6 months of life using an alternative 
definition of exposure* on rates of diarrhea from 6 months to 3 years of age among 465 children 
in a birth cohort in Vellore, Tamil Nadu, India 2009-2013. 
    Incidence rate ratio (95% CI) 
 
  
No. of 
children  
Rate of 
diarrhea† Crude Adjusted‡ 
Antibiotics <6 
months 
No 208 10.8 1.  1. 
Yes 257 15.5 1.44 (1.21, 1.71) 1.25 (1.06, 1.48) 
Number of 
antibiotic 
courses 
0 208 10.8 1.  1. 
1 134 14.6 1.35 (1.11, 1.66) 1.28 (1.06, 1.54) 
2 73 16.6 1.53 (1.20, 1.96) 1.30 (1.03, 1.63) 
3+ 50 16.6 1.54 (1.15, 2.06) 1.07 (0.80, 1.43) 
*Children were considered exposed based on caregiver-report only if an antibiotic name was recorded 
†Rate per 100 person-months 
‡Adjusted for child sex, socioeconomic status, maternal education, household hygiene, household 
crowding, low birth weight, number of diarrhea episodes in first 6 months, total number of days with 
diarrhea in first 6 months, maximum Vesikari score of diarrhea episodes in first 6 months, number of 
severe (Vesikari ≥ 11) episodes in first 6 months, prolonged or persistent diarrhea episode in first 6 
months, hospitalization for diarrhea in the first 6 months, fever during diarrhea in first 6 months, 
dehydration during diarrhea in first 6 months, underweight, stunted, and wasted in the first 6 months, any 
severe illness in first 6 months, number of other infections in first 6 months. 
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Table 6.7. Estimated effect of specific antibiotics in the first 6 months of life on rates of diarrhea 
from 6 months to 3 years of age among 398* children in a birth cohort in Vellore, Tamil Nadu, 
India 2009-2013. 
 
 
No. of 
childre
n Adjusted IRR† (95% CI) 
No antibiotics 198 1. 
Amoxicillin only 68 1.46 (1.12, 1.90) 
Cotrimoxazole only 79 1.32 (1.04, 1.69) 
Amoxicillin and cotrimoxazole  53 1.31 (0.97, 1.76) 
*67 children who were exposed an antibiotic other than amoxicillin or cotrimoxazole or to unknown 
antibiotics were excluded 
†Incident rate ratio adjusted for child sex, socioeconomic status, maternal education, household hygiene, 
household crowding, low birth weight, number of diarrhea episodes in first 6 months, total number of 
days with diarrhea in first 6 months, maximum Vesikari score of diarrhea episodes in first 6 months, 
number of severe (Vesikari ≥ 11) episodes in first 6 months, prolonged or persistent diarrhea episode in 
first 6 months, hospitalization for diarrhea in the first 6 months, fever during diarrhea in first 6 months, 
dehydration during diarrhea in first 6 months, underweight, stunted, and wasted in the first 6 months, any 
severe illness in first 6 months, number of other infections in first 6 months 
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Table 6.8. Estimated effect of antibiotic treatment of specific illnesses in the first 6 months of 
life on rates of diarrhea from 6 months to 3 years of age among 394* children in a birth cohort in 
Vellore, Tamil Nadu, India 2009-2013. 
 
 
No. of 
childre
n Adjusted IRR† (95% CI) 
No antibiotics 198 1. 
Antibiotics for diarrhea only 49 1.30 (0.94, 1.79) 
Antibiotics for non-diarrheal illnesses only 147 1.41 (1.16, 1.71) 
*71 children who were treated with antibiotics for both diarrhea and non-diarrheal illnesses were 
excluded 
†Incident rate ratio adjusted for child sex, socioeconomic status, maternal education, household hygiene, 
household crowding, low birth weight, number of diarrhea episodes in first 6 months, total number of 
days with diarrhea in first 6 months, maximum Vesikari score of diarrhea episodes in first 6 months, 
number of severe (Vesikari ≥ 11) episodes in first 6 months, prolonged or persistent diarrhea episode in 
first 6 months, hospitalization for diarrhea in the first 6 months, fever during diarrhea in first 6 months, 
dehydration during diarrhea in first 6 months, underweight, stunted, and wasted in the first 6 months, any 
severe illness in first 6 months, number of other infections in first 6 months 
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Table 6.9. Estimated effect of antibiotic treatment of specific illnesses in the first 6 months of 
life on rates of diarrhea from 6 months to 3 years of age among 465 children in a birth cohort in 
Vellore, Tamil Nadu, India 2009-2013. 
No. diarrhea 
episodes 0-6 
months 
Antibiotics <6 
months 
No. of 
children 
Adjusted IRR* 
(95% CI) 
0 No 98 1. 
Yes 67 1.31 (0.99, 1.75) 
1 No 52 1. 
Yes 75 1.30 (0.96, 1.78) 
2 No 34 1. 
Yes 68 1.44 (1.02, 2.03) 
3+ No 14 1. 
Yes 57 1.30 (0.80, 2.10) 
*Incident rate ratio adjusted for child sex, socioeconomic status, maternal education, household hygiene, 
household crowding, low birth weight, number of diarrhea episodes in first 6 months, total number of 
days with diarrhea in first 6 months, maximum Vesikari score of diarrhea episodes in first 6 months, 
number of severe (Vesikari ≥ 11) episodes in first 6 months, prolonged or persistent diarrhea episode in 
first 6 months, hospitalization for diarrhea in the first 6 months, fever during diarrhea in first 6 months, 
dehydration during diarrhea in first 6 months, underweight, stunted, and wasted in the first 6 months, any 
severe illness in first 6 months, number of other infections in first 6 months 
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Table 6.10. Estimated effect of antibiotic exposures in the first 6 months of life on rates of 
diarrhea from 6-18 months and 18-36 months among 465 children in a birth cohort in Vellore, 
Tamil Nadu, India 2009-2013. 
 
Outcome  
No. of 
children 
Adjusted IRR* 
(95% CI) 
Diarrheal rates from 6-18 months of age   
Antibiotics <6 months No 198 1.  
Yes 267 1.30 (1.08, 1.56) 
Number of antibiotic courses‡ 0 198 1.  
1 135 1.32 (1.07, 1.62) 
2 74 1.28 (1.00, 1.64) 
 3+ 58 1.26 (0.94, 1.69) 
Diarrheal rates from 18-36 months of age†   
Antibiotics <6 months No 182 1.  
 Yes 247 1.35 (1.05, 1.72) 
Number of antibiotic courses 0 182 1.  
 1 128 1.41 (1.07, 1.85) 
 2 70 1.44 (1.04, 1.99) 
 3+ 49 0.90 (0.59, 1.37) 
*Incident rate ratio adjusted for child sex, socioeconomic status, maternal education, household hygiene, 
household crowding, low birth weight, number of diarrhea episodes in first 6 months, total number of 
days with diarrhea in first 6 months, maximum Vesikari score of diarrhea episodes in first 6 months, 
number of severe (Vesikari ≥ 11) episodes in first 6 months, prolonged or persistent diarrhea episode in 
first 6 months, hospitalization for diarrhea in the first 6 months, fever during diarrhea in first 6 months, 
dehydration during diarrhea in first 6 months, underweight, stunted, and wasted in the first 6 months, any 
severe illness in first 6 months, number of other infections in first 6 months 
†Excludes 36 children who dropped out of the study before 18 months of age 
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Figure 6.1. Number of diarrhea episodes after 6 months of age among 465 children in a birth 
cohort in Vellore, Tamil Nadu, India 2009-2013. 
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CHAPTER VII: REDUCTION IN DIARRHEAL RATES THROUGH INTERVENTIONS 
THAT PREVENT UNNECESSARY ANTIBIOTIC EXPOSURE EARLY IN LIFE 
 
Abstract 
Background 
Antibiotic exposure before 6 months of age has been associated with increased rates of 
subsequent diarrhea. We estimated the impact of realistic interventions that would prevent 
unnecessary antibiotic exposures early in life on childhood diarrheal rates. 
Methods 
In data from a prospective observational cohort study conducted in Vellore, India, we 
used the parametric g-formula to model diarrheal incidence rate differences contrasting the 
observed incidence of diarrhea to the incidence expected under hypothetical interventions. The 
interventions prevented unnecessary antibiotic treatments for non-bloody diarrhea, vomiting, and 
upper respiratory infections before 6 months of age. We also modeled targeted interventions, in 
which unnecessary antibiotic use was prevented only among children who had already stopped 
exclusive breastfeeding. 
Results 
More than half of all antibiotic exposures before 6 months (58.9%) were likely 
unnecessary. The incidence rate difference associated with removing unnecessary antibiotic use 
before 6 months of age was -0.28 (95% CI: -0.47, -0.11) episodes per 30 child-months. This 
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implies that preventing unnecessary antibiotic exposures in just 4 children would reduce the 
incidence of diarrhea by one from 6 months to 3 years of age. 
Conclusions 
Interventions to reduce unnecessary antibiotic use among young children could result in 
an important reduction in diarrheal rates. This work provides an example application of statistical 
methods which can further the aim of presenting epidemiologic findings that are relevant to 
public health practice. 
 
Introduction 
Antibiotic treatment of childhood illnesses is common around the world, including for 
uncomplicated cases of acute gastroenteritis (AGE) and upper respiratory infections (URI) [218–
220]. However, antibiotic treatment is often unnecessary for these illnesses, which are usually 
self-limited regardless of etiology [221,222]. Further, antibiotics are not effective against the 
viral pathogens often responsible for these illnesses [218,223,224], and antibiotics may elicit 
adverse reactions or make the illness worse [191,218]. Indiscriminate antibiotic use also 
contributes to antimicrobial resistance and the potential for antibiotics to become ineffective for 
future treatment of disease [191,218,221]. Correspondingly, international organizations, 
including the World Health Organization, recommend against routine use of antibiotics to treat 
non-bloody diarrhea and URI [10,188,218]. 
In a recent publication, we provided evidence that antibiotic treatment of any illness early 
in life may increase diarrheal risk [438]. Specifically, the relative incidence rate of diarrhea from 
6 months to 3 years of age was 33% higher among all children who received at least one course 
of antibiotics before 6 months of age compared to children who did not receive antibiotics 
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(adjusted IRR: 1.33, 95% confidence interval: 1.12, 1.57). There was effect modification by 
exclusive breastfeeding, such that children who were exclusively breastfed until at least 6 months 
of age did not have increased diarrheal rates associated with antibiotic exposure [438]. We 
hypothesize that these effects were mediated by the gastrointestinal microbiota, which is 
important for intestinal immune function [433,434]. Antibiotics alter the composition of the 
microbiota [17], and have been associated with increased intestinal inflammation, intestinal 
permeability, and susceptibility to infections [433,434]. 
In this previous work, we compared a counterfactual scenario in which all of the children 
were exposed to antibiotics before 6 months to a scenario in which none of the children were 
exposed to antibiotics before 6 months. This all-versus-none contrast is the default effect 
reported in most statistical analyses and is termed in the methodological literature as the average 
treatment effect or population average causal effect [425]. This contrast implies an intervention 
that would remove all antibiotic exposures before 6 months of age. However, some illnesses 
require antibiotic treatment, and the benefits of curing these illnesses likely outweigh any costs 
associated with future diarrheal risk. Therefore, the population average causal effect represents 
an intervention that is unrealistic and unethical.  
A more plausible public health intervention would be one that prevents only unnecessary 
antibiotic use, such as antibiotic exposures for the treatment of AGE without bloody diarrhea and 
URI. Here, we used the parametric g-formula [420,421,424,425] to estimate intervention effects 
that are more relevant to public health policy in addition to the usual exposure effects 
[420,425,446]. Specifically, we estimated the effects of interventions that would remove only 
unnecessary antibiotic exposures before 6 months of age, both in the general study population 
and when targeted to children no longer exclusively breastfed since children who stopped 
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exclusive breastfeeding before 6 months of age had the greatest increase in diarrheal risk 
associated with antibiotics [438].  
 
Methods 
We analyzed data from a prospective observational cohort study of immune responses in 
cryptosporidiosis in 497 children followed from birth to 3 years of age. The study population 
consisted of all children born in four geographically adjacent, semi-urban slums of Vellore, 
Tamil Nadu, India between April 2009 and May 2010. Children were followed twice-weekly for 
diarrhea episodes, defined as at least three loose or watery stools in a 24-hour period [10], and 
antibiotic use. Other illnesses were assessed and treated at a conveniently located and free study 
clinic. The study population, enrollment strategy, and data collection methods have been 
previously described [28]. The data and analytic definitions were described in our previous 
analysis of the effect of early life antibiotic use on diarrheal rates in this study population [438]. 
Briefly, we used negative binomial regression to estimate IRRs for diarrhea from 6 
months to 3 years comparing children who received any antibiotics before 6 months of age to 
children who did not. Because we did not detect a dose-response relationship between the 
number of antibiotic courses received and diarrheal rates, we used a binary classification of 
antibiotic exposure comparing at least one antibiotic course received to no courses received. We 
adjusted for demographic characteristics and measures of illness in the first 6 months as 
indicated in the footnote of Table 2. 
To classify potentially unnecessary antibiotic use, we characterized antibiotic treatments 
by indicating diagnosis: AGE (further categorized into bloody diarrhea, non-bloody diarrhea, or 
vomiting only), URI, and other. Diagnoses for diarrhea and presence of bloody stools were 
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recorded in the cohort study data. Diagnoses for all other illnesses were extracted from study 
clinic records as documented by clinic physicians and did not correspond to specified illness 
definitions. We classified antibiotics for non-bloody diarrhea as “not indicated” according to 
clinical guidelines given our confidence in the diarrhea case definition. We considered 
antibiotics for URI and vomiting as “likely not indicated” to reflect the potential variability and 
uncertainty in clinic diagnoses. Antibiotics given for all other illnesses, including cases of bloody 
diarrhea, were considered necessary. 
 
Statistical methods 
We used the parametric g-formula [420–425] to estimate contrasts associated with the 
effect of antibiotic use on diarrheal rates. Broadly, the parametric g-formula can be understood as 
a parametric approach to standardization to specific covariate and exposure distributions [422]. 
More specifically, the procedure for fitting the g-formula was as follows: we 1) estimated beta 
coefficients for the observed exposure and covariates using the negative binomial model with 
rates of diarrhea from 6 months to 3 years as the outcome; 2) used the estimated coefficients to 
predict the incidence rate of diarrhea in all individuals under the index exposure and again under 
the referent exposure; 3) averaged the predicted outcomes across individuals in the exposure 
groups; and 4) compared the average outcomes to estimate the population-standardized rate 
difference. Confidence intervals were constructed by bootstrap of the above steps with 200 
replicates [419]. We also estimated the number needed to treat (NNT) for each contrast as the 
reciprocal of the rate difference. In this setting, the NNT is more precisely the “number needed to 
intervene” by withholding unnecessary antibiotic treatment in the first 6 months of life. 
However, we maintain the usual terminology here for simplicity. Because the NNT is calculated 
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from the rate difference, it is interpreted as the NNT to see a one episode reduction in diarrhea 
incidence over the 30-month period from 6 months to 3 years of age. The parametric g-formula 
in this setting is equivalent to parametric standardization to the full population distribution of 
covariates [422]. 
We considered two interventions: (i) removing all antibiotics that were classified as not 
indicated before 6 months of age, and (ii) additionally removing those likely not indicated before 
6 months of age. All other antibiotic exposures were not affected by the simulated interventions. 
Given our binary exposure classification (exposed to at least one course of antibiotics versus 
none), children remained exposed to antibiotics if they had any necessary antibiotic exposures. 
Children who received only unnecessary antibiotics moved from exposed to unexposed after the 
interventions. When targeted, the interventions were applied only to children who were treated 
after they had stopped exclusive breastfeeding.  
The index and referent exposures are described for each contrast in Table 1. The referent 
exposures correspond to the observed exposures in all cases except for the population average 
causal effect, in which the referent is a counterfactual scenario in which all children were treated 
with at least one course of antibiotics. The index exposures refer to counterfactual scenarios that 
would occur if all antibiotic exposures were removed (in the cases of the population average 
causal effect and population attributable contrast) or if the interventions were to be implemented 
(in the cases of the generalized and targeted intervention contrasts).  
In sensitivity analyses, we estimated the population average and generalized intervention 
contrasts in the exposed population only. These effects, commonly termed the “effect of 
treatment in the treated,” estimate the contrasts for a target population with the same distribution 
of covariates as the exposed population instead of as the total study population. Correspondingly, 
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the parametric g-formula in this setting is equivalent to a parametric approach to standardization 
to the exposed population distribution of covariates [422]. The referent and index exposures are 
the same as those in the corresponding contrasts in the total study population. These effects are 
appropriate when effect measure modification is expected by covariates that differ between the 
exposed and unexposed groups [447–449]. 
In a second sensitivity analysis, we expanded our models to estimate separate coefficients 
for the effects of necessary and unnecessary antibiotics and included the interaction between 
them to account for any differences in the antibiotic effect by indicating condition.  
 
Results 
Among 465 children in the parent cohort who remained in the study for more than 6 
months (93.6%), 25.4% and 12.6% of antibiotic exposures from birth to 3 years of age were 
given for non-bloody diarrhea (not indicated) and URI or vomiting (likely not indicated) 
respectively (Figure 1). More than half (n=267, 57.4%) of children were given at least one course 
of antibiotics in the first 6 months of life, among whom the median number of antibiotic courses 
received was one (mean=1.9, SD=1.14). Nearly one-third of antibiotics before 6 months (32.3%) 
were not indicated according to our classification, and another 26.6% were likely not indicated. 
Under Intervention (i), which removed antibiotics that were not indicated (32.3%), 217 children 
(46.7%) remained exposed to necessary antibiotics. Under Intervention (ii), which removed 
antibiotics that were not or likely not indicated before 6 months of age (58.9%), only 162 
children (34.8%) remained exposed, resulting in more than a 20% absolute reduction in exposed 
children. The average length of follow-up was 2.29 years (27.24 months). 
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The effect estimates for each contrast are shown in Table 2. The rate difference 
associated with the population average causal rate difference was the largest in magnitude 
(incidence rate difference (IRD): -1.11 diarrhea episodes per 30 person-months, 95% CI: -1.96, -
0.47) since this effect represents the most extreme contrast (all children versus none exposed to 
antibiotics) and does not correspond to a realistic reduction in antibiotic use. The population 
attributable incidence rate difference (IRD: -0.67 episodes per 30 person-months, 95% CI: -1.14, 
-0.27) was smaller since the exposure was unchanged among the 42.6% of children who were 
not exposed to antibiotics before 6 months of age in this index scenario. 
We then estimated the contrasts associated with the impact of implementing the 
hypothetical interventions to reduce antibiotic use. The implementation of Intervention (i) in the 
total study population—removing antibiotic treatment for non-bloody diarrhea—would result in 
0.15 fewer diarrhea episodes per child on average from 6 months to 3 years of age (IRD: -0.15 
episodes per 30 person-months, 95% CI: -0.27, -0.04; Table 2). Further removing antibiotics for 
URI and vomiting in Intervention (ii) would result in nearly double that effect: 0.28 fewer 
diarrhea episodes per 30 person-months (IRD: -0.28 episodes per 30 person-months, 95% CI: -
0.47, -0.11).  
The effects of the interventions were smaller in magnitude than the population average 
causal rate difference since the interventions would remove only a proportion of (rather than all) 
antibiotic exposures. Comparatively, the generalized intervention rate difference for Intervention 
(i) was 14% of the population average causal rate difference and 25% of this effect for 
Intervention (ii), which removed a greater proportion of antibiotics. 
The targeted intervention rate differences were smaller in magnitude than the generalized 
intervention rate differences because while the majority of children stopped exclusive 
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breastfeeding before 6 months (n=394, 84.7%), over half of antibiotic exposures occurred while 
the children were still exclusively breastfed (55.5%) and were therefore not removed by the 
targeted intervention. Intervention (ii) implemented only after children stopped exclusively 
breastfeeding would result in 0.17 fewer diarrhea episodes on average per child over the 30 
months from 6 months to 3 years of age (IRD: -0.17 episodes per 30 person-months, 95% CI: -
0.27, -0.10; Table 2).  
The corresponding NNTs were very low for these effects (Table 2). Assuming the 
generalized intervention rate difference for Intervention (ii) was unbiased, we would need to 
remove unnecessary antibiotic exposures before 6 months of age for only 3.6 children to see a 
reduction in diarrhea incidence by one episode during the 30 months between 6 months to 3 
years of age (NNT: 3.6, 95% CI: 2.1, 9.1).  
 
Sensitivity analyses 
The population average causal and generalized intervention incidence rate differences 
among the children exposed to antibiotics were slightly larger in magnitude than the 
corresponding contrasts in the full study population since average rates of diarrhea were higher 
among the exposed children (4.80 episodes per 30 person-months). For example, the population 
average causal incidence rate difference in the exposed was -1.17 episodes per 30 person-months 
(95% CI: -2.01, -0.47), which is slightly larger than that in the total study population, although 
this result was not statistically significant. The intervention effects were also larger; the effect of 
Interventions (i) and (ii) in the exposed were -0.26 (95% CI: -0.47, -0.08) and -0.48 (95% CI: -
0.82, -0.19) episodes per 30 person-months respectively. However, similar effects in the exposed 
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and total study population suggest that there were not strong effect measure modifiers of the 
effect of antibiotics on either the difference or ratio scales. 
When allowing for different effects of necessary and unnecessary antibiotics in the 
models, the results did not change qualitatively. The magnitudes of the estimated contrasts were 
very similar, though the estimates were less precise (Table 3). 
 
Discussion 
This study provides estimates of the potential impact of interventions to reduce antibiotic 
use among children in the first 6 months of life. These findings are more relevant to public health 
policy than our previously reported population average causal effect [425,450,451], which best 
corresponds to patient-level effects and may be more appropriate when making individual 
treatment decisions. The population average causal rate difference and the population attributable 
rate difference do not correspond to any meaningful or expected changes in diarrheal rates on a 
population level because some illnesses require antibiotic treatment, and it would be unethical to 
remove all antibiotic exposures. By estimating the impact of removing only unnecessary 
antibiotics, the generalized intervention incidence rate differences provide a more realistic 
expectation of the outcomes of public health interventions.  
While the estimates of these contrasts are necessarily smaller in magnitude than the 
population average causal effect since only a portion of antibiotic exposures would be removed, 
our models suggest that the proposed interventions would have an important impact on child 
health given the high prevalence of antibiotic treatment and risk of diarrhea in this population. 
The low estimated NNTs (Table 2) highlight this potential impact. Because diarrhea is almost 
universal and recurring among these children, even a partial reduction of antibiotic exposure 
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could substantially reduce diarrheal rates at the population level. This effect would improve 
overall child development since diarrhea is a leading cause of death among children in the 
developing world [1] and can lead to life-long morbidity associated with stunted growth and 
cognitive impairment when not fatal [3]. 
We do not calculate NNTs for the population average causal and population attributable 
incidence rate differences because these effects do not correspond to a plausible intervention, and 
therefore the NNTs would be misleading to interpret. The intervention that implicitly 
corresponds to these two estimates is one in which even necessary antibiotic exposures would be 
removed. This would almost certainly lead to negative outcomes associated with severe illnesses 
being left untreated and could potentially increase risk of death. Any such intervention would be 
unethical, and therefore estimating its effects would be fundamentally uninformative for public 
health. In addition, from a data-modeling standpoint, we do not have data concerning the 
complex effects of withholding antibiotic treatment for necessary illnesses that would be 
required for estimating the impact of such an intervention. 
The rate differences for the targeted interventions were smaller than those for the 
generalized interventions because the targeted interventions prevented antibiotic exposures only 
after children stopped exclusive breastfeeding. Thus, more children remained exposed under the 
targeted interventions due to antibiotic use during exclusive breastfeeding. These results suggest 
that a general intervention applied to all children before 6 months of age would be most 
effective.  
This study was limited by the inability to definitively characterize antibiotic treatment as 
unnecessary. Only information concerning the indicating illness was available, and other 
symptoms that may have indicated antibiotic treatment were unknown. Further, clinical criteria 
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for diagnoses could have varied by physician at the study clinic. A subset of URI and AGE cases 
could have been of bacterial etiology and responded to antibiotics. In these cases, worse 
outcomes due to withholding of antibiotic treatment might have outweighed effects of increased 
diarrheal risk. On the other hand, it is also likely that some fever cases were viral and did not 
require antibiotics, which would make our definition of unnecessary antibiotic use conservative. 
Our classification is likely reasonable since diagnostic capabilities in the area where the 
underlying study was conducted are not sufficient to distinguish between bacterial versus viral 
etiologies, and thus treatment decisions are based on clinical signs alone. Presence of bloody 
stools during diarrhea is a common clinical indicator that justifies antibiotic treatment [10] and is 
used here to distinguish cases of diarrhea for which antibiotics were or were not indicated. 
Because international guidelines do not recommend antibiotic treatment for the majority of cases 
of non-bloody diarrhea, URI, and vomiting [10,188,218], classification of these treatments as not 
indicated was likely warranted. However, in practice, antibiotic treatment decisions should be 
made on a case-by-case basis and take into account both the potential benefits and harms of 
antibiotic treatment. 
Because there were few severe illnesses and deaths in our cohort, we retained diarrhea 
incidence as the main outcome of interest. However, we acknowledge that the impact of the 
interventions on more serious diarrhea-related outcomes may also be of interest. Given the 
available cohort data, we were also unable to model other potential negative outcomes of 
antibiotic use such as risk of adverse drug reactions, healthcare costs, and development of 
antimicrobial resistance. 
Our effects may not represent the true impact of the interventions proposed if necessary 
antibiotic exposures have a different causal effect on subsequent diarrheal risk than unnecessary 
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antibiotics. However, we have no evidence to support such a difference and validated the 
assumption of consistent effects in sensitivity analyses. There were no differences in the results 
after adding flexibility in the models to allow for differential effects between necessary and 
unnecessary antibiotic exposures. In addition, there was no difference in the effect of antibiotics 
on diarrheal rates in our previous work [438] depending on the indicating illness for antibiotic 
treatment.  
Finally, our use of the g-formula relied on parametric modeling, which like other models, 
may have been misspecified. However, we expect our model to be appropriate given the model-
predicted outcomes matched the observed incidence. The consistency of results in sensitivity 
analyses further support the assumption of no model misspecification. Because our models did 
not include a dose-response relationship between diarrheal rates and the number of antibiotic 
courses received, children who had at least one necessary antibiotic exposure remained exposed 
under the interventions. Our estimates are therefore likely conservative since they ignore the 
possibility of a benefit due to reducing, but not eliminating, all antibiotic exposures for a given 
child. 
To understand the impact of early life antibiotics on diarrheal risk, we used the 
parametric g-formula as a unifying method to estimate multiple exposure and intervention 
contrasts. The parametric g-formula in the time-fixed setting is relatively straightforward to 
implement, in contrast to its application in the time-varying setting [424,425]. We suggest that 
the parametric g-formula is a viable alternative to regression modeling that allows simple 
extensions to estimate population intervention effects in addition to exposure effects [425]. The 
method is also useful for quantitatively comparing potential interventions, such as universal 
versus targeted interventions, which have been the subject of much debate [452]. Here, we show 
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that interventions to reduce unnecessary antibiotic use among young children could substantially 
reduce diarrheal rates. This work responds to recent calls for a consequentialist epidemiology 
[453] by providing an example application of methods which can further the aim of presenting 
epidemiologic findings that are relevant to public health practice and implementation science. 
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Table 7.1. Referent and index exposure distributions for effect contrasts. 
Contrast Referent exposure Index exposure 
Population average 
causal effect 
The counterfactual exposure 
distribution had all children 
been treated with at least one 
course of antibiotics 
The counterfactual exposure 
distribution had no children been 
treated with any antibiotics 
Population attributable 
contrast 
The observed exposure 
distribution among all 
children 
The counterfactual exposure 
distribution had no children been 
treated with any antibiotics 
Generalized intervention 
contrast 
The observed exposure 
distribution among all 
children 
The counterfactual exposure 
distributions after each 
intervention (above, i and ii) 
among all children 
Targeted intervention 
contrast 
The observed exposure 
distribution among all 
children 
The counterfactual exposure 
distributions after each 
intervention (above, i and ii) only 
among children who were no 
longer exclusively breastfed at 6 
months of age* 
*Exposures for children who were exclusively breastfed until at least 6 months did not change from the 
observed 
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Table 7.2. Estimated population-level impact of antibiotic exposure before 6 months of age and 
of potential interventions to reduce exposure on rates of diarrhea from 6 months to 3 years 
among 465 children in a birth cohort in Vellore, Tamil Nadu, India 2009-2013. 
Contrast 
Number  
exposed 
Mean 
rate of 
diarrhea* 
Incidence rate* 
difference  
(95% CI) 
Number needed 
to treat§  
(95% CI) 
Population average causal 
incidence rate difference 
 
    
All exposed 465 4.47 0.   
None exposed 0 3.36 -1.11 (-1.96, -0.47)  
Population attributable incidence 
rate difference      
Observed 267 4.04 0.   
None exposed 0 3.37 -0.67 (-1.14, -0.27)  
Generalized intervention incidence 
rate difference     
Observed  267 4.03 0.  
Intervention (i)† 217 3.88 -0.15 (-0.27, -0.04) 6.7 (3.7, 25.0) 
Intervention (ii)‡ 162 3.75 -0.28 (-0.47, -0.11) 3.6 (2.1, 9.1) 
Targeted intervention incidence 
rate difference     
Observed  267 4.03 0.  
Intervention (i)† in children if 
no longer exclusively 
breastfed 
237 3.91 -0.12 (-0.20, -0.07) 8.3 (5.0, 14.3) 
Intervention (ii)‡ in children if 
no longer exclusively 
breastfed 
220 3.86 -0.17 (-0.27, -0.10) 5.9 (3.7, 10.0) 
*Model estimated rate per 30 person-months from 6 months to 3 years of age, adjusted for exclusive 
breastfeeding at 6 months of age including an interaction with antibiotic exposure, child sex, 
socioeconomic status based on the Kuppuswamy scale [431], maternal education, household hygiene 
[432], household crowding, low birth weight (<2.5 kg), number of diarrhea episodes in first 6 months, 
total number of days with diarrhea in first 6 months, maximum Vesikari score [412] of diarrhea episodes 
in first 6 months, number of severe (Vesikari ≥ 11) episodes in first 6 months, prolonged or persistent 
diarrhea episode in first 6 months, hospitalization for diarrhea in the first 6 months, fever during diarrhea 
in first 6 months, dehydration during diarrhea in first 6 months, underweight (average weight-for-age z-
score before 6 months of age <−2 SD from the 2006 WHO growth reference [435]), stunting (average 
height-for-age z-score <−2 SD), and wasting (average weight-for-height z-score <−2 SD) in the first 6 
months, any severe illness in first 6 months, number of other infections in first 6 months 
†Intervention (i) – removes all antibiotics for the treatment of non-bloody diarrhea (32.3% of antibiotics 
before 6 months of age) 
‡Intervention (ii) – removes all antibiotics for the treatment of non-bloody diarrhea, upper respiratory 
infection, and vomiting (58.9% of antibiotics before 6 months of age) 
§The number of children for whom we would need to prevent unnecessary antibiotic use in the first 6 
months of life to expect a one episode reduction in diarrhea incidence over the 30-month period from 6 
months to 3 years of age 
CI – confidence interval by bootstrap with 200 resamples  
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Table 7.3. Estimated population-level impact of antibiotic exposure before 6 months of age and 
of potential interventions to reduce exposure on rates of diarrhea from 6 months to 3 years 
including separate effects for necessary and unnecessary antibiotics among 465 children in a 
birth cohort in Vellore, Tamil Nadu, India 2009-2013.  
Contrast 
Number 
treated 
Mean 
rate of 
diarrhea* 
Incidence rate* 
difference  
(95% CI) 
Number needed 
to treat§  
(95% CI) 
Population average causal 
incidence rate difference 
 
    
All treated 465 4.46 0.  
None treated  0 3.37 -1.10 (-2.23, -0.21)  
Population attributable incidence 
rate difference      
Observed 267 4.04 0.   
None treated 0 3.37 -0.67 (-1.11, -0.26)  
Generalized intervention incidence 
rate difference     
Observed  267 4.04 0.  
Intervention (i)† 217 3.86 -0.18 (-0.35, 0.06) 5.6 (2.9, - ) 
Intervention (ii)‡ 162 3.72 -0.32 (-0.62, 0.15) 3.1 (1.6, - ) 
Targeted intervention incidence 
rate difference     
Observed  267 4.04 0.  
Intervention (i)† in children if 
no longer exclusively 
breastfed 
237 3.85 -0.19 (-0.43, -0.05) 5.3 (2.3, 20.0) 
Intervention (ii)‡ in children if 
no longer exclusively 
breastfed 
220 3.80 -0.24 (-0.48, -0.08) 4.2 (2.1, 12.5) 
*Model estimated rate per 30 person-months from 6 months to 3 years of age, including separate effects 
for necessary and unnecessary antibiotics and their interaction. Model adjusted for exclusive 
breastfeeding at 6 months of age including an interaction with antibiotic exposure, child sex, 
socioeconomic status based on the Kuppuswamy scale [431], maternal education, household hygiene 
[432], household crowding, low birth weight (<2.5 kg), number of diarrhea episodes in first 6 months, 
total number of days with diarrhea in first 6 months, maximum Vesikari score [412] of diarrhea episodes 
in first 6 months, number of severe (Vesikari ≥ 11) episodes in first 6 months, prolonged or persistent 
diarrhea episode in first 6 months, hospitalization for diarrhea in the first 6 months, fever during diarrhea 
in first 6 months, dehydration during diarrhea in first 6 months, underweight (average weight-for-age z-
score under 6 months of age <−2 SD from the 2006 WHO growth reference [435]), stunting (average 
height-for-age z-score <−2 SD), and wasting (average weight-for-height z-score <−2 SD) in the first 6 
months, any severe illness in first 6 months, number of other infections in first 6 months 
†Intervention (i) – removes all antibiotics for the treatment of non-bloody diarrhea  
‡Intervention (ii) – removes all antibiotics for the treatment of non-bloody diarrhea, upper respiratory 
infection, and vomiting 
§The number of children for whom we would need to prevent unnecessary antibiotic use in the first 6 
months of life to expect a one episode reduction in diarrhea incidence over the 30-month period from 6 
months to 3 years of age  
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Figure 7.1. Number of antibiotic courses received by age among 465 children in a birth cohort in 
Vellore, Tamil Nadu, India 2009-2013. Dark gray – antibiotics given for non-bloody diarrhea 
(not indicated); light gray – antibiotics given for upper respiratory infections and vomiting 
(likely not indicated); white – antibiotics given for other illnesses. 
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CHAPTER VIII: NO ASSOCIATION OF EARLY LIFE ANTIBIOTIC EXPOSURE WITH 
GROWTH IN YOUNG CHILDREN OF VELLORE, INDIA 
 
Abstract 
Background 
Early antibiotic exposure has recently been associated with increased weight gain in 
children in high-income countries. However, antibiotic use early in life has also been associated 
with increased diarrheal risk, which could contribute to poor growth outcomes. The net effect of 
antibiotic exposures on growth among children in low and middle-income countries is unknown. 
Methods 
We estimated the effects of antibiotic exposures in the first 6 months of life on short- and 
long-term growth. Short-term effects were measured during the first 6 months, using longitudinal 
general linear regression to model weight-for-age, height-for-age, and weight-for-height z-scores 
in monthly intervals. To estimate long-term effects, we modeled growth measurements from 6 
months to 3 years of age as a function of antibiotic use in the first 6 months. We also estimated 
the effects of antibiotics on the monthly relative risks of underweight, stunting, and wasting in 
the first 6 months and to 3 years.  
Results 
Underweight, stunting, and wasting were common in this population: 31%, 32%, and 
15% on average after 6 months of age respectively. There was no association between antibiotic 
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exposures before 6 months and growth during that period. From 6 months to 3 years, adjusted 
absolute differences in size were small (approximately -100 g and no more than -2 mm overall) 
and not statistically significant.  
Conclusions 
Antibiotic exposures early in life were not associated with increased or decreased growth. 
The combination of malnutrition and recurrent illness likely complicate the relationship between 
antibiotic exposures and growth among children in low and middle-income countries.  
 
Introduction 
In an era of concern over the growing obesity epidemic in developed countries, antibiotic 
exposures early in life have been recently identified as a potential contributor to excessive weight 
gain [24,454]. This hypothesis originated from the clear growth-promoting effects of antibiotics 
in livestock when given long-term and in sub-therapeutic doses [361]. While the biological 
mechanism is largely unknown, it is hypothesized that antibiotics affect growth through 
interaction with the GI microbiota [361,455], which plays an important role in supporting 
nutrient absorption and other metabolic functions [22,23]. Several epidemiologic studies among 
children in high-income countries have supported this hypothesis, finding associations between 
antibiotic use early in life and increased risk for obesity in later childhood [11,228,373]. 
In LMICs, this potential relationship is complicated by the high prevalence of 
malnutrition and recurrent illnesses that can cause major height and weight shortfalls [109,110]. 
Subclinical infections associated with living in unhygienic environments are associated with 
environmental enteropathy, which results in impaired function and structure of the small 
intestine and reduces nutrient absorption [3,161,163]. For children with severe acute 
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malnutrition, antibiotics are recommended to treat and prevent subclinical infections in an effort 
to improve recovery [456,457]. In several studies, acutely malnourished children who received 
antibiotics showed improved recovery rates, lower mortality, and in some cases improved weight 
gain compared to children receiving nutritional supplements alone [369,457].  
However, as our group showed recently, antibiotics may also increase risk for diarrhea 
[438,458], which is associated with poor growth and can contribute to the synergism between 
infections and growth failure [111]. Therefore, it is unclear what the net impact of antibiotic 
treatment for common childhood illnesses may be among children in low-income settings.  
We aimed to estimate the effect of antibiotic use before 6 months of age on short-term 
(within the first 6 months) and long-term (up to 3 years of age) growth in an observational birth 
cohort from Vellore, India. We focused on antibiotic use in the first 6 months since antibiotics 
have the largest impact on the developing microbiota [20,24,280] and subsequent diarrhea at this 
age [438], and we expect this exposure period to correspondingly have the largest effects on 
growth, as previously shown [11].  
 
Methods 
We analyzed data from a prospective observational cohort study of immune responses to 
cryptosporidiosis in 497 children from semi-urban slums of Vellore, India from 2009-2013. The 
study population, enrollment strategy, and data collection methods have been previously 
described [28]. Briefly, baseline information on demography, socioeconomic indicators, 
environment, and delivery characteristics were collected within 45 days of birth. Fieldworkers 
interviewed caregivers twice per week from birth to 3 years of age about all illnesses since the 
last visit, and further recorded details of diarrhea severity, hospitalization, and treatments given. 
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Antibiotic use was reported by caregivers at birth and for diarrhea, and antibiotic prescriptions 
for other illnesses were extracted from study clinic records. 
Height and weight were measured each month of follow-up at the study clinic using 
single measurements. Weight was measured using a Salter weighing scale to the nearest 100 
grams. Recumbent length was measured using a standard infantometer for the first year of life, 
and subsequently height was measured with a stadiometer, both to the nearest millimeter. 
Biologically implausible height and weight values were discarded, and we considered 
measurements taken within one week before or after a child’s monthly birth anniversary as their 
weight/height at that month of age. 
We used the 2006 WHO child growth standards [435] as the reference population to 
calculate weight-for-age (WAZ), height-for-age (HAZ), and weight-for-height (WHZ) z-scores. 
Children were classified as underweight (weight-for-age z-score < −2 SD from the growth 
reference), stunted (height-for-age z-score < −2 SD), and/or wasted (weight-for-height z- score < 
−2 SD). We also translated the effects on z-scores to their equivalents in absolute height and 
weight using the age and gender-specific SD differences in weight/height from the WHO 
expanded z-score tables [426,427]. 
Because the proportion of missing data was less than 3% for all baseline variables (see 
footnote in Table 8.1), we imputed the median values of variables for individuals with missing 
data. 
 
Data analysis – Short-term effects 
We used longitudinal general linear regression to model WAZ, HAZ, and WHZ at 
monthly intervals from 0 through 5 months of age. Specifically, we estimated the effects of 
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antibiotic exposures in a given month on WAZ, HAZ, and WHZ at the end of the following 
month (conceptually depicted in Figure 4.2A), and accounted for correlation between outcomes 
from the same child using GEE with a robust variance estimator. This model structure allowed 
for a one month lag between antibiotic exposure and the measurement of growth outcomes. To 
assess the sensitivity of results to this lag period, we repeated the analyses with outcomes both at 
the end of the same month as the exposure (Figure 4.2B; 0 months exposure lag) as well as at 
two months following the exposure month (Figure 4.2C; 2 months exposure lag). 
Confounding variables for the exposure model were chosen by a causal DAG [415] to 
account for determinants of antibiotic use which also affect child growth, including growth status 
before exposure, other baseline characteristics, and illness burden. These variables were included 
to isolate the effects of antibiotics from the underlying conditions for which they were given. 
Optimal variable coding was determined by QIC, which is appropriate for GEE models [428]. 
The final models included child sex, socioeconomic status (based on the modified 
Kuppuswamy scale [431]), maternal education, household hygiene [432], household crowding, 
low birth weight (<2.5 kg), preterm birth (<37 weeks of gestation), and characteristics of the 
exposure month: growth z-score at the beginning of the month, exclusive breastfeeding, number 
of days with infections and severe illnesses, number of days with diarrhea, severe diarrhea 
episodes (Vesikari score [412] ≥ 11), prolonged or persistent diarrhea episodes (≥7 days), 
dehydration during diarrhea, ORS given during diarrhea, hospitalization, and days with diarrhea 
in the previous month. We separately stratified effects using interaction terms by month of 
antibiotic exposure, gender, exclusive breastfeeding in the exposure month, baseline malnutrition 
status (underweight, stunted, or wasted), and illness burden. 
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To validate our results with an alternate model that eliminates potential unmeasured 
child-level confounding, we used a fixed-intercept model in which the effects of antibiotic use in 
monthly intervals were estimated within-child (a child’s exposed and unexposed months served 
as the index and reference exposures respectively) [429]. We used the robust variance estimator 
to account for correlation between observations within-child and necessarily included only the 
time-varying covariates [429] listed above.  
 
Data analysis – Long-term effects 
We created descriptive height and weight growth curves after 6 months of age by 
grouping measurements by month and averaging heights and weights across children given the 
same number of antibiotic courses before 6 months.  
We then used longitudinal general linear regression with GEE to model all WAZ, HAZ, 
and WHZ after 6 months of age as a function of antibiotic use in the first 6 months. We included 
the corresponding growth z-score at 6 months in the models to account for differences in growth 
occurring prior to and during the antibiotic exposure period; this ensured estimation of long-term 
effects on growth rates following 6 months of age. Baseline confounding variables included all 
those in the short-term analysis, as well as Cesarean section birth. Indicators of illness burden 
were summarized over the first 6 months as: total number of days with diarrhea, infections, and 
severe illnesses, maximum Vesikari score [412] of diarrhea episodes, prolonged or persistent 
diarrhea episodes, and fever or dehydration during diarrhea, and exclusive breastfeeding at 3 
months. We stratified effects by sex, number of antibiotic courses received before 6 months, and 
age period of growth (6 months-1 year, 1-2 years, 2-3 years). We further assessed modification 
of effects by exclusive breastfeeding, illness burden, and malnutrition status at 6 months.  
178 
 
We estimated the effects of antibiotics on the relative risks of underweight, stunting, and 
wasting in both the short and long-term with the same exposure groups and covariates as the 
linear regression models. We used longitudinal Poisson regression with the robust variance 
estimator as an approximation of log-binomial regression [430] since the log-binomial models 
did not converge. 
We validated results by repeating analyses with a more specific, but less sensitive, 
definition of antibiotic exposure which required the caregiver to list a confirmed antibiotic name 
for diarrhea instead of only replying ‘yes’ when asked if antibiotics were given. 
 
Results 
The birth cohort consisted of 497 children, 456 (91.8%) of whom remained in the study 
and were measured at least once after 6 months of age. In the remaining study period, 46 (9.3%) 
more children were lost to follow-up. Nine drop-outs were due to death. The majority of 
participants were from families of low socioeconomic status with poor household hygiene and 
crowding in the home (Table 8.1). 
More than half of children (n=262, 57.5%) were exposed to antibiotics by 6 months of 
age, and 137 (28.1%) had received more than one course (Figure 8.1). Antibiotic use was highest 
from 3-5 months of age, with an average monthly exposure prevalence of 20.3%. 
Growth failure early in life was common (Figure 8.2). By 6 months, on average 30.6% of 
children were underweight (maximum prevalence 40.7% at 27 months) and 31.8% of children 
were stunted (maximum prevalence 34.7% at 32 months). Prevalence of wasting (WHZ < -2 SD) 
was lower, at 15.0% overall.  
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Short-term antibiotic effects 
Averaged across months from birth through 5 months, there was no crude difference in 
WAZ or WHZ associated with antibiotic exposure in a given month (WAZ difference: 0.01, 95% 
CI: -0.05, 0.06; WHZ difference: 0.05, 95% CI: -0.04, 0.14). These effects were uniform by sex. 
Conversely, antibiotic use was crudely associated with slightly lower HAZ (HAZ difference: -
0.12, 95% CI: -0.19, -0.06); this effect was more pronounced among girls (HAZ difference: -
0.17, 95% CI: -0.26, -0.07) than boys (HAZ difference: -0.09, 95% CI: -0.17, 0.00).  
After multivariable adjustment, the absence of effects on WAZ and WHZ remained. The 
effect on HAZ was no longer significant and moved toward the null, entirely for boys and 
reduced by more than half among girls (Table 8.2). The adjusted weight and height differences 
among boys translated to a difference of -1 g and -0.1 mm respectively. Among girls, the effects 
corresponded to differences of -32 g and -1.2 mm. Effects were largest for exposures in the first 
month of life, but were imprecise due to few exposed children (n=30). There was no statistically 
significant effect modification by month (p for heterogeneity=0.7; Table 8.3), malnutrition status 
of the child (underweight, stunted, or wasted), exclusive breastfeeding, diarrhea burden, or other 
infections and severe illness burden (results not shown).  
There was also no difference in the relative risks of underweight or wasting among 
children who received antibiotics compared to those who did not (Table 8.4). However, girls 
who received antibiotics in a given month had a higher risk of being stunted in the next month 
(RR: 1.27, 95% CI: 1.04, 1.56). There was no effect on stunting among boys. 
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Long-term antibiotic effects 
For the analysis of the effect of antibiotics before 6 months of age on growth from 6 
months to 3 years, a total of 12,694 growth measurements were available among 456 children 
remaining in the study at 6 months (mean of 27.8 measurements/child). The majority of children 
(n=388, 85.1%) had at least 29 growth measurements before 3 years of age. 
Crude average growth curves after 6 months of age stratified by gender and early life 
antibiotic exposure are shown in Figure 8.3. Children receiving no or one course of antibiotics 
had similar growth trajectories, while those receiving 2 or more courses of antibiotics weighed 
less and were shorter at all ages. Correspondingly, there was a crude negative association of 
antibiotic use in the first 6 months on WAZ (difference: -0.18, 95% CI: -0.35, -0.02) and HAZ 
(difference: -0.20, 95% CI: -0.38, -0.02) from 6 months to 3 years of age. 
Adjusted effects were smaller in magnitude and no longer statistically significant, but still 
negative, such that antibiotic use before 6 months of age was associated with lower WAZ, HAZ, 
and WHZ after 6 months (Table 8.5). The associations were largest after 1 year of age (p for 
heterogeneity < 0.0001). There was no evidence for a difference in effect by gender or number of 
antibiotic courses received (p for heterogeneity >0.4). All effects were minimal when translated 
to weight and height differences. The largest differences in weight (occurring at 2-3 years of age) 
corresponded to approximately -150 g. The largest differences in height were -3.1 mm from 2-3 
years, and the difference was -1.5 mm overall. There was no significant effect modification by 
burden of illnesses, hospitalization, baseline malnutrition status, or exclusive breastfeeding 
(results not shown). 
There was an increase in the relative risk of underweight after 6 months of age among 
children who received antibiotics in the first 6 months compared to children who did not receive 
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antibiotics (RR: 1.33, 95% CI: 1.07, 1.64; Table 8.5). The risk of wasting was also elevated, but 
the estimates were not statistically significant. There were no effects on long-term stunting.  
 
Sensitivity analyses  
The effects of antibiotics in a given month were not sensitive to the time period between 
the antibiotic exposure and outcome (Figure 4.2B and 4.2C; Table 8.6). Results from the fixed-
intercept model, which eliminated potential unmeasured child-level confounding, were 
qualitatively and quantitatively similar to results from the general linear models (Table 8.7). 
Using an alternative definition of exposure which required the caregiver to list a confirmed 
antibiotic name, there was no change in short or long-term effects (results not shown). 
 
Discussion 
Our study provides the first evidence from a prospective observational cohort study 
concerning the impact of early life antibiotic exposures on growth among LMIC children. Unlike 
other investigations of the relationship between antibiotics and growth, we did not find evidence 
that antibiotic exposures early in life were associated with growth promotion. Antibiotic 
exposures before 6 months of age did not have any short-term associations with growth, and 
were associated only with small, but not statistically or clinically significant, differences in 
height and weight from 6 months to 3 years. These differences were near the limits of detection 
of the measurement instruments (approximately 100 g and 1-2 mm overall). We suggest these 
small negative effects on growth may be due to residual confounding or chance given the large 
number of comparisons made.  
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There are several potential explanations for the lack of a growth-promoting effect. Most 
of the previous studies showing increased weight gain or risk of obesity associated with 
antibiotics [11,228,373,389,390] were conducted in high-income countries with Western diets. 
Animal studies have shown that the growth-promoting phenotype associated with an altered 
microbiota is amplified when the animals are fed a high-fat diet [24,363,459]. Our study 
population from semi-urban slums did not have access to a high-fat diet after weaning such that 
an interaction between antibiotics and increased caloric intake was unlikely. Also, no children in 
this study were diagnosed with acute severe malnutrition, for which antibiotics have shown to 
improve recovery and/or growth [369,375]. Our study population was community-based, and 
few would have met the inclusion criteria (e.g. preterm, very low birth weight, with severe 
illness) for the trials demonstrating improved growth associated with antibiotics 
[363,371,375,460]. 
In LMICs, previous studies of the effects of antibiotics on growth have been 
inconclusive. A recent meta-analysis of 10 trials of antibiotics conducted over a 60 year period 
concluded that antibiotics improved growth, though the summary effect sizes were likely not 
clinically important (less than 1 mm/month difference in height and 24 g/month in weight) [375]. 
An international cross-sectional study also reported that overall adjusted BMI at age 5-8 was 
higher in children exposed to antibiotics in infancy. However, the effects varied across sites and, 
critically, a lower in BMI associated with antibiotics was found in all countries classified as non-
affluent except Thailand [376].  
The small association of antibiotics with lower WAZ and HAZ in the long-term may be 
due to increased diarrheal rates following antibiotic exposure [438], which may be associated 
with poor growth. However, diarrhea likely had minimal impact on growth in our study 
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population due to high use of ORS during diarrhea (88%), counselling to continue breastfeeding, 
and good access to healthcare. Therefore, appropriate treatment may have mitigated any effects 
increased diarrhea burden would have had on growth. It is also possible that the two competing 
pathways: antibiotics as growth-promoters and antibiotics as causing future illness and harming 
growth, may both have been occurring, resulting in a null net effect on growth.  
Because the study was observational in design, we cannot exclude the possibility of 
uncontrolled confounding. Even after multivariable adjustment, we may not have been able to 
completely capture aspects of child illness needed to separate the effects of antibiotics from their 
indicating illnesses. However, a randomized clinical trial would be unethical since treatment of 
some illnesses with antibiotics is necessary, and our study provides results in a community-based 
setting that may be more generalizable [461] to communities in LMICs. 
The study was also limited by potential misclassification of antibiotic exposures due to 
recall errors among caregivers and missed antibiotic prescriptions received outside of the study 
clinic. However, because the clinic was located within the residential area of study subjects and 
provided free care and medicines, we expect almost all prescriptions to have originated in the 
study clinic.  
The combination of malnutrition and recurrent illness complicate the relationship 
between antibiotic exposures and growth among children in LMICs. Our study among children 
in south India did not replicate previous associations between early life antibiotic use and 
increased growth demonstrated among children in high-income countries and when given in 
combination with nutritional rehabilitation for more severely malnourished children. Conversely, 
antibiotic exposure in the first 6 months of life was not associated with differences in growth 
both during the first 6 months and up to 3 years of age.  
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Table 8.1. Demographic characteristics of 497 children in a birth cohort in Vellore, Tamil Nadu, 
India 2009-2013.  
 
No. children 
(%) 
Household characteristics  
Socioeconomic status*  
Low 328 (66.0) 
Medium 160 (32.2) 
High 9 (1.8) 
Maternal education  
No formal education 184 (37.0) 
Primary/middle school 167 (33.6) 
Higher secondary school 129 (26.0) 
College/polytechnic/professional 
school 
17 (3.4) 
Poor household hygiene†‡ 256 (53.5) 
Crowding  
High (>4 people/room) 164 (33.0) 
Medium (3.1-4 people/room) 190 (38.2) 
Low (≤ 3 people/room) 143 (28.8) 
Child characteristics  
Sex of child  
Male 263 (52.9) 
Female 234 (47.1) 
Cesarean section 90 (18.1) 
Low birth weight‡ 84 (17.1) 
Preterm birth 50 (10.3) 
Antibiotics at birth‡ 13 (2.7) 
Age (months) at stopping exclusive 
breastfeeding (mean, SD) 
3.9 (2.10) 
Age (months) at stopping all 
breastfeeding (mean, SD) 
15.9 (8.72) 
*Socioeconomic status categories defined from the modified Kuppuswamy scale based on educational 
and occupational level of the family, house ownership, total number of rooms in the house, and household 
possessions [431] 
†Poor household hygiene was based on a score of less than 12 on a scale developed from an assessment 
of water, food, and personal hygiene [432] 
‡2 missing observations for hygiene; 7 missing observations for low birth weight; 12 missing 
observations for preterm birth; 15 missing observations for antibiotics at birth; SD – standard deviation 
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Table 8.2. Estimated adjusted effects of antibiotic treatment in one month on growth at the end 
of the following month in a birth cohort of 497 children in Vellore, Tamil Nadu, India 2009-
2013. 
Antibiotics in 
exposure month No. (%) 
WAZ in next month  HAZ in next month WHZ in next month 
β* (95% CI) β* (95% CI) β* (95% CI) 
No   0. 0. 0. 
Yes Boys 155 (58.9) -0.00 (-0.07, 0.08) -0.01 (-0.09, 0.10) -0.00 (-0.13, 0.13) 
 Girls 121 (51.7) -0.05 (-0.13, 0.04) -0.06 (-0.16, 0.03) 0.05 (-0.09, 0.19) 
 Overall 276 (55.5) -0.02 (-0.08, 0.04) -0.03 (-0.10, 0.04) 0.02 (-0.07, 0.12) 
*Absolute difference in z-score adjusted for child sex, previous growth z-score, socioeconomic status 
[431], maternal education, household hygiene [432], household crowding, low birth weight, preterm birth, 
exclusive breastfeeding, infections and severe illnesses, and indicators of diarrhea severity 
WAZ – weight-for-age z-score; HAZ – height-for-age z-score; WHZ – weight-for-height z-score; CI – 
confidence interval 
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Table 8.3. Stratified by month, estimated adjusted effects of antibiotic treatment in one month on 
growth at the end of the following month in a birth cohort of 497 children in Vellore, Tamil 
Nadu, India 2009-2013. 
Age at 
exposure No. (%) 
WAZ in next month  HAZ in next month WHZ in next month 
β* (95% CI) β* (95% CI) β* (95% CI) 
None   0. 0. 0. 
0 months 30 (6.0) -0.28 (-0.61, 0.05) 0.05 (-0.32, 0.42) -0.13 (-0.62, 0.35) 
1 month 48 (9.7) -0.05 (-0.26, 0.16) -0.10 (-0.32, 0.12) 0.11 (-0.29, 0.51) 
2 months 81 (16.6) 0.03 (-0.10, 0.16) -0.06 (-0.22, 0.10) 0.17 (-0.06, 0.40) 
3 months 89 (18.5) -0.01 (-0.11, 0.09) -0.04 (-0.16, 0.09) -0.00 (-0.17, 0.16) 
4 months 104 (21.8) 0.01 (-0.08, 0.10) -0.06 (-0.17, 0.05) 0.01 (-0.17, 0.19) 
5 months 97 (20.7) -0.02 (-0.14, 0.09) 0.01 (-0.12, 0.15) -0.06 (-0.25, 0.13) 
*Absolute change in z-score adjusted for child sex, previous growth z-score, socioeconomic status [431], 
maternal education, household hygiene [432], household crowding, low birth weight, preterm birth, 
exclusive breastfeeding, infections and severe illnesses, indicators of diarrhea severity, and antibiotic 
exposure history 
WAZ – weight-for-age z-score; HAZ – height-for-age z-score; WHZ – weight-for-height z-score; CI – 
confidence interval 
 
  
187 
 
Table 8.4. Estimated adjusted effects of antibiotic treatment in one month on underweight, 
stunting, and wasting at the end of the following month in a birth cohort of 497 children in 
Vellore, Tamil Nadu, India 2009-2013. 
Antibiotics in 
exposure month 
Underweight* Stunting† Wasting§ 
RR** (95% CI) RR**  (95% CI) RR**  (95% CI) 
No  1. 1. 1. 
Yes Boys 0.93 (0.78, 1.11) 0.94 (0.77, 1.14) 0.94 (0.73, 1.20) 
 Girls 1.07 (0.88, 1.31) 1.27 (1.04, 1.56) 0.98 (0.72, 1.33) 
 Overall 0.98 (0.86, 1.13) 1.07 (0.92, 1.23) 0.96 (0.78, 1.18) 
*Weight-for-age z-score < -2 SD 
†Height-for-age z-score < -2 SD 
§Weight-for-height z-score < -2 SD  
**Relative risk adjusted for child sex, previous growth z-score, socioeconomic status [431], maternal 
education, household hygiene [432], household crowding, low birth weight, preterm birth, exclusive 
breastfeeding, infections and severe illnesses, indicators of diarrhea severity, and antibiotic exposure 
history 
WAZ – weight-for-age z-score; HAZ – height-for-age z-score; WHZ – weight-for-height z-score; CI – 
confidence interval 
  
  
Table 8.5. Estimated adjusted effects of antibiotic treatment under 6 months of age on growth from 6 months to 3 years in a birth 
cohort of 497 children in Vellore, Tamil Nadu, India 2009-2013. 
Antibiotics  
< 6 mo. 
WAZ Underweight HAZ Stunted WHZ Wasted 
β* (95% CI) RR† (95% CI) β* (95% CI) RR†  (95% CI) β* (95% CI) RR†  (95% CI) 
No (n=194) 0. 1. 0. 1. 0. 1. 
Yes (n=262) -0.08 (-0.19, 0.02) 1.33 (1.07, 1.64) -0.05 (-0.17, 0.06) 1.07 (0.88, 1.31) -0.10 (-0.23, 0.02) 1.25 (0.94, 1.67) 
By gender       
Males -0.08 (-0.23, 0.06) 1.39 (1.03, 1.87) -0.02 (-0.18, 0.14) 1.03 (0.79, 1.35) -0.15 (-0.32, 0.02) 1.37 (0.94, 2.01) 
Females -0.08 (-0.23, 0.06) 1.26 (0.96, 1.66) -0.09 (-0.24, 0.06) 1.13 (0.87, 1.47) -0.06 (-0.22, 0.10) 1.13 (0.76, 1.69) 
By courses       
1 course -0.09 (-0.21, 0.03) 1.48 (1.16, 1.88) -0.03 (-0.16, 0.10) 1.08 (0.85, 1.38) -0.11 (-0.26, 0.03) 1.35 (0.98, 1.87) 
2+ courses -0.08 (-0.21, 0.05) 1.22 (0.95, 1.55) -0.08 (-0.22, 0.06) 1.07 (0.86, 1.34) -0.10 (-0.24, 0.05) 1.13 (0.80, 1.60) 
By age       
6 mo.-1 yr. 0.01 (-0.07, 0.08) 1.23 (0.96, 1.58) -0.01 (-0.10, 0.08) 0.96 (0.76, 1.22) 0.01 (-0.10, 0.11) 0.94 (0.68, 1.30) 
1-2 yr. -0.12 (-0.24, 0.01) 1.46 (1.15, 1.87) -0.06 (-0.18, 0.07) 1.16 (0.90, 1.49) -0.15 (-0.30, -0.00) 1.36 (0.97, 1.89) 
2-3 yr. -0.11 (-0.25, 0.03) 1.25 (0.98, 1.60) -0.09 (-0.25, 0.07) 1.07 (0.85, 1.35) -0.12 (-0.27, 0.03) 1.37 (0.91, 2.06) 
*Absolute change in z-score adjusted for child sex, previous growth z-score, socioeconomic status [431], maternal education, household hygiene 
[432], household crowding, low birth weight, preterm birth, Cesarean section birth, exclusive breastfeeding, infections and severe illnesses, and 
indicators of diarrhea severity 
†Relative risk adjusted for the same covariates as above 
WAZ – weight-for-age z-score; HAZ – height-for-age z-score; WHZ – weight-for-height z-score; CI – confidence interval 
1
8
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Table 8.6. Estimated adjusted effects of antibiotic treatment in one month on growth at the end 
of the month and at the end of the second following month in a birth cohort of 497 children in 
Vellore, Tamil Nadu, India 2009-2013. 
Antibiotics in 
exposure month 
WAZ  HAZ  WHZ  
β* (95% CI) β* (95% CI) β* (95% CI) 
    
Outcome: at end of exposure month   
No  0. 0. 0. 
Yes Boys -0.03 (-0.10, 0.04) -0.01 (-0.10, 0.09) -0.03 (-0.16, 0.09) 
 Girls -0.01 (-0.09, 0.07) -0.11 (-0.20, -0.03) 0.17 (0.04, 0.31) 
 Overall -0.02 (-0.08, 0.03) -0.05 (-0.12, 0.01) 0.05 (-0.04, 0.16) 
    
Outcome: at end of second following month  
No  0. 0. 0. 
Yes Boys 0.05 (-0.02, 0.12) 0.03 (-0.05, 0.12) 0.01 (-0.11, 0.12) 
 Girls -0.03 (-0.10, 0.04) -0.05 (-0.14, 0.04) 0.01 (-0.12, 0.14) 
 Overall 0.01 (-0.04, 0.07) -0.00 (-0.07, 0.06) 0.01 (-0.08, 0.10) 
*Absolute change in z-score adjusted for child sex, previous growth z-score, socioeconomic status [431], 
maternal education, household hygiene [432], household crowding, low birth weight, preterm birth, 
exclusive breastfeeding, infections and severe illnesses, indicators of diarrhea severity, and antibiotic 
exposure history 
WAZ – weight-for-age z-score; HAZ – height-for-age z-score; WHZ – weight-for-height z-score; CI – 
confidence interval 
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Table 8.7. Estimated adjusted effects of antibiotic treatment in one month on growth at the end 
of the following month using the fixed-intercept model in a birth cohort of 497 children in 
Vellore, Tamil Nadu, India 2009-2013. 
Age at antibiotic 
exposure 
WAZ in next month  HAZ in next month WHZ in next month 
β* (95% CI) β* (95% CI) β* (95% CI) 
No antibiotics 0. 0. 0. 
0-5 months 0.02 (-0.04, 0.08) -0.02 (-0.09, 0.05) 0.03 (-0.07, 0.12) 
 Boys 0.05 (-0.02, 0.12) 0.02 (-0.07, 0.11) 0.00 (-0.13, 0.13) 
 Girls -0.01 (-0.10, 0.08) -0.07 (-0.16, 0.02) 0.06 (-0.08, 0.20) 
0-2 months 0.02 (-0.08, 0.12) -0.02 (-0.15, 0.11) 0.09 (-0.09, 0.27) 
3-5 months 0.01 (-0.05, 0.08) -0.01 (-0.09, 0.07) -0.01 (-0.12, 0.10) 
*Absolute change in z-score adjusted for child sex, previous growth z-score, socioeconomic status [431], 
maternal education, household hygiene [432], household crowding, low birth weight, preterm birth, 
exclusive breastfeeding, infections and severe illnesses, indicators of diarrhea severity, and antibiotic 
exposure history 
WAZ – weight-for-age z-score; HAZ – height-for-age z-score; WHZ – weight-for-height z-score; CI – 
confidence interval 
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Figure 8.1. Antibiotic exposures before 6 months of age in a birth cohort of 497 children in 
Vellore, Tamil Nadu, India 2009-2013. Dark gray bars – children exposed to one course of 
antibiotics in a given month; light gray – children exposed to more than one course of antibiotics 
in a given month; Black line (dotted lines) – cumulative proportion of children exposed to at 
least one course of antibiotics (95% confidence interval). 
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Figure 8.2. Prevalence of underweight (black line), stunting (gray line), and wasting (black 
dotted line) from 0-3 years of age in a birth cohort of 497 children in Vellore, Tamil Nadu, India 
2009-2013. 
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Figure 8.3. Crude average height and weight growth curves by antibiotic exposure in the first 6 
months of life in a birth cohort of 497 children in Vellore, Tamil Nadu, India 2009-2013. A – 
weight among boys; B – weight among girls; C – height among boys; D – height among girls. 
Black line – no antibiotic courses; grey line – 1 antibiotic course; black dotted line – 2+ 
antibiotic courses.   
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CHAPTER IX: DISCUSSION 
 
 Antibiotics play an indispensable role in our defense against microbes and have quickly 
become a common exposure in early childhood. However, the unintended consequences of 
antibiotic treatment have not been fully realized. In addition to concerns over antibiotic 
resistance, the growing evidence of a disruptive effect of antibiotics on the gastrointestinal 
microbiota has demonstrated the potential for collateral damage to the developing immune 
system and metabolic pathways. These changes could further affect susceptibility to infections 
and growth among children. Given the high morbidity associated with childhood diarrhea and 
ease of access to antibiotics in India, we aimed to assess the effects of antibiotics on diarrheal 
risk and growth outcomes among young children in Vellore. 
 First, does antibiotic treatment increase risk for future diarrhea? We initially focused on 
antibiotic treatment of diarrhea specifically and its effects on the incidence of subsequent 
diarrhea. Because antibiotic treatment for diarrhea represented only a proportion of all antibiotic 
exposures, we then expanded our exposure definition to include any antibiotic exposures under 6 
months of age. We focused on exposures in the first 6 months of life since this is the period 
during which the microbiota is developing and microbial communities are less able to recover 
from perturbations. We then estimated the impact of plausible interventions that would remove 
unnecessary antibiotic exposures, since antibiotic treatment of some illnesses is necessary and 
preventing all antibiotic exposures would be unethical. These results indicated what gains in 
diarrhea morbidity could be expected due to programs that enforce rational antibiotic use. 
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 Second, does antibiotic treatment affect growth among children? This question was 
complicated by conflicting hypotheses that antibiotics might both promote and/or impede 
growth. The former is based on evidence from antibiotic-associated growth promotion in 
livestock and the associations of antibiotics with obesity among children in high-income 
countries. The latter is based on an indirect mechanism in which antibiotics may cause more 
diarrhea, which is then associated with poor growth. Without being able to effectively tease apart 
these pathways, we assessed the impact of antibiotic exposure on growth overall, in both the 
short and the long-term. We again focused on antibiotic exposure in the first 6 months of life 
given the importance of the microbiota and the increased impact of disturbances at this time. 
Short-term effects were estimated within monthly intervals of exposure with growth outcomes in 
the next month. We then assessed longer-term effects of early life antibiotic exposure by 
comparing growth from 6 months to 3 years among children exposed and unexposed to 
antibiotics under 6 months. These analyses provided the first evidence from an observational 
LMIC setting of the effects of antibiotics given for common childhood illnesses on growth. 
 
Summary of findings 
Diarrhea was a common and recurrent illness among children in the birth cohorts. 
Incidence of diarrhea was highest around 6 months of age, with an incidence of over 30 episodes 
per 100 person-months among children between 5 and 7 months of age. Diarrheal rates then 
decreased by more than half from 6 months to 3 years; still, children had more than 3 episodes 
on average during this period.  
Antibiotics were frequently given to treat diarrhea. Nearly 30% of episodes were treated 
with antibiotics, and more than half of children reported at least one antibiotic course for 
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diarrhea. Antibiotic treatment of diarrhea was associated with older age at the time of the episode 
and increased episode severity and duration. The most common antibiotic given for diarrhea was 
cotrimoxazole, accounting for more than half of all antibiotics given. Cefixime accounted for 
another third, while all other antibiotics were reported for less than 5% of diarrhea cases. 
More generally, antibiotic exposure due to treatment of any illness was almost universal. 
More than half of children were given at least one course of antibiotics in the first 6 months of 
life. By 1 year of age, more than 85% of children had received at least one course. This 
proportion increased to 94% by 3 years of age, with more than half receiving 6 or more courses. 
Antibiotic prescriptions were most frequently associated with diagnoses for respiratory 
infections, acute gastroenteritis, and acute otitis media. While only approximately 6% of upper 
respiratory infections were treated with antibiotics at the study clinic, the high burden of this 
illness resulted in many cases being treated with antibiotics. Amoxicillin was given in two-thirds 
of non-diarrheal diagnoses at the study clinic, with azithromycin, co-trimoxazole, cephalexin, 
and amoxicillin/clavulanic acid making up the majority of other prescriptions. 
In the US and UK, the proportion of children treated with antibiotics under 6 months of 
age based on caregiver-report is reported to be lower, at approximately one third of children 
[11,12]. In Denmark, approximately 40% of children receive antibiotics in the first year of life as 
determined by antibiotic sales data [387]. Higher rates of antibiotic use in our study population 
may be due to higher rates of infection, better capture of antibiotic prescriptions in clinic records, 
and greater availability of antibiotics without prescriptions. Also, healthcare providers may 
prescribe antibiotics at higher rates because they perceive greater pathogen burden or lower rates 
of retention in care in slum areas. Reductions in antibiotic usage rates in India may be achieved 
by intervening on these factors. Specifically, the lack of enforcement of antibiotic purchasing 
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restrictions in India indicate a key potential point of intervention for preventing unnecessary 
antibiotic use. 
 
Aim 1 
 The results from Aim 1A provide the first evidence that antibiotic treatment of diarrhea 
may shorten the time between episodes, especially among younger infants. Children who 
received antibiotics for their first diarrhea episode had their second episode on average two 
months earlier than children who did not receive antibiotics. The effect of antibiotics on time to 
next diarrhea was largest among children who were treated with antibiotics for diarrhea under 6 
months of age and among children who were treated with cefixime (in contrast to 
cotrimoxazole). These differences aligned with expectations since the microbiota is 
underdeveloped and more susceptible to disturbances during early infancy [20,280]. In addition, 
cefixime is more effective against Gram-negatives common in the gut [439], and AAD is more 
commonly reported for cefixime compared to cotrimoxazole [439,440].  
These conclusions were further strengthened by evidence from Aim 1B of an increase in 
diarrheal rates from 6 months to 3 years of age associated with any antibiotic treatment under 6 
months of age, regardless of indicating illness. Antibiotic exposure during this early period of 
life—at the same time as the microbiota is developing—appears to have consistent negative 
effects on diarrheal risk. Further, we found that exclusive breastfeeding during antibiotic 
exposure may be protective against the effects of antibiotics since children who were exclusively 
breastfed for at least the first 6 months did not have increased diarrheal rates associated with 
antibiotic exposure.  
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We hypothesize that the effect of antibiotic treatment on diarrheal risk may be mediated 
by a prolonged effect of the antibiotics on microbiota composition [17] or through collateral 
effects on intestinal structure and function relating to inflammation, permeability, and intestinal 
immunity [247,357]. The strong effect modification by exclusive breastfeeding may also be 
explained by interactions with the microbiota since bacteria present in breast milk, such as 
Lactobacillus, have been shown to reduce risk of gastrointestinal infections [441,445].  
To translate these results into those that would be relevant for public health practice and 
policy, we estimated the impact of realistic interventions (Aim 1C) that would prevent only 
unnecessary antibiotic use (for non-bloody diarrhea, upper respiratory infections, and other 
episodes of acute gastroenteritis). The interventions removed more than half of all antibiotic 
treatments in the first 6 months of life. While the effects on diarrheal rates were necessarily 
smaller than the average treatment effects presented in Aim 1B since only a portion of antibiotic 
exposures were removed, the interventions resulted in substantial decreases in diarrhea burden, 
with numbers needed to treat between 4 and 8 based on the effect contrast. When targeted to 
children who were no longer exclusively breastfed, the effects were slightly smaller, suggesting 
general interventions may be most effective. Because it would be unethical to remove all 
antibiotic exposures, these results provided estimates of a real population impact that could be 
achieved by rational antibiotic use interventions. 
 
Aim 2 
Study children fell consistently below the normal growth curve, and growth failure was 
common early in life. The prevalences of underweight and stunting rose quickly in the first 6 
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months of life from below 15% to almost 30%. After 6 months, more than 30% of children were 
underweight and/or stunted on average. Prevalence of wasting was lower, at 15% overall.  
There were no effects of antibiotics on growth in the short-term. In primary analyses, 
children who received antibiotics in monthly intervals under 6 months of age did not demonstrate 
differences in growth compared to unexposed children. This lack of effect remained in all 
secondary analyses conducted within subgroups, with alternative exposure definitions, and using 
different models and dichotomous outcomes. In the long-term, children who received no or one 
course of antibiotics had similar growth trajectories, while those receiving 2 or more courses of 
antibiotics weighed slightly less and were shorter at all ages. However, adjusted effects were 
close to the null and not statistically significant. Notably, all z-score differences translated to 
very small equivalents in absolute weight and height (approximately 100 g and 1-2 mm), which 
are within the error margin of the anthropometric instruments and likely not clinically important. 
Because there was an increase in relative risk of underweight associated with antibiotics in the 
long-term analyses, it may be useful to focus future investigations of antibiotics on weight 
effects. However, statistical significance of effects in this case may be due to chance given the 
large number of comparisons made. 
The lack of a growth-promoting effect of antibiotics in our study population may be 
explained by differences from previous studies in methodology, child diet, and indicating 
illnesses. Most studies demonstrating increased weight gain associated with antibiotics were 
conducted among those with a Western high-fat diet [11,228,373,389,390]. The lack of an effect 
in our population, which did not have access to a high-fat diet, suggests that the growth 
promoting effect of antibiotics may occur only when increased energy and nutrient intakes are 
possible. Further, antibiotic treatment in our study was largely given for common childhood 
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illnesses, and the children were not diagnosed with acute severe malnutrition for which 
antibiotics have shown to improve growth, especially when given in combination with nutritional 
supplementation [369,375].  
Our study also differed methodologically from previous studies. Most used BMI as the 
main growth outcome [11,228,373,376,389], which can be difficult to interpret since it combines 
weight and height measures. For example, if antibiotics had a positive effect on linear growth, 
but no effect on weight gain, antibiotics would counterintuitively be associated with lower BMI 
despite the positive effect of antibiotics on height. The separate assessment of height and weight 
effects is an important strength of our study. Previous studies also commonly did not control for 
the illnesses that triggered antibiotic use [11,373,376], which may have resulted in estimates that 
were subject to residual confounding. We considered the indicating illness as an important 
confounder of the effect of antibiotics on growth, and correspondingly included multiple aspects 
of child sickness in the multivariable models. Finally, previous studies rarely reported the types 
of antibiotics given [11,373,376], which could have potentially differed from those given in our 
study population and may have different effects on growth. Inconsistency in the effect of 
antibiotics on weight gain has been documented in animal studies and suggests that many factors 
may play a role in the complicated relationship between antibiotic exposure and growth [24]. 
 
Strengths 
 Our study was based on rich longitudinal data and applied sophisticated statistical 
analyses to assess the effects of antibiotics on diarrhea and growth. Both the quantity and quality 
of data available for this study was high. The cohort provided highly detailed information about 
diarrhea incidence and severity such that presence of diarrhea and other symptoms was known 
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for each child on every day of follow-up. The recall period for diarrhea was short (3 days) such 
that recall bias was unlikely to affect the validity of our results. The proportion of missing values 
for covariates was low, less than 5% for baseline covariates. These data were high quality given 
the extensive quality control strategy including frequent retraining of field workers, regular 
instrument calibration and standardization of protocols, validation of information collected at 
home visits, monitoring of missing data, and double entry of data into the electronic database. In 
addition, the encouragement of study participants to visit the study clinic when ill allowed data 
linkage with clinic records to validate data from home visits and access non-diarrheal illness 
burden and treatments, which were important for antibiotic exposure classification and control of 
confounding. The availability of data from two previous cohorts allowed the comparison of Aim 
1A results across studies from the same geographic area over time. 
 We used appropriate statistical analyses to account for analytic complications associated 
with longitudinal data, multiple diarrhea episodes per child, and repeated growth measurements. 
Previous studies have demonstrated the importance of modelling diarrhea longitudinally to 
describe the complicated relationships between age and repeated diarrhea episodes [25,26]. We 
accounted for changes in diarrhea incidence rates with age by analyzing closed cohorts in which 
all children were followed from birth to 3 years of age, and by adjusting for age flexibly with 
splines in analyses. Repeated diarrhea episodes required analysis methods that took into account 
clustering among observations within individuals. We used general estimating equations with 
robust variance estimators and bootstrapping to appropriately address correlation between 
episodes within children. We also appropriately handled time-varying exposures and 
confounders in Aim 1A, which changed for each diarrhea episode over the study period. 
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 This study also involved developing and providing examples of relatively novel 
epidemiologic methods. In Aim 1A, we used inverse-probability weighted KM curves to 
estimate time differences and time ratios for the effect of antibiotic treatment of diarrhea on 
incidence of subsequent diarrhea episodes. The resulting estimates from this analysis were more 
interpretable than hazard ratios because they describe absolute differences in the timing of the 
subsequent episode between exposure groups. Because the majority of children experienced a 
subsequent diarrhea episode, an estimate of increased relative hazard from a Cox model would 
have been harder to conceptualize because an increase in hazard would not have necessarily 
translated to more children having diarrhea. We developed a SAS macro to perform this type of 
analysis more generally, which we have described in a manuscript in preparation for the 
American Journal of Epidemiology.  
In Aim 1C, we used the parametric g-formula to estimate the impact of population-based 
interventions. This method has rarely been used to date, partly because it can be prohibitively 
complicated in the time-varying covariate setting. In contrast, our application of the parametric 
g-formula in a time-fixed setting was relatively straightforward to implement. By further 
increasing the visibility of this method, we hope more epidemiologists will find it an accessible 
analytic tool to estimate effects that are more relevant to public health. 
 
Limitations 
 Because the parent studies were not designed to study antibiotic use, the assessment of 
antibiotic exposure information was suboptimal. Treatment was recorded systematically in the 
parent studies only for diarrhea, and quality of treatment information may have been variable 
since antibiotic types were recorded based on caregiver-report in a free-response question. 
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Dosage and duration of treatment were not recorded. In addition, we do not have information 
about prenatal antibiotic exposures or exposure through breastfeeding due to antibiotic treatment 
of the mother. Antibiotics are commonly given to mothers before Cesarean sections and at the 
beginning of labor if they are Group B Streptococcus positive [24]. However, we expect the 
effect of maternal antibiotic exposures on the infant to be minimal compared to direct exposures 
based on previous research [268,297,342].  
 While treatment information for non-diarrheal illnesses was not collected during routine 
field worker visits, prescriptions from clinic records were sufficient to classify children by 
exposure to any antibiotics regardless of clinical indication for treatment. We expect that almost 
all antibiotic exposures were captured in these clinic records since the study clinic was 
conveniently located in the residential area where study children lived and provided clinical care 
and medicines free of charge. We validated self-reported information by comparing antibiotic 
prescriptions for diarrhea from the clinic with self-reported antibiotic treatments from the cohort 
data. High concordance between caregiver-reported and antibiotic prescriptions for diarrhea 
supports our assumption that most antibiotic exposures were recorded in clinic records (78% of 
antibiotic prescriptions during diarrhea episodes were associated with caregiver-reported 
antibiotic treatment). Further, our results were consistent in sensitivity analyses when using 
alternative and more restrictive definitions of antibiotic exposure that required caregivers to 
report the name of the antibiotic given. 
 We were also unable to definitively characterize antibiotic treatment as necessary or 
unnecessary for Aim 1C analyses. Only information concerning the indicating illness was 
available, and other symptoms that may have indicated antibiotic treatment were unknown. 
Clinical criteria for diagnoses could have varied by physician at the study clinic, and some URI 
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and AGE cases could have been of bacterial etiology and responded to antibiotics. However, 
diagnostic capabilities in this area were not sufficient to distinguish between bacterial versus 
viral etiologies, such that treatment decisions must be made based on clinical signs alone. 
Because international guidelines do not recommend antibiotic treatment for the majority of cases 
of diarrhea, URI, and other AGE, classification of these treatments as not indicated was likely 
warranted. 
The modified version of the Vesikari scale used in this study was designed to assess the 
severity of rotavirus diarrhea and has not been validated for all-cause diarrhea. However, this 
scale has been successfully applied to diarrhea due to Cryptosporidium previously in this 
population [402]. Increased severity of diarrhea episodes as indicated by the Vesikari scale was 
associated with higher prevalence of antibiotic treatment in the cohort, which was expected since 
more severe symptoms are likely to trigger greater care-seeking behavior. Given that a 
substantial proportion of diarrhea episodes were associated with rotavirus and the scale 
functioned as expected, we argue that severity measured using the Vesikari scale was appropriate 
when applied to all-cause diarrhea in this population. 
As in any observational study, there was the potential for bias due to uncontrolled 
confounding in our study. However, the cohort had the advantage of detailed records of illness 
characteristics that were likely the main indications for treatment, and we adjusted for multiple 
components of disease severity. Because a clinical trial which randomized all antibiotic 
treatment in this setting would be unethical, we believe this evidence from a well-conducted 
prospective observational cohort study with good follow-up has a critical role in understanding 
the impact of antibiotics on diarrhea and growth. Also, by assessing antibiotic exposures given 
for common childhood illnesses in a realistic setting, our study may provide estimates of the 
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impact of antibiotics that are more generalizable to communities in LMICs when compared to 
trial results. 
Finally, our results may not be generalizable to other populations since all three cohorts 
were sampled from the same source population in a fairly limited geographic area in southern 
India, which may not be comparable to other LMICs or even to the country of India as a whole. 
Treatment patterns, risk factors for diarrhea, and etiologic agents are variable across geographic 
sites and patient populations. Specifically, access to antibiotics varies based on local policy and 
law enforcement, and geographic variations in microbiota composition may affect the outcomes 
of antibiotic exposure. On the other hand, we do not expect the biological mechanism for the 
effects of antibiotics on diarrhea and growth to vary to such an extent that would preclude 
replication of our findings in other populations. Similar urban slum settings are common across 
Asia and Africa, such that results from this study likely also apply to other resource-poor 
settings. 
 
Public health significance  
This study is highly relevant to clinical policy and practice surrounding antibiotic 
treatment of diarrhea and other childhood illnesses. Because treatment of these illnesses is often 
not necessary, further evidence to inform treatment decisions will be useful for case 
management. Specifically, our evidence of harm to children treated with antibiotics early in life 
through increased diarrheal risk suggests that antibiotic exposure in the first 6 months of life 
should be limited where possible. In addition, because antibiotic treatment of diarrhea is 
associated with quicker onset of a subsequent episode, non-bloody diarrhea should generally not 
be treated with antibiotics unless other clinical signs or history indicates treatment would be 
appropriate.  
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We hope these recommendations will support efforts to improve rational antibiotic use. 
The overuse of antibiotics is a serious concern, and efforts to reduce overuse are a priority in the 
US and abroad. In September 2014, the White House published the “Report to the President on 
Combating Antibiotic Resistance” by the Council of Advisors on Science and Technology [462]. 
This report stressed the severity of antibiotic resistance as a public health threat and provided 
recommendations to maintain the effectiveness of antibiotics. Our results could support these 
efforts by providing physicians with evidence that antibiotics may be harmful, which would 
counter pressure from caregivers who demand antibiotics. In places where antibiotics can be 
purchased without a prescription, education efforts describing these harms may lead to a 
reduction in use for the treatment of illnesses for which antibiotics are not indicated.  
We estimated the potential population-level impact of interventions with this aim in 
analysis 1C. These estimates are relevant to policy makers with interest in understanding the 
potential impact of policies to reduce antibiotic use. Direct effects on treated individuals would 
be only one component of a potential health policy decision, and our results concerning 
increased diarrheal risk contribute an important piece to the evidence base for constructing 
rational antibiotic use policies. Reduction of inappropriate antibiotic use at a large scale would 
benefit society in the long-term by reducing the prevalence of drug-resistant bacteria [393,394], 
preserving the efficacy of antibiotics for the treatment of serious human infections.  
Finally, this study contributes epidemiologic evidence towards the rapidly growing area 
of research on the microbiota and its association with health and disease. Because our results are 
consistent with a potential biological mechanism that antibiotics can cause dysbiosis of the 
microbiota and increase susceptibility to diarrhea, the study indicates that future study of 
antibiotics in association with childhood development is warranted. Our results may inform 
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hypotheses for laboratory-based in vitro or animal studies to understand the complex 
relationships between microbiota diversity and composition, diarrhea, and growth in early 
childhood. 
 
Future directions 
 Since our study provides the first evidence that antibiotic treatment may increase risk for 
future diarrhea, replication of our findings in other populations is needed. Specifically, it would 
be useful to assess these relationships in a setting with better assessment of antibiotic exposures. 
The study of Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and 
the Consequences for Child Health (MAL-ED) would be an appropriate choice given close 
follow-up of children and complete records of caregiver-reported antibiotic use [463]. This study 
was conducted in 8 countries and, similar to our study, involved birth cohorts followed 
longitudinally until 2 years of age. One of the study sites was based in Vellore in a similar source 
population as our cohorts (from a community across town). Replication of our analyses in these 
birth cohorts would allow validation of our findings in the same geographic area, and also 
indicate if the results are generalizable to children in other LMICs. Results from the current 
study and potential replication studies could be combined by incorporating the current results as 
Bayesian priors or including all results in a meta-analysis. 
Our lack of evidence for an effect of antibiotics on growth was contrary to other recent 
studies which suggest antibiotics promote growth in children. Further investigation of the 
relationship between antibiotic exposure and growth is needed given the complex interactions 
between nutrition, illness, and child development that are further complicated in low-resource 
settings. Specifically, the potential competing mechanisms for an effect of antibiotics on growth 
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must be isolated to understand if either or both mechanisms (antibiotics as growth-promoters and 
antibiotics as causing future illness which hinders growth) are occurring. This may be most 
feasible in animal studies where conditions can be controlled and isolated. Future studies in 
human populations will also be needed to tease apart the potential pathways through which 
antibiotics could affect growth. Again, the MAL-ED study may provide a useful platform for 
these types of studies. Inclusion of the assessment of environmental enteropathy will likely be a 
key component to understanding the complex relationships between antibiotics and child 
development. 
In collaboration with CMC, a follow-up study may be developed to assess the diversity 
and composition of the gut microbiota to better understand underlying biological mechanisms. 
The parent studies for this analysis included the collection and storage of a large number of stool 
samples for each study child, which were collected during every diarrhea episode (1-3 samples) 
and every 15 days regardless of illness. Sequencing of the microbiome in a subset of these stool 
samples may help explain how antibiotics affect diarrheal risk and growth. While many studies 
of the effects of antibiotics on the microbiota have been completed in mice and other animal 
models, studies in humans are more unusual and often involve a small number of adult subjects. 
Most studies are cross-sectional and compare the microbiotas in diarrhea cases with healthy 
controls [248,286,330,333]. For example, three studies from Vellore documented differences in 
microbiota composition in diarrhea cases [319,320,335], and acute diarrhea was associated with 
decreased microbiota diversity among children in Bangladesh [331,332]. However, because 
responses to antibiotics are individualized and influenced by prior exposure to antibiotics, 
aggregation of microbiota composition data across subjects may not be valid. Further, while 
studies have consistently documented changes in the microbiota during diarrhea, they do not 
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establish temporality. Based on fecal samples collected during the diarrhea episode alone, it is 
not clear if diarrhea causes the modifications in the microbiota, if dysbiosis of the microbiota is 
instead a risk factor for diarrhea, or if both processes are possible. Longitudinal comparison of 
samples taken from the same individuals before and after illness would allow comparison within-
subjects, establish temporality, and hence provide results that will be more interpretable 
[17,286,340]. Therefore, the stool samples available in the parent studies provide an ideal 
resource for analyzing the effects of antibiotics on the microbiota in a longitudinal series of stool 
samples from the children before and after diarrhea episodes.  
In the long-term, these results may contribute to the development of therapeutic and 
preventive interventions that could improve the resiliency of the microbiota against perturbations 
by antibiotics and reduce diarrheal risk. Interventions involving prebiotics or probiotics may 
stabilize and strengthen the microbiota in this way. Overall, a more complete understanding of 
the interactions between the microbiota, environmental enteropathy, and child development is 
needed to develop interventions to combat the long-term morbidity associated with childhood 
diarrhea. 
 
Conclusions 
 While antibiotics are undeniably one of the most important public health discoveries in 
the last century, we are quickly learning that exposure to antibiotics has collateral effects both on 
individuals and at the population level. Antibiotics are commonly given during infancy at a time 
in which the developing gastrointestinal microbiota is most sensitive to perturbations. Concerns 
over the spread of antibiotic resistance have garnered the most attention by those promoting 
rational antibiotic use. However, explanations about the perils of antibiotic resistance are hard 
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for the public, and even clinicians, to conceptualize. An important outcome of this dissertation 
will be to highlight the impact of antibiotics on individual patients. By demonstrating that 
antibiotic treatment of diarrhea, and antibiotic exposure in general early in life, increases future 
rates of diarrhea, we provide an alternative and potentially more powerful argument for reducing 
antibiotic use. We counter the “at least they can’t hurt” mentality towards antibiotics – 
antibiotics can cause sustained adverse effects among young children, and these effects should be 
considered when making treatment decisions for childhood illnesses.   
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